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ABSTRACT
The present investigation provides information on the 
genetics of susceptibility to diabetes. Patients and controls 
from five ethnic groups have been studied.
i
Australian Population: Patient series were available from
hospital sources in Melbourne and from surveys in three 
localities in Western Australia (W.A.). Controls were blood 
bank donors in Canberra and Sydney.
For genetic markers on chromosome 6, the results 
demonstrate a strong association for the Properdin factor B 
(Bf) factors BfF^ and BfS^ in the insulin dependent diabetes mellitus 
(IDDM) patients of Melbourne. Bf F is present in 1.0% of controls 
compared with 6.0% in the IDDM series. This is an age- 
dependent association which declines at the older ages. The 
relative risk for BfS^ and BfF^ combined for patients below 
10 years of age is 9.4. Another important feature is a 
significant decrease of BfF factor in the Western Australian 
non-insulin dependent diabetes mellitus (NIDDM) patients. This 
points to the importance of the Bf system, not only in IDDM, but 
also in NIDDM patients.
The complement C/2 system also shows a significant 
association with IDDM in the Melbourne series. A third 
chromosome 6 marker, the red cell enzyme Glyoxalase (GLO) 
shows an apparent association by an increase of the GLO 2-2 
phenotypes among the NIDDM patients in Melbourne, but this 
is due to the ethnic stratification of the population.
Among the non-chromosome 6 markers studied there is a
significant association of the phosphoglucomutase (PGM)
allele PGM  ^in the NIDDM patients above the age of 70 years.
A multivariate analysis of the genetic markers for the 
Australian series indicates genetic differences between the 
various patient series, as well as between these and the 
control series.
Indian Population: Among the Indian IDDM patients, the distri­
bution of the chromosome 6 marker Properdin B (Bf) differs 
from that in Caucasian IDDM. Unlike the latter there is an 
absence of BfF^ in the Indian IDDM patients, but an associa­
tion with the other rare factor BfS^ (3.2% controls vs 11.4%
IDDM) is noted. In the NIDDM series, there is an increase 
of the BfF factor. Typing of C^2 was not carried out for 
this series. For red cell enzyme glyoxalase (GLO), an 
increase in the GLO 2-2 phenotype was noted and like the 
Australian series this is due to the ethnic stratification 
within the Indian population.
2For the non-chromosome 6 markers there is an increase of PGM--- 1
allele unlike that observed in NIDDM series of Australia.
Samoan Population: In the NIDDM series from Samoa, for the
chromosome 6 markers there is a decrease of the common allele
FBf , which is similar to that for the Australian NIDDM
series. The C^2 typing was not carried out for the Samoan
series. At the GLO locus no significant disturbance in
phenotypes or gene frequencies are observed. Among the
2non-chromosome 6 markers, PGM  ^also shows a decrease in 
the NIDDM series, similar to that noted in the Australian 
NIDDM series in patients over the age of 70 years. The
other non-chromosome 6 markers do not yield informative
results for the Samoan series.
Nauru Population: For the chromosome 6 marker Properdin
Ffactor B (Bf), there is an increase of B£ among the NIDDM 
patients similar to the phenomenon noted in the Indian NIDDM 
series. The other markers on chromosome 6, C'2 and GLO, 
were not studied in this population.
Among the non-chromosome 6 markers, there is an
2increase of the PGM  ^ allele, a reverse trend to that in
the Australian NIDDM series. This may be due to the
difference in the age structure of the population. A
significant association with a non-chromosome 6 marker, 
c6GPD , was noted in the Nauru NIDDM series.
Pima Indian population: There is no significant distur­
bance in the distribution of the chromosome 6 markers Bf
and GLO phenotypes or gene frequencies in the NIDDM series
2of Pima Indians. For the C'2 system, an increase of C'2 
allele is noted in the NIDDM series.
Among the non-chromosome 6 markers, there is a signifi-
2cant increase of PGM“ allele (8.4%) in the NIDDM series 
compared to controls. This is unlike the Australian NIDDM 
series, and may be due to the lower age of individuals in 
this population. The association of phosphoglycolate 
phosphatase (PGP) with NIDDM among Pima Indians, which has 
been claimed by other workers, is not supported by this 
study.
In conclusion, the study shows the importance of two 
markers (other than HLA) on chromosome 6 which are inform­
ative for indicating the risks of persons carrying the
„ 2properdin factors BfF^ and complement allele C 2 , for
the IDDM type of disease.
In the NIDDM type of disease, association of the PGM 
markers requires further study for confirmation.
The other important points highlighted in this investi­
gation are: (1) ethnic stratification within a population
may produce artifacts of association with genetic markers, 
and (2) breakdown of the population into age groups also 
may be important in revealing the effect of association in
particular age groups.
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1Chapter 1 
INTRODUCTION
The prevalence of diabetes ranks it as one of the leading 
health problems in the world. The notion that it is a disease 
only of affluent societies is erroneous, since many developing 
countries also show high prevalence rates of the disease. In 
fact, it is regarded as a universal problem affecting human 
societies at all stages of development (WHO, 1980).
Definition of Diabetes Mellitus
The effects of diabetes are recognised by the state of 
chronic hyperglycaemia, a consequence either of insulin lack 
or due to a number of factors which inhibit its action.
Since insulin is one of the major regulators of blood glucose 
concentration, an imbalance leads to abnormalities of carbo­
hydrate, protein and lipid metabolism. As the disease 
progresses other effects may include characteristic 
symptoms, such as ketoacidosis, gradual degeneration 
resulting in disease of capillaries of the kidney and 
retina, damage to the peripheral nerves and excessive arter­
iosclerosis (WHO, 1980). For long it was regarded as a 
single disorder of metabolism, For example, one of the
standard medical textbooks defined diabetes as "...... a
disorder of carbohydrate metabolism characterized by hyper­
glycemia and glycosuria associated with a disturbance
of the normal insulin mechanism ...." (Bondy 1963). A more recent
definition by Fajans et at. (1978), however, indicates a 
broadening of this concept." Idiopathic diabetes mellitus
2is a genetically determined disorder of metabolism associated 
with absolute or relative insulin insufficiency which, in its 
fully developed clinical expression, is characterised by 
fasting hyperglycaania, atherosclerotic and microangiopathic 
vascular disease and neuropathy". Apart from these essential 
characteristics Fajans et at, (1978) point out that variation 
in the clinical presentation may occur, such that the disease 
may be a mild form and without complications.
The basis for separation of diabetes into various types 
has been greatly stimulated by the discovery of associations 
between markers such as HLA and islet cell antibodies in 
some diabetic subjects and not in others. This has led to 
fresh attempts to classify diabetes on the basis of clinical 
and laboratory features.
Classification Schemes:
The first attempt at classification was made by a work­
shop on "Etiology and pathogenesis of insulin-dependent 
diabetes mellitus" (Philadelphia Workshop 1977) co-sponsored 
by the National Institute of Arthritis, Metabolism and 
Digestive Diseases and the Juvenile Diabetes Foundation.
The main emphasis of this workshop centered specifically 
on the juvenile type of diabetes with some reference to non­
insulin or maturity onset type of diabetes.
In 1978 the Kroc Foundation sponsored a conference on 
the "Epidemiology of diabetes and its macrovascular complica­
tions" which discussed some of the definitions and schemes 
of classification (West 1979). These discussions were of
3assistance to the National Diabetes Data Group (NDDG) of the 
National Institutes of Health which also published a report 
on classification and diagnosis of diabetes mellitus (NDDG/ 
1979). This classification is the basis for that adopted in 
1980 by the World Health Organization (WHO, 1980). Since this 
scheme is based on contemporary knowledge incorporating the 
heterogeneity of the syndrome, it will form the basis of this 
thesis. An outline of this classification, given in table 1.1, 
will be briefly described below.
Type I: Insulin dependent diabetes mellitus (IDDM), usually
characterized clinically by abrupt onset of symptoms, insulin- 
opaenia and dependence on injected insulin to sustain life, 
and proneness to ketosis. Classically, this type of disease 
occurs in juveniles and was formerly termed juvenile diabetes. 
Since it can be recognized and becomes symptomatic at any age, 
diagnosis on an age basis is abolished. IDDM appears to be 
heterogeneous in terms of genetic and environmental factors 
which precipitate the disease (Rotter and Rimoin, 1978).
Genetic determinants are important in most patients, 
confirmed by the associated increased or decreased frequency 
of certain histocompatibility antigens (HLA) controlled by 
genes on chromosome 6 (Nerup et ais 1974; Cudworth and Wood- 
row, 1974).
Type II: Non-insulin dependent diabetes mellitus (NIDDM) ,
frequently presents with minimal or no symptoms referable to 
the metabolic aberrations of diabetes. Patients with NIDDM 
are not dependent on insulin for prevention of ketonuria and
are not prone to ketosis. They may require insulin for corr-
- j a  -
Table 1.1
National Diabetes Data Group: Classification of
Diabetes Mellitus
A. Clinical Classes:
DIABETES MELLITUS
Insulin dependent type (IDDM) Type I 
Non-insulin dependent type (NIDDM) Type II
1. Non-obese
2. Obese (NIDDM)
Other types, including diabetes mellitus associated with 
certain conditions and syndromes:
1. Pancreatic disease
2. Hormonal
3. Drug or chemical induced
4. Insulin receptor abnormalities
5. Certain genetic syndromes
6. Other types.
The classification includes also a set of categories for 
persons with impaired glucose tolerance but without other 
clinical signs of diabetes.
Gestational diabetes is listed as a separate category.
B. Classification based on statistical risk
(subjects with normal glucose tolerance but substantially 
increased risk of developing diabetes)
1. Previous abnormality of glucose tolerance (prevAGT)
2. Potential abnormality of glucose tolerance (PotAGT)
4ection of symptomatic or persistent fasting hyperglycaemia 
if this is not achieved by use of diet or oral agents. Ketosis 
may develop under stress or trauma. A range of insulin responses 
to glucose, from low to supranormal, has been found in patients 
of this class, many of whom do not have fasting hyperglycaemia.
Complications of diabetes, namely macro- and microangio­
pathy, neuropathy, retinal damage and cataracts, are often 
associated with Type II or NIDDM. NIDDM is also of a hetero­
geneous nature and use of age of onset is not recommended 
(NDDG, 1979). NIDDM has a strong genetic basis, which is 
evidenced by a more frequent familial pattern of occurrence 
(NDDG, 1979). Included under this type are families in whom 
diabetes occurs in children, adolescents and adults with an 
autosomal dominant inheritance known as MODY and described by 
Tattersall and Fajans (1975).
Intake of excessive calories leading to weight gain and 
obesity is probably an important factor in the pathogenesis of 
NIDDM. Although small changes in weight may be important,
NIDDM has been subdivided according to the presence or 
absence of obesity. 60%-90% of all NIDDM patients are obese, 
especially noted in the Western societies (NDDG, 1979).
Unlike IDDM, the NIDDM type of diabetes is not associated 
with HLA types and islet cell antibodies among Caucasians. 
However, recent reports from South Africa for the Xhosa tribe 
(Briggs et at. 1980) and for Fiji Indians (Serjeantson et at., 
1981) have shown association of NIDDM with some HLA antigens 
in these populations. These will be discussed more fully in
a later section.
5Other types of diabetes: In this subclass, diabetes forms
part of certain other conditions and syndromes which often have 
many clinical features not generally associated with the dia­
betic state. Only in some cases the co-occurrence of glucose 
tolerance and other features may be of some importance aetio- 
logically. In others, it can imply a causal relationship.
This class has been further subdivided depending upon the known 
or suspected aetiologic relationship. (1) It may be second­
ary to pancreatic diseases or removal of pancreatic tissue,
(2) it may be due to endocrine disease such as acromegaly, 
Cushing's syndrome, pheochromocytoma, glucagonoma, somatas- 
tatinoma and primary aldosteronism, or (3) it may result 
from the administration of certain hormones, drugs and 
chemicals which cause hyperglycaemia.
Diabetes may also be associated with defects of the 
insulin receptors which may be caused either by abnormal­
ities in numbers or to affinity of insulin receptors or 
antibodies to receptors with or without associated immune 
disorders (Roth et al3 1979). As well carbohydrate intol­
erance is often seen in association with a number of genetic 
syndromes (Rimoin and Schimke, 1971; Rimoin, 1976). Finally, 
this class incorporates special types of diabetes found 
among specific populations and environmental conditions, e.g. 
diabetes associated with malnourished people (NDDG, 1979).
Prevalence of diabetes mellitus in the world populations
Historically, diabetes was known to occur in certain 
populations since ancient times, and original records have 
been found in the literature from Egypt (Ebers papyrus),
6China, Japan, India and from Cappadocia (now called Iraq).
More recently, epidemiological surveys have shown diabetes 
to be universally distributed among all populations. Rates 
for various parts of the world are summarized from West (1978) 
for IDDM in Table 1.2 and for NIDDM in Table 1.3. It should 
be remembered, however, that the rates have been determined 
by different methods and therefore are not always reliable.
The main points of interest which emerge from the survey 
of diabetes prevalence rates, as shown in these tables, is 
that there is a high rate of IDDM among Caucasian populations, 
ranging from 0.3 in France to 3.7 for 20 year-old conscripts 
in Australia , whilst in non-Caucasian populations IDDM has a 
very low rate. By contrast a high rate of NIDDM is commonly 
found among non-Caucasian populations whilst it is relatively 
low among Caucasians.
Recent interest has focussed on populations showing high 
prevalence rates of diabetes of the NIDDM type and also in 
situations where there is a striking contrast in diabetes 
prevalence rates among populations inhabiting the same geo­
graphical area.
The first focus of attention permits a discussion of 
possible environmental factors influencing the prevalence of 
diabetes, whilst the second suggests the possibility of 
environmental-genetic interaction. This possibility will 
be discussed below after examining environmental factors 
alone.
Among the populations exhibiting very high prevalence 
rates are the Micronesians of Nauru (Zimmet et di, 1978) ,
Pima Indians of Arizona (Bennett et at. 1971), Natal 
Indians of South Africa (Jackson, 1970) and Aborigines of
- 6a -
Table 1.2 Prevalence rate of juvenile onset type of diabetes 
mellitus, or IDDM, in different populations.
Note: Ref. for investigations listed in table will be found
in West 1978 (except where indicated +)
[nvestigator & Year Population Age Rate/1,000 Source
Palumbo e t  al . (1976) Rochester Minn. 
School Children
5-18 1.0 Survey of clinical 
records
>ultz e t  al . (1968) Erie County
N. Y.
0-16 0.6 Counting of known 
cases
falconer e t  al . (1971) Edinburgh 10-19 0.93 Diagnosed cases
Wadsworth & Jarrett 
(1974)
Britain 11 0.1 Diagnosed cases in 
cohort
_,estradet (?) France 0-19 0.3 Registry (insulin 
treated only)
Cruger (1965) Schwerin 
E. Germany
1-9 0.16 Urine screening
>inelli (1976) Venice, Italy 0-13 0.26
iolmgren e t  al . (1974) Vasterbotten 
County. Sweden
0-15 2.2 Known cases
^hristau e t  al . (1976) Denmark 0-29 0.7 Registry
houst & Smithurst 
(1968)
Australia 20 yrs 
(males)
3.7 Interview and regis­
tration for Nat.Service
1iki & Maruyama (1970) Japan 0-15 0.025 Survey estimate of 
diagnosed cases
Sathe (1973) India - Rare
?ulloch (1962) 
Jeftel (1964)
Primitive 
blacks of 
several areas 
and in Chinese 
Indians & 
Malays of 
Singapore
Rare
lai e t  al . (1965) Vietnam - Rare
tfang (1937) Chinese - Rare
Cassidy (1967) Indians & 
Melanesians 
of Fiji
Uncommon
Belcher (1970) Ethiopia - Uncommon
larrett & Keen (1975) Malta, Ceylon 
Cook Island 
Maoris & 
Trinidad blacks
Uncommon
Sirnmet. e t  a l3 
(1978)
Polynesians 
& Micronesians
- Rare
Bennett et  al . (1971) Pima - Rare
6b
Table 1.3 Prevalence of Adult onset diabetes, or NIDDM, among
different populations
Population Rate inInvestigator & Year * Age %
Wilkerson & Krall (1947) Massachusetts
Oxford
Adults 1.1
Palumbo et at. (1976) Rochester Over 40 4.1
Redhead (1966) England Over 30 0.5
(Newcastle)
Nilsson et at. (1964) Sweden Adults 2.7
(Kristianstad)
Welborn et at. (1968) Australia
Busselton) Adults 0.9- Cunderdin) 1.3
Cardonnet & Nusimovich Argentina Adults 2.9
(1968) Rosaria
Mateo de Costa et at. Cuba, Artmisia ) Adults 0.7(1973) Rural areas ) 0.2
Sasaki et at. Japan, Yao over 39 1.3
Rural
Mouratoff (1967) Eskimo all ages 0.03
Mouratoff (1969) Alaska; Atha- all ages 0.02
bascan
Stein et at. (1965) Cherokee Indians all ages 10
Reinhard & Greenwalt Papago Indians all ages 5.3
(1975) Arizona
Bennett et at. (1971) Pima Indians above 30 40
West (1974) Oklahoma Indians Adults 10
Wise et at. (1970) Australian
Urbanized
Aborigines
over 20 8
Hingston & Price (1964) Papua Rural Adults 0
Zimmet et at> (1976) Nauru over 14 34
+Marine et at. (1969) South Africa - 
Indians
over 15
10.4
Malay 6.6
Bantu 3.6
■k References for investigations listed in table will be found in 
West 1978 (except where indicated +)
7South Australia (Wise et al} 1976).
These high rates seem to coincide with a change from a 
traditional to a 'Western' life style, associated with a 
high carbohydrate diet, often including excessive alcohol 
intake and a reduced output of exercise, thus encouraging obesity
Environmental factors influencing prevalence of diabetes mellitus 
Diet» obesity and exercise
The possibility that risk of diabetes is related to carbo­
hydrate consumption has been frequently suggested. This hypo­
thesis was based on several considerations. Although the 
ingestion of fat and protein also stimulates pancreatic beta 
cell function, the ingestion of carbohydrate presents a 
challenge to beta cells which is stronger, more direct and 
more immediate than when protein or fat are ingested alone.
Blood glucose, levels are higher immediately after ingestion 
of carbohydrates than after protein or fat. Improvement in 
diabetes is seen when the carbohydrate intake is restricted.
It was once considered that rates of diabetes would 
reflect the dietary intake of the population, particularly 
the intake of sugar. Although supporting evidence does 
come from some sources, equally strong evidence against the 
hypothesis has been presented, such as the observation that 
West Indies cane cutters rarely experience diabetes despite 
the high dietary sugar intake (Brigham 1868). High sugar­
consuming Hawaiians and Cubans also had low diabetes death 
rates, although the rich sweet-eating Bengalis of India did 
show a high rate of the disease (West 1978).
8A very important issue is whether the increase in serum 
insulin levels is related mainly to obesity itself or to assoc­
iated factors such as indolence or the increased levels of 
food intake. Probably all three factors (obesity, overeating 
and inactivity) are significant (Grey & Kipnis 1971).
Himsworth (1935) cited evidence that high carbohydrate regimens 
might increase sensitivity to insulin. Perhaps Africans, who 
are obese, are less hyperinsulinaemic than Americans who eat 
more fat and less carbohydrate (West 1978). Diet is a 
variable factor in different ethnic groups, but it is not 
the only index of variation in clinical features. For example, 
Rimoin & Schimke (1971) have shown variation in ketosis occurr­
ence in some countries when fat and carbohydrate consumption 
is the same (table 1.4).
For more than a century the dilemma of obesity causing 
diabetes or diabetes being the cause of obesity has been under 
intensive investigation. Vallence Owen (1962) and 
Mirsky (1949) are of the opinion that obesity may be secondary 
to the diabetic diathesis. No available evidence suggests 
any causal role for hyperglycaemia in obesity. On one hand, 
there is a debate of obesity and risk to diabetes and, on 
the other hand, that of leanness. In one study in the Gondar 
area of Ethiopia (Belcher 1.970) the incidence of diabetes 
decreases sharply with age in the very lean population.
While leanness is not considered to confer a lesser or 
greater risk, obesity is considered a contributing factor 
in the manifestation of diabetes. The reported incidence 
shows a relatively lower rate among the lean or non-obese
9Table 1.4
Ethnic variation in diabetes mellitus, 
(taken from Rimoin and Schimke 1971).
Ethnic Group
DIETARY
Fat Carbohydrate Ketosis VascularComplications
European high high common common
Pima Indians (1 II rare II
Seneca Indians If If II II
Eskimo ft low II rare
Japanese low high If uncommon
Indian II II If common
South African Zulu II If common rare
South African Indian It It rare very common
Ashkenazi Jews High high common common
10
group (Rao e t  a l , 1966). Gupta e t  a l , (1976) have shown 
diabetes to be 1.0% in thin persons and 9.3% in fat persons. 
Similar conclusions from other sources are compatible.
Evidence is set forth that much of the family aggregation 
of NIDDM is attributable to the family aggregation of obesity. 
This familiality of obesity has both genetic and non-genetic 
determinants. Observations of Baird (1973) illustrate 
the inter-relationships of the familiality of obesity and 
diabetes. Rates of diabetes were determined by testing 
siblings of obese and non-obese diabetics. In obese siblings 
of non-obese diabeticsthe rate of diabetes was highest, while 
in the non-obese siblings of obese diabetics these rates were 
lowest (West 1978). Based on studies of populations such as 
New Zealand Maoris (Prior 1962), Hawaiians (Sloan 1963), 
urbanized Australian Aborigines (Wise e t  a t , 1970) and Sumo 
Wrestlers of Japan (Kuzuva e t  a l , 1975) , it is suggested 
that obesity may precipitate diabetes in individuals 
genetically susceptible to diabetes since, in other popula­
tions when obesity is rare, diabetes is rare (West 1978).
The debate, however, can only be resolved by more detailed 
studies.
Inactivity is known to lead to diabetes, although the 
short and long-term effects of exercise on carbohydrate 
metabolism are incompletely understood (West 1978). It 
has been demonstrated that an inactive life impairs glucose 
tolerance (Altman e t  a l , 1969) and that it is improved with 
physical exercise (Bjorntorp e t  a l , 1977). An example of 
this can be seen among some tribes, such as Broayas of the 
Sahara where diabetes is rare and this is attributed to the
11
high levels of energy expenditure (Rubinstein et dl3 1969).
Age and Stress
The important relationship between age and diabetes, 
although indicative of the physiological status of individuals, 
suggests either direct effects of aging itself or increasing 
susceptibility due to decreased resistance to infectious 
agents. Alternatively, it could reflect only secondary 
relationship with the disease.
Stress is reported to have some influence in precipita­
ting one form of diabetes. Claude Bernard's (1855) experi­
ments showed central nervous system lesions to produce 
diabetogenic effects. Interestingly, however, during World 
War I, despite stress of maximum degree, glycosuria was 
observed in only 2 of 40,000 American soldiers in a hospital 
centre in France. Similarly, the profound anxieties of 
civilian populations in Nazi-occupied territories during 
World War II were attended by substantial declines in the 
incidence of diabetes (Joslin et at, 1933).
Viral aetiology
One of the strongest suspected environmental components 
in the case of IDDM is virus infection. Viral suspects are 
many, but the main weakness to the hypothesis is the non­
isolation of the exact virus responsible. Some of the 
viruses implicated in diabetes include mumps virus (Craighead 
1975), Coxsackie B (Kibrick and Benirschke 1958), cytomegalo­
virus (Cappell and McFarlane 1947) and Rubella (Forrest et al3
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1971).
Animal models, particularly in mice, have shown that a 
picorna virus-like coxsackie B and FMDV can produce a diabetes 
mellitus-like syndrome (Craighead and McLane, 1968; Boucher 
and Notkins 1973) characterized by polydipsia and polyphagia.
Mechanisms are known by which virus infections may trigger 
the subsequent development of immunological events in the 
pancreas and other organs, progressing long after the acute 
infection (Nakhooda et at, 1977). The mechanism outlined by 
Freytag in 1974 shows the possibility that there can be a loss 
of immunologic tolerance so that the pancreatic islets are at 
risk to additional pancreatotropic viruses or to an ongoing 
smouldering, auto-immune process long after the initial 
infection subsides, leading to clinical diabetes mellitus 
(Rayfield and Seto 1978).
An added source of evidence for viral aetiology comes 
from the study by Gamble and Taylor (1969). A correlation 
between the variations in incidence of Coxsackie B4 infection 
and the number of new cases of insulin-dependent diabetes 
was observed. Among the insulin-dependent diabetics in the 
age range 0-19 years, the lowest incidence was in June, with 
an increase in early summer, to a broad peak about October. 
There was a progressive decline until the following
summer, supporting Adams1 observations in 1926 (Gamble and 
Taylor 1969). There was no significant seasonal variation 
in the number of cases with onset before 5 years, but in the 
age group 5-16 the rate of onset in winter was more than 
twice as common as in summer (Bloom et at, 1975). In data 
by age of onset and sex differences, only males aged 10-19
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years indicated a significant seasonal variation in inci­
dence (Gray et at, 1979). Evidence of diabetic cases 
(IDDM) as a consequence of mumps infection have been reported 
since the last century (Stang 1864; Harris 1899) such that a 
direct causal relationship was suggested. Since then evidence 
for mumps preceding diabetes has been accummulating (Menser 
et at, 1978; Craighead 1975).
In some patients with juvenile diabetes, especially 
early in the course of the disease, inflammatory cells have 
been observed in the islets of Langerhans (Gepts 1965).
The number of insulin-producing beta cells is decreased 
and exogenous insulin is generally required. These features 
and the seasonal variation in the incidence of IDDM give 
support to the hypothesis that viruses are one cause of 
IDDM (Craighead 1975; Notkins 1977; Rayfield and Seto 
1978).
Antibodies to coxsackie type B4 virus was more often 
found in diabetics than in controls in the same age group 
(Gamble et at, 1973). High titre of neutralizing anti­
bodies to a virus related to a diabetogenic variant derived 
from coxsackie B4, was obtained. Innoculations of mice 
with the human isolate produced hyperglycaemia, inflamma­
tory cells in islets of Langerhans and beta cell necrosis. 
Staining revealed viral antigens in beta cells, suggesting 
that this IDDM case was virus induced (Yoon et al, 1979).
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The age-based correlation is known only for the coxsackie 
B4 viral incidence. Significance of infection in this age 
group can be due to a number of possibilities as suggested by 
Gamble (1976). Most viruses have their highest incidence at 
the age of 5 to 6 years, the infectivity of the virus may be 
low with a peak at 12-15 years. There may be a long period 
of latency between infection and development of overt diabetes. 
A single pancrea-trophic infection may produce sub-diabetogenic 
damage and several such infections may be required to produce 
overt diabetes. Alternatively, the infection may depend upon 
the strain of the virus, the passage history of the virus and 
the genetic background of the host (Notkins 1977).
Genetic factors influencing prevalence of diabetes mellitus
Having considered above the influence of environmental 
factors on the prevalence of diabetes, it was noted in the 
sections under diet and obesity that there is not always a 
high correlation between increased diet and prevalence of 
diabetes (table 1.4). This suggested to some investigators 
(Zimmet 1979; Wise et als 1976 and Jackson 1970) , that 
environmental factors are not responsible alone for the 
manifestation of diabetes. Each ethnic group, therefore, 
may have a different predisposition to diabetes.
Two types of studies indicate the importance of this 
genetic/environmental interaction. The first is a compari­
son of prevalence rates among populations in the Pacific 
region - Melanesians, Polynesians and Micronesians, who 
have recently undergone a change in life-style to a western 
dietary and activity patterns. According to Zimmet and Kirk
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(1979) diabetes is rare in Melanesians, even when they become 
westernized but high diabetes prevalence rates have been 
reported in urbanized Polynesian and Micronesian populations. 
Diabetes is rare in Polynesians and Micronesian populations 
who have maintained a traditional life-style. They conclude, 
therefore, that the latter two groups may have a genetic 
susceptibility to diabetes which has been unmasked by the 
change from traditional to western life-style, in comparison 
with the former who, despite similar circumstances, show a low 
rate of diabetes.
The second type of study is concerned with the expression 
of diabetes in inbred strains of mice. Several distinct 
recessive genes have been detected in mice which lead to a 
diabetes-like syndrome in the homozygous animal. Coleman 
and Hummel (1973)have shown that two of these recessive 
genes, ob and db, result in an identical syndrome when incor­
porated into strains with the same genetic background.
However, the db gene on a BL/Ks background has a more severe 
diabetes-like condition with less pronounced obesity than 
the db gene on a BL/6 background. Thus the same genes may 
vary in their interaction with the environment when placed 
in a different general genetic background. Another valuable 
example is provided by the Japanese KK strain and New 
Zealand NZO strain of mice (Herberg and Coleman 1977).
Both the KK and NZO strains show moderate hyperglycaemia 
and hyperinsulinaemia when allowed to feed ad lib. However, 
if dietary calories are restricted the KK mouse returns to 
normal, but the NZO mouse never loses its hyperglycaemia and
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remains moderately obese. These two distinct forms of genetic 
susceptibility to diabetes in the mouse demonstrate clearly 
the way in which they may differ in the response to changes 
in dietary patterns. Such differences could well be true 
for various ethnic groups in man. The following section will 
briefly consider the different approaches used in the genetic 
investigations in an attempt to uncover the mechanism of 
inheritance for the disease manifestation.
Previous studies of genetics in diabetes mellitus
The earliest record which exists suggesting a genetic basis 
and difference in types of diabetes, comes from Sanskrit trans­
lations. It is reported, by early Hindu physicians, that 'a 
person suffering from congenital Prameha (diseased urine) owing 
to the fact that his birth from a father afflicted with 
Mahumeha (honey urine) cannot be cured for the primary defect 
in the seed'. The disease was due to two causes, one, 
attributable to use of injudicious diet and, the other, due 
to defect in the seeds of one's parent ^Sushruta Samhita , cited 
in Simpson 1976). Rondoletius (1574) also reported the disease 
to be hereditary in nature.
In more recent studies, pooled family data has been 
examined for the best fit to Mendel's ratios of dominant, 
recessive and X-linked inheritance and analyses have utilized 
sib/parent and proband/sib incidence data to calculate the 
genetic pattern.
Data on 1000 diabetic pedigrees led to the conclusions 
that mild mature onset diabetes was controlled by a dominant
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gene and early onset diabetes by a recessive gene, and that 
this was due to independent genes and these were not alleles, 
distinguishing between two types of diabetes (Cammidge 1928; 
1934).
Mendelian expectations were applied to the data of off­
spring of parents, neither one or both of whom were affected 
The proportions obtained approximated values for recessive 
inheritance (Pincus and White 1933; Steinberg and Wilder 
1952b) and further support for recessive inheritance came 
from Allan (1933) and Hanhart (1939). One study proposed 
X-linked inheritance (Penrose and Watson 1945) and received 
support (Barker et al3 1951) but was later altered to an 
autosomal recessive hypothesis.
From a study of 222 probands, without distinction 
into ages, however, a dominant gene with incomplete pene­
trance was proposed (Levit and Pessikova 1934; von Kries 
1953). These conclusions were based on the fact that the 
frequency of diabetes among the parents of probands was about 
equal to that among the sibs. Young diabetics were more 
likely to have diabetic relatives than the older onset types, 
and thus early onset type of diabetes was due to a homozygous 
condition and late onset type due to a heterozygous 
condition of the gene. Therefore, more sibs of the proband 
should be diabetic when onset is early, than when it is late 
and this frequency would not be influenced by the presence 
or absence of diabetes in a parent ( Harris 19'49; 1950) .
This was not, however, true for other cases (Thomson and
Watson 1952; Steinberg and Wilder 1952b).
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The attempt to estimate frequency of diabetes from the 
age of onset among parents was not successful due to the 
variable nature of diabetes and its mode of inheritance. 
Despite the lack of agreement on a clear-cut genetic basis 
for diabetes, family studies provide an empirical basis for 
estimating the risks of predisposition to the disease, 
particularly with respect to age of onset. Results from a 
study of 100 pairs of parent and child diabetics, showed 
that the average age at onset decreases 20 years per 
generation and that a child would rarely, if ever, become 
diabetic at a greater age than that when his parents became 
affected. This was known as 'anticipation' (Woodyatt and 
Spetz 1942). Since this was a statistical phenomenon and 
not a biological one, support was meagre (Steinberg and 
Wilder, 1950; 1952a).
Later methods were developed to improve estimation . 
such as K-ratio (Penrose 1953) used to estimate the 
familial/population frequencies of diabetes in the first 
degree relatives (Edwards 1960). In families of (IDDM) 
juvenile onset diabetes corrected for age by weighted 
means from the different age groups, familial incidence 
was much higher than incidence in the general population 
(Simpson 1962). Although, in the earlier data, the first 
degree relatives of a clinical subgroup (early onset, 
insulin dependent (IDDM))ketotic diabetes did not fit an 
autosomal single gene hypothesis, it was close to that 
expected for multifactorial inheritance. Based on the 
multifactorial inheritance of diabetes mellitus Falconer
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(1965) used a quantitative approach to study the genetics of 
diabetes. This involved the use of 'heritability of liabili­
ties'. The method developed, utilised data on the incidence 
of diseases to answer the question of relative importance 
of heredity and environment.
The degree of genetic determination which, in the study 
of human populations is called heritability, is the fraction 
of variation between individuals which causes some to be 
affected and others not. This was applied to obtain an 
estimate of correlation or regression coefficient.
'Liability' was referred to as a hypothetical attribute 
that gave a graded scale of the degree of affectedness or of 
normality. This term was preferred to 'susceptibility' 
because it expressed the susceptibility and whole combination 
of external circumstances which makes an individual more or 
less likely to develop the disease, whereas susceptibility 
implies the innate tendency as distinct from the external 
circumstances (Falconer 1965).
Despite the sophisticated statistical approach, the 
method was not satisfactory in determining the mode of 
inheritance for diabetes mellitus.
Analysis by complex segregation among families was used 
to discriminate between the hypotheses of two allele single­
locus inheritance and multifactorial inheritance. Three 
situations were considered using age of onset for the 
distinction into early onset, middle and late onset diabetes. 
In the IDDM (early onset diabetes) the heritability estimated 
from the multifactorial model was too high and indicated a
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major gene action (Goodman and Chung 1975) whereas, when the 
families were divided into IDDM and NIDDM types, based on 
insulin treatment in the proband, for IDDM no evidence for a 
major locus was obtained (Zavala et at, 1979). However, for 
NIDDM or middle and late onset cases, the data fit both a 
single locus model and a multifactorial model (Goodman and 
Chung 1975). In some cases of NIDDM, a suggestion of 
recessive inheritance was indicated and, in others, a strong 
evidence for a major locus was noted^avala et at, 1979).
Attempts to identify the 'diabetic genotype' were 
encouraged by use of glucose tolerance tests as an index 
(Fajans and Conn 1954; Taylor et at, 1967; Köbberling 
1969). For a single gene hypothesis one would expect bi­
modality in the distribution of blood sugar values among 
first degree relatives. However, a continuous distribution 
was obtained with no clear-cut division into normal and 
affected individuals (Thomson 1965). Since impaired 
glucose tolerance had a much higher frequency among the 
relatives of diabetics than in controls, an estimate was 
made to predict the risk of diabetes in children, based on 
age.
Different values were assumed by different authors.
In some cases it was estimated that 100% of children would 
have impaired glucose tolerance if they lived long enough 
(West 1960; Post 1962). In other cases it was assumed 
30% would be affected by the age of 85 years (Kahn et at, 
1969) and Tattersall and Fajans (1975) expected 60% of 
children to be affected by the age of 60. These estimates, 
however, do not contribute to the exact knowledge of the
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mode of inheritance. Family studies of GTT in different 
ethnic groups gave fits to various genetic hypotheses.
Among the Pima Indians of North America, where a high frequency 
of impaired glucose tolerance prevails, a bimodal distribution 
of glucose levels was obtained. Steinberg et (1970) using
a maximum likelihood method of classifying genotypes from a 
bimodal distribution showed a fit to recessive inheritance.
Data on Seminole Indians of Oklahoma, however, with a 
similar analysis gives fits to both recessive and dominant 
modes of inheritance. But the Seminole Indians in Florida 
did not fit either hypothesis (Elston et al3 1974).
Family data on GTT among Caucasians from the U.S.,
Britain and Japan (Neel et al3 1965; Thomson 1965;
Mimura et al> 1964) fit a multifactorial hypothesis. On 
the basis of a tolbutamide tolerance test on parents of 
early-onset patients, it was concluded that parents were 
heterozygous and children homozygous for a gene at the same 
locus (Braunsteiner et al3 1966), a conclusion similar to 
that of Harris (1950). Thus the results from GTT studies 
do not give a consistent explanation of the mode of 
inheritance.
Besides studies of families, population data can be 
used to distinguish whether a trait is autosomal dominant 
or recessive. This has been demonstrated in one such study 
by MacDonald (1980). The frequencies of IDDM are compared 
in two populations in which there has been a unidirectional 
influx of genes from the gene pool of one i.e. U.S. Caucasians 
into that of the other i.e. Black U.S. populations and this
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proportion of genes is estimated to be about 20% (Reed 1969).
Accordingly, if IDDM is inherited in a recessive manner 
then its frequency in the U.S. Black population should be 
l/25th of the frequency in Caucasians. However, from the 
results of Macdonald's (1980) studies it is seen that the 
ratio of the frequency of IDDM in U.S. Blacks to that in 
Caucasians is of the same order as the ratio of Caucasian 
genes in the Black population and this data gives a better 
fit to a dominant mode of inheritance than a recessive one.
In response to the above hypothesis another study 
(Rotter and Hodge, 1980) showed that the data can also be 
explained by a three allele model taking into account the 
heterogeneity within IDDM. More data may perhaps enable 
assessment of the mode(s) of inheritance within IDDM more 
clearly.
Other studies have utilized data on destruction, 
production and rate of release of insulin among patients.
One study showed that a high level of synalbumin, the 
insulin antagonist, among diabetics was dominantly inherited 
(Vallence Owen 1966). In another study, it was suggested 
that NIDDM patients were heterozygous for a gene for 
increased synalbumin and IDDM patients were homozygous for 
the same gene (Ehrlich and Martin 1966). These results were, 
however, not reproducible.
Twin studies
Evidence of familial aggregation of diabetes mellitus 
suggested the role of genetic factors in susceptibility for
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the disease. This was further recognized on the basis of 
studies on twins whereby a genetic component was demonstrated. 
Since twins may be monozygotic (MZ), sharing the same genetic 
components and environment, the influence of genetic factors 
will be stronger as compared to that of ordinary sibs within 
a family. Dizygotic (DZ) twins, on the other hand, share a 
similar environment but not all the genetic components.
Early work on diabetic twins by May (1914), Curtis 
(1929) and Watson (1934) demonstrated the importance of 
the genetic component in diabetes through a difference in 
the concordance of diabetes between monozygotic and 
dizygotic twins. The concordance rate in monozygotic twins 
was greater than in the dizygotic twins. Then Bergh (1938) 
reported on 46 MZ and 87 DZ twins, of which 36 MZ and 50 DZ 
could be studied clinically and also with an oral glucose 
tolerance test. Clinical concordance was observed in 17/36 
MZ and 9/50 DZ twin pairs. Concordance after glucose load 
was found in 30/36 MZ and 18/50 DZ twin pairs. No discord­
ance was seen after glucose load in MZ twins aged over 43 
years. This was interpreted as being due to a complete 
manifestation of the hereditary trait, i.e. 'absolute 
heredity' in older MZ twins. The clinical concordance 
rates in diabetic twins given by various authors is
presented in Table 1.5.
24
Table 1.5
Clinical concordance rates for diabetic twins.
(taken from Langenbeck and Jörgensen 1976)
Authors Monozygotic T. Dizygotic T.
Then Bergh 1938 17/36 9/50
Lemser 1938 9/12 3/14
White and Pincus 1946 16/33 2/63
Harvald and Hauge 1963 36/76 22/238
Gottlieb and Root 1968 9/30 2/60
Mean 87/187 38/425
= 46.5% = 8.9%
In juvenile IDDM familial incidence of the disease is 
higher among concordant MZ twins than in discordant twins 
(Tattersall and Pyke 1972) confirming Luxenberger's expec­
tation (1935). This implies a predominantly exogenous cause 
among the discordant MZ twin pairs.
The question raised by discordance of twins, in the IDDM 
cases, may be related to the time between the diagnosis of 
the first twin and the development of diabetes in the other 
twin. Most concordant twins develop diabetes within a time 
span of 3-10 years of each other. However, in these studies 
the discordant pairs have remained so even beyond 32 years. 
The possibility of the discordant twins becoming con­
cordant over a period of longer time (Rosenthal et als 
1976) did not receive support (Pyke et at3 1976). Therefore, 
it was concluded that early onset twin pairs will remain 
discordant, perhaps indefinitely, and the unaffected 
identical twin is not always destined to become a diabetic
(Pyke 1977).
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The IDDM twins were investigated for HLA antigens (to be 
discussed more fully in the next section) and the relative 
risk for HLA-B 8 positive individuals was 1.5, whereas, for 
HLA Bwl5 = 3.5. Further analysis revealed an increase of 
Bwl5 antigens in both concordant and discordant twins 
whereas B8 was increased only in concordant pairs. No HLA 
association was seen among the NIDDM twin pairs (Nelson et aZ3 
1975).
One study of identical triplets showed triplet A 
became diabetic at age 13; triplet B, 8 years later, while 
C remained non-diabetic, showing normal glucose tolerance 
tests 11 years later. HLA-B15 was present in all three.
The two diabetic triplets showed capillary basement membrane 
thickening but this was not true for the normal one (Ganda 
et al3 1977) .
It can thus be concluded that the twin studies have 
been important in indicating the different genetic contribution 
to the susceptibility to the two major types of diabetes.
From the above discussion it is noted that concordance rates 
for IDDM among identical twins is approximately 50%, even 
after a sufficient time lapse between the onset and 
diagnosis of the disease in the co-twin of the proband.
This suggests that, for IDDM, environmental factors are very 
important in its aetiology, although genetic factors are 
also involved. The possible environmental factors may be 
biochemical in nature, such as the insulin response to 
glucose infusion, a trait which shows discordance in MZ 
twins (Cerasi and Luft 1967; Pyke and Taylor 1967;
Gottlieb and Root 1968) or due to infection by virus
26
(Gamble and Taylor 1969; Notkins 1977).
By contrast to the results in IDDM, twin data for NIDDM 
suggests a very strong genetic component. This is evidenced 
by Then Bergh's (1938) study, whereby identical twins above 
the age of 43 are 100% concordant for abnormal glucose metab­
olism. This phenomenon was further supported by another study 
of Pyke (1977) where in his large series, over the age of 45 
years all twins are concordant for NIDDM, although he points 
out that other workers have found a few discordant twins with 
NIDDM.
These observations do not deviate significantly from 
that expected under recessive inheritance hypothesis.
According to Steinberg (1959) the individuals with a genetic 
susceptibility (which he determined on the basis of affected 
relatives present in a pedigree) will eventually become 
diabetic in their life span. Although Steinberg does not 
clearly state the type of diabetes, this mechanism could 
apply for the NIDDM type of diabetes due to a long natural 
history of the disease. However, careful studies are still 
necessary to examine whether the hypothesis can be accepted 
or rejected.
Present status of genetic markers in diabetes mellitus
This section will be discussed in two parts - A and B. 
Part A will deal briefly with HLA markers in diabetes
mellitus and Part B with other,non-HLA markers.
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Part A
HLÄ associations with diabetes mellitus
The Major Histocompatibility Complex in man consists of 
at least 4 loci (A, B, C and D). The A, B and C loci were 
detected first using serological methods. The fourth locus,
D, was designated initially on the basis of reactions in 
mixed leucocyte cultures (MLC). More recently, however, D 
locus antigens have been detected by serological tests against 
B lymphocytes. The locus controlling these antigens has 
been termed DR and it is very close to or identical with the 
D locus controlling MLC reactions.
From the analogous studies in mice and monkeys, the 
MHC system has been found to control specific immune 
responsiveness to certain antigens (Benacerraf 1974;
McDevitt and Benacerraf 1969). The fact that nearly all 
associations so far observed between diseases and HLA are 
stronger with B or D series antigens than with A and C 
series antigens has been taken as evidence in favour of 
the existence of immune response (Ir) genes located between 
the B and D loci.
In an early study no HLA associations with IDDM 
were observed by Finkelstein et at. (1972). However, in a 
sample of unrelated Caucasian patients a slight increase 
in the B locus antigen, Bwl5 was noted by Singal and 
Blajchman (1973). Following this, reports from two 
independent sources, almost simultaneously, demonstrated 
significant association of IDDM with HLA-B8 and Bwl5 (Nerup 
et at, 1974; Cudworth and Woodrow 1974). Later a strong
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association of the HLA-D locus antigen Dw3 was noted (Thomsen 
et at3 1975). A brief review of association with HLA antigens 
will be considered, details of which are found in reviews by 
Cudworth (1978) and those in Creutzfeldt et at3 (1976).
HLA-A locus antigens in IDDM
The frequency of HLA-A antigens in patients below 30 
years of age indicate relative risks (RR) ranging from 1.61 
for Al to 0.47 for A32 in Caucasians (table 1.6). This 
increase is secondary to the strong A1B8 linkage disequilib­
rium (LD). This is a phenomenon whereby, despite crossing 
over between the various loci of HLA, some HLA genes tend to 
occur together significantly more frequently in the same 
haplotype than would be expected under the assumption of 
equilibrium (Svejgaard et al3 1975). Similarly for A2, the 
increase is due to LD with B15.
HLA All remains significantly decreased over all popula­
tions showing no heterogeneity between the results (Cudworth 
1978; Nerup et al3 1977). Reports from other sources 
(Svejgaard 1974; Seignalet et al3 1975) also showed a 
similar decrease of HLA All.
HLA-B locus antigens in IDDM
Table 1.7 shows the results obtained from several sources. 
In each case, an increase in the RR values of antigens B8, B15 
and B18, and a decrease of B7, is noted (Cudworth and Woodrow 
1976; Nerup et al3 1977; Ludvigsson et at3 1977).
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Table 1.6
HLA--A locus antigens in IDDM
HLA-A Cudworth 1978
Nerup et al. 
1977
antigens RR RR
Al 1.61 1.32
A2 1.38 1.15
All 0.31 0.56
A32 0.47 0.51
Table 1.7
HLA-B locus antigens: Relative risk
values given by different studies
HLA
Cudworth 
-B Cudworth 
Woodrow
1978; 
& + 
1977
Nerup
et al.
(1977)
Svejgaard 
& Ryder 
(1977)
Ludvigsson 
et al 
(1977)
B8 2.63 2.42 3.1 2.37
B15 1.85 1.89 2.1 2.03
B18 2.26 1.65 - -
B40 1.30 1.32 - 1.60
B7 0.40 0.56 - 0.46
+B8 B15 5.4 - 9.8 -
''B8 B40 6.87 - - -
1B8 B18 2.52
30
In the Copenhagen data, B18 has a lower RR value of 
1.65 compared to the Liverpool data of 2.26. HLA phenotype 
combinations have provided interesting high risk values for 
B8 + B15; B8 + Bw40 and B8 + B18 with 5.40, 6.87 and 2.52 
respectively. Svejgaard and Ryder (1977) using combined 
data showed a RR = 9.8 for B8 + Bl5.
HLA-C locus antigens in IDDM
A significant increase in the frequency of the Cw3 
antigen has been observed. The relative risks for IDDM 
conferred on individuals with this antigen in two studies 
is 2.2 and 2.3 (Ludwig et at, 1977 ; Solow et at, 1977).
HLA-D locus specificities in IDDM
A stronger association with the HLA-D locus specifi­
cities than with the B locus antigens has been demonstra­
ted by several investigators and this led to the suggestion 
that the 'diabetogenic' gene(s) may be closer to the HLA-D 
locus than.to the A, B or C loci.
The relative risks for the two main D and DR 
specificities, from studies on Europeans, are given in 
table 1.8a and b. It will be noted that the RR values 
for Dw3 and Dw4 are higher than the corresponding values 
given by Svejgaard et at, (1977) or by Platz et at, (1977) 
particularly for Dw3. Similar high RR values for the 
serologically determined antigens, DRw3 and DRW4 have been 
reported by many groups of workers (Jeannet et at, 1977; 
Svejgaard et at, 1980; Deschamps et at, 1979;
Serjeantson et at, 1980) and a strong negative association
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Table 1.8a
Relative risk values for HLA-D and DR locus 
specificities and IDDM given by 
different authors
HLA-D
Specificities
Thomsen 
et al. 
(1975)
Svejgaard 
et al. 
(1977)
Platz 
et al. 
(1977)
Dw3 6.4 3.8 3.7
Dw4 3.7 3.5 4.9
Dw3/Dw4 - - 9.4
Table 1.8b
HLA-DR
Specificities
Svejgaard 
et al. 
(1980)
Jeannet 
et al. 
(1977)
Deschamps 
et al. 
(1979)
Serjeantson 
et al. 
(1980)
DRw3 3.7 8.07 4.0 -
DRw4 6.7 3.12 6.0 -
DRw3/DRw4 - - 46.6 37.3
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(with relative risk values of less than one) with DRw2 
in IDDM (Platz et al3 1977; Mayr et al3 1977).
HLA associations with NIDDM and late onset insulin dependent 
diabetes
Among Caucasian non-insulin dependent diabetes
mellitus (NIDDM) no disturbance in the frequencies of HLA 
antigens has been observed (Cudworth and Woodrow 1976;
Nerup ct <2^  1974). Recently, however, two studies have 
disclosed an HLA antigen association with NIDDM among non- 
Caucasian populations.
There is a significant increase in frequency of Bw35 
and A2 among the IDDM and NIDDM patients of some South 
African Black populations (Xhosa) unlike the South African 
white population, relative risk being 2.92 and 2.34 
respectively among NIDDM patients (Briggs et als 1980).
For the Fiji Indian population, at the HLA-B locus there 
is a significant increase in Bw61, RR = 3.65 (Serjeantson 
et al3 1980) .
Some investigations have attempted to distinguish 
another type of insulin dependent diabetes which they 
call late-onset IDDM. Singal and Blajchman (1973) and 
Cathelineau et al3 (1975) studied the HLA types in insulin 
dependent patients in the age range 31-71 years and found 
an increased relative risk for HLA B8 and Bwl5 (2.19 and 
2.25 respectively) and a decreased risk for HLA B7 (0.49).
No increase in relative risk was found for HLA B18 or for
any of the A series antigens.
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Ethnie variation in HLA association with IDDM populations
HLA typing among Europeans and North American Caucasians 
have shown striking increase in A1, B8, B15, B18, Cw3, Dw3 
and Dw4 antigens among the IDDM patients. In contrast, 
other antigens HLA Aw32, B5, B7 and Bw35 and particularly 
Dw2 are found less commonly in IDDM patients. Studies of 
the HLA system in non-Caucasian populations have revealed 
a variety of associations of HLA-B and D locus antigens 
among IDDM patients.
Among the South African Negro populations, mainly Zulus 
in Durban, an increased frequency of B8 and B14 are noted 
(table 1.9). HLA-B7, which is considered a protective 
antigen among Caucasians, is increased in this population.
However, Bw42 detected only in the Black populations, is 
seen to be lower (Hammond et dls 1980). In another study 
of South African IDDM patients (Hammond and Asmal 1980)
Indians who originated in south India showed a positive 
association with B8 but not with B15, whilst Indians who 
originated in north India showed an increase of Bw52.
Among Chinese a strong association of DRw3 and DRw4 
was noted in IDDM whereas for the B locus antigens there 
was an increase only of B17 (Maeda et at. 1980). Previous results 
among the Japanese IDDM showed an increase of B12 (Nakao et at3 
1977). Later, however, a split of Bw22-J (Bw54) was also 
shown to be increased (Okimoto et al3 1978).
Among Mexican American and Black American IDDM 
similarity with Caucasians is seen in the increased
frequency of DRw3 and DRw4, but there is a
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complete absence of DRw2 in both populations (Zeidler ct al3 
1980; Rodney et ai 3 1979). As well, DRw3 and DRw4 were 
increased in USA Black patients: RR 16.7 and 3.9 respectively
(Duquesnoy et al3 1979).
That the HLA antigens are not themselves the susceptibility 
genes can be seen from the ethnic distribution of the HLA assoc­
iations with IDDM, which suggests that susceptibility alleles 
are in linkage disequilibrium with different HLA alleles in 
different ethnic groups.
Genetic interpretation of the HLA studies in IDDM and NIDDM
Two lines of explanation emerge from the increased 
relative risk values among IDDM patients in Caucasians. a. 
that there is one disease susceptibility gene for IDDM which 
is in varying disequilibrium with the whole of the HLA system 
(Cudworth and Woodrow, 1976; Barbosa et al3 1977) or in link­
age disequilibrium with two or more alleles or HLA (Suciu- 
Foca et at3 1977) and this gene may be recessive with 50% 
penetrance (Rubinstein et at3 1977). b. alternatively, there 
are two susceptibility alleles within the HLA complex.
Supporting evidence comes from the additive relative risk 
observed in subjects who are both HLA B8 and B15 positive.
Since B8 is in linkage disequilibrium with DRw3 and Bwl5 
with DRw4, association of D locus antigens was observed and, 
as noted above, RR's are higher for D than for B specifici­
ties. A high risk for heterozygotes DRw3/DRw4 (table 1.8b) 
has been reported among Australian IDDM patients: RR = 37.3
(Serjeantson et al3 1980) similar to 46.6 in a French popula­
tion (Deschamps et al, 1979). More detailed study showed Dw4 
having an increased risk before age 16, whereas Dw3 increased 
the risk at all ages supporting the assumption that Dw3 and
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Dw4 act by two different mechanisms (Svejgaard et als 
1978). If a single recessive gene is in linkage disequilibrium 
with all other antigens, B8, B15, B18, Dw3 and Dw4, then the 
relative risk for B8/B15, Dw3/Dw4 heterozygotes should be 
intermediate to the IDDM risks for B8 or B15 and Dw3 or Dw4 
alone. But the heterozygotes for B8/Bwl5 and Dw3/Dw4 show 
a greater relative risk than that of either the B8 or B15 
and Dw3 or Dw4 by themselves (see tables 1.7 and 1.8b).
These increased relative risks form the basis for the 
hypothesis that two susceptibility alleles are required 
for clinical IDDM in some cases, refuting the concept of a 
single autosomal recessive susceptibility allele.
The susceptibility could occur at different HLA-linked 
loci or at the same locus. If they are at the same locus, 
inheritance being recessive, then the increased risk of 
heterozygotes B8/Bwl5 may "be caused by an increased risk 
for individuals heterozygous for two different 'disease' 
predisposing alleles compared to those homozygous for one 
disease albele" (Thomson 1980). Thomson goes on to suggest that 
a better explanation i n keeping with the observed values 
of the disease incidence in the population is given by assuming 
that there is one susceptibility allele within the HLA 
complex and another at a non-HLA locus, since data indicate 
the possible involvement of more than one locus in predis­
posing individuals to the disease. The latter allele 
exhibits no linkage disequilibrium with the HLA disease 
locus but is relevant in determining an individual's disease 
susceptibility status (Thomson 1980).
The evidence for heterogeneity within IDDM is based on 
differential immunologic correlations with different HLA
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phenotypes. Using only the information on B8 and B15 but not 
B18 it is hypothesized (Rotter and Rimoin 1978) that there 
are three forms of the disease. B8 is associated with an 
autoimmune form (Form 1). B15 is associated with the insulin
antibody responder form (Form 2) and a compound form (Form 3) 
with both B8 and B15. Hodge et at, (1980) have outlined the 
way in which the three forms could fit with the clinical 
types of IDDM as outlined in table 1.9.
Table 1.9
Forms of IDDM resulting from different allelic 
combinations at postulated disease locus (DS) (from
Hodge et dl3 1980)
DS genotypes Diseaseform
Associated
with Characteristics
sisi or Sis 1 B8 Autoimmunity to the pancreas
S2S2 or S2S 2 B15 Antibody response to exogenous insulin
s s 1 2 3 Both Both of above
ss No disease - -
Mechanisms of action of HLA linked genes
If the immune response genes do exist close to the human
HLA locus then linkage disequilibrium may account for specific 
HLA genes or combinations of them accompanying putative genes 
responsible for susceptibility to the disease.
Mechanisms are still speculative as to the way in which 
susceptibility in individuals is conferred. The sources of
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evidence suggest two possibilities in the pathogenesis of 
IDDM. Circulating antibodies (autoantibodies) lead to a 
suspected autoimmune disease process and, based on the 
presence of neutralizing antibodies, a viral aetiology is 
favoured.
In the first case evidence shows that organ-specific anti- 
pancreatic autoimmunity is a characteristic feature of 
IDDM (Nerup et al3 1977). Insulitis- that is a lympho­
cytic infiltration of the islets of Langerhans, together 
with a selective destruction of beta cells is the typical 
pathological finding in IDDM patients autopsied within the 
first year (Gepts 1965; Egeberg et at, 1976). Circulating 
islet cell antibodies (ICA)are present in approximately 85% 
of newly diagnosed diabetic children (Lendrum et at, 1976), 
this feature is characteristic and may aid in distinguishing 
two types of diabetes. Doniach and Bottazzo (1977) have 
suggested that, in Type 1A, ICA's are present for a 
relatively short period whilst, in Type IB, ICA's are 
persistent. The latter type is the less common form. The 
increased duration of IDDM is associated with persistence 
of islet cell antibodies and the relative risk of having 
persistent ICA is 2.4 and 3.3 in HLA B8 and B40 patients 
respectively, increasing in the combined form B8/B40 to 7.2 
(Cudworth 1978). In patients with B8/B18, B8/B15 and 
persistent ICA, relative risk is 4.1 and 2.6. Therefore, 
a possible pathogenetic mechanism is that the inheritance 
of 'high risk' alleles produces an appropriate or abnormal 
immune response to environmental factors (e.g. pancreato-
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tropic viruses) compared with subjects who possess genes 
which may exert a 'protective' effect (e.g. linked with HLA 
B7) by reducing or modulating the immune response to such 
agents (Cudworth 1978).
In the second case, however, as reviewed before, 
evidence of viral infection was seen from the temporal 
association between outbreaks of viral diseases and onset 
of IDDM. Further support is provided by the high titres 
of neutralizing antibodies to Coxsackie B4 virus (Gamble 
1976) with increased frequency. Similarly a high prevalence 
of IDDM has been shown among patients with congenital 
rubella, predominantly in HLA-B8 positive individuals 
(Menser et al> 1974). However, analysis of mean log anti­
body titres in relation to HLA phenotypes demonstrated 
a significant increase in Coxsackie B4 antibody titres 
in subjects positive for B8/B15 as compared to those 
positive for either or for B7, and five of the six B8/B15 
positive subjects who developed diabetes in 1976 winter 
peaks had high neutralizing antibody titres to Coxsackie 
B4 (Cudworth 1978). It is possible that the HLA antigens 
may act as receptor sites for viral attachment (Svejgaard 
and Ryder 1977).
Part B
Association of diabetes mellitus with ABO and other blood 
groups
The suggestion that the ABO blood groups discovered by 
L an d s te in e r in 1900, might be involved in the aetiology of a 
disease, was made as early as 1905 by Dienst (Mourant et at,
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1978).
For diabetes there is a highly significant overall 
association with blood group A compared with group 0. The 
total data show a combined relative A/0 incidence of 1.07 
(Mourant et al3 1978). The considerable excess of group A, 
particularly among men, was significant. This was true for 
diabetics of "insulin sensitive type" (McConnell et al3 
1956; Roberts 1957). An increase of blood group A was also 
noted in Estonian diabetic persons (Ksenofontov 1972). Those 
cases with onset below 10 years of age show an A/0 ratio 
below unity, which rises throughout life, such that all 
adult ages show an excess of group A (Andersen and Lauritzen 
1960).
In another study by Williams and Cartwright (1979) 
among the non-insulin dependent diabetics there is an increased 
frequency of blood group Al (and Al + A2), when compared with 
controls. This difference is particularly marked in male 
diabetics of the Durham, U.K. population.
Since the occurrence and severity of infections are 
largely the results of the immunological response of the 
body to invading micro-organisms it would not be expected 
if the ABO blood group of an individual were found to be 
one of the factors determining such a response since A and 
B blood group substances are commonly found as components 
of the bacterial cell surface (Mourant 1973). Thus the 
difference in the frequency of the ABO groups in the patient 
population, perhaps is due to surface differences in the 
membrane of the red cells (Dintenfass 1974), or due to
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differences in the receptor number and size (Roth <xl 
1979).
In addition to differences in the ABO blood group 
frequencies Vague et at> (1978) have reported an increased 
frequency of Lewis-negative blood groups among diabetics in 
France. However, no association with the Lewis blood groups 
was found among Durham, U.K. diabetics (Williams and Cartwright 
1979). Chakravartti (1967), on the other hand, in a review of 
blood groups and disease, reported that Lewis-positives were 
increased in diabetics. All these conflicting results 
suggest the need for further study of the Lewis blood group 
system in relation to susceptibility to diabetes.
The reported associations of diabetes with various blood 
groups opens the possibility of susceptibility alleles being 
located on some chromosome(s) other than chromosome 6, 
particularly in the case of NIDDM. As note above, it has 
been suggested that IDDM and NIDDM may be genetically 
related (MacDonald, 1974). To explore this possibility 
further Thomson (1980) suggests that there are two disease 
loci, D^ with alleles D^ and d^ and D^ with alleles D^ and 
d^. Susceptibility to NIDDM is determined either solely by 
D^ (one locus) or by D^ and another locus plus environmental 
factors, while susceptibility to IDDM is determined by at 
least two loci, D^  and D^ plus environmental factors.
It is further assumed that D^ and HLA are closely linked 
loci while D^ is unlinked to either. The susceptibility to 
NIDDM is then conferred by the D^ locus (which in the above 
instance may be the Lewis-negative blood group) plus
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environmental factors.
Chlorpropamide alcohol flushing (CPAF) and diabetes 
mellitus
CPAF is defined as the occurrence of a facial flush 
among some individuals after the challenge of 250 mg 
chlorpropamide followed by 20 mis of dry sherry (Leslie 
and Pyke 1978).
In NIDDM patients in London with a family background 
of diabetes, 81% were positive for the CPAF test, whereas 
only 41% of those without first degree affected family members 
were CPAF positive. This compares with 1% and 9% in the IDDM 
and control series. This suggested to one group of workers 
(Leslie and Pyke 1978) a strong association with NIDDM 
patients and this was particularly true for the Mason type 
diabetes, which shows a dominant pattern of inheritance.
The relative risk values for CPAF positives given by Leslie 
and Pyke (1978) are 9 and 38 respectively for individuals 
without and with a family history of diabetes. On the 
other hand, in a study of German NIDDM families, no differ­
ence in the frequency of the chlorpropamide alcohol 
flushing was found between those with and without a family 
history of diabetes (Köbberling et al3 1980). The conflict 
in results from the two sources emphasizes the need for 
further investigations in order to determine the validity
of the CPAF associations.
42
Scope of the present investigation
Genetic marker studies in relation to disease can use two 
approaches. The first is that of disease association studies, 
where the association of the disease with a marker may be 
statistical in nature and may have an indirect or direct role 
in the disease process or, alternatively, the subpopulation 
under study shows an increased frequency of particular 
alleles at the marker locus, but without a causal relation­
ship.
The second approach is the use of linkage disequilibrium. 
The close location of genes together on the same chromosome, 
which travel together without segregation can be used to 
detect marker gene(s). In such studies the detection of a 
marker gene linked to genes predisposing to the development 
of diabetes, clearly could be of great significance in 
identifying persons at risk.
The present investigation has focussed on both these 
approaches. In the first approach, data for genetic 
markers has been collected for NIDDM and control populations 
from several different ethnic groups in Australia and the 
Western Pacific. Since the presence of a 'diabetic genotype' 
has been suggested above it may be expected that there is 
a significant genetic component in the environmental- 
genetic interaction contributing to the susceptibility to 
NIDDM and therefore different patterns of genetic markers 
may occur in some ethnic groups as compared to others.
The second approach, utilizing the concept of linkage 
disequilibrium, which is known to occur for the HLA region
on the short arm of chromosome 6, focusses especially on the 
polymorphic systems such as properdin factor B(Bf), comple­
ment factor C' 2 of the complement system and the red cell
enzyme system Glyoxalase (GLO).
44
Chapter 2
POPULATIONS STUDIED AND METHODS
Sources of samples
Samples from five populations were studied comprising 
affected and non-affected individuals. They were provided 
from the sources, outlined below:
Australia
Melbourne 
Western Australia
Pacific Islands
W. Samoa 
Nauru
India New Delhi
Amerindian Pima
(Arizona)
Australia
In Western Australia blood samples were collected as part 
of a state-wide survey of diabetes sponsored by the Lions Save 
Sight Foundation and Diabetes Research Foundation. Samples 
from Kalgoorlie and Geraldton were made available by Dr T. 
Welborn.
Melbourne
Samples of patients attending Royal Southern Memorial 
Hospital, were supplied by Professor P. Zimmet, while those
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attending Royal Children's Hospital were supplied by Dr J. 
Court. In both places diagnosis was made on the basis of 
clinical criteria supplemented by biochemical information 
on the level of glucose in the blood, insulin response and 
presence of ketones, among other parameters. The patients 
from the Royal Children's Hospital were all dependent on 
insulin for maintenance and were classified as IDDM.
Patients from RSMH were divided into two categories. Those 
below age 40 at onset of the disease and receiving insulin 
were classed as IDDM. Those 40 or older at age of onset 
were classed as NIDDM. Some of these were receiving 
insulin to maintain them in balance and these are considered 
separately in the analysis of the data.
Western Australia
Patients examined as part of the diabetes survey were 
diagnosed by local medical practitioners as diabetic on 
clinical signs supplemented with abnormal glucose levels. 
They were divided into categories of IDDM and NIDDM on the 
basis of age of onset using the criteria outlined for the 
Melbourne patients. Insulin status also was noted.
Pacific Islands (Western Samoa and Nauru)
Samples collected from Western Samoans and Nauruans 
were from an epidemiologic survey being carried out in 
Pacific Islanders under the direction of Professor Zimmet. 
Diagnosis was done on the basis of 2 hour oral glucose
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tolerance test with a glucose load of 75 gm, values above 
160 mg glucose/100 ml plasma were considered to be diabetic. 
Samples were screened from urban and rural areas of W. Samoa. 
All the patients were described as non-insulin dependent 
diabetics and treatment was by diet control.
New Delhi
Patients attending the diabetic clinic at the All India 
Institute of Medical Research, were diagnosed on the clinical 
criteria. They were classed into categories similar to the 
Melbourne patients and the samples were kindly supplied by 
Professor M.M.S. Ahuja.
Pima Indians
Samples were provided by Dr Peter Bennett from his continu­
ing studies of diabetes among Pima Indians living in Arizona. 
They have been classified as diabetic on the basis of a blood 
glucose level above 200 mg per cent 2 hours after a 75 mg oral 
glucose load. Some hyperglycaemic patients were receiving oral 
anti-diabetic drugs, others were receiving insulin.
Laboratory Methods 
Handling and transport of samples
The red cell and plasma samples were sent to the laboratory
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after the separation of the whole blood. They were packed in 
dry ice and transported to the laboratory in Canberra. The 
samples arrived frozen and, in the laboratory, care was taken 
to thaw the frozen samples for the day's use and store the 
unused samples in liquid nitrogen.
Laboratory techniques
Discrimination of phenotypes in the haptoglobin, transferrin 
and ceruloplasmin serum protein systems and all the red cell 
enzyme systems was made using horizontal starch gel electrophor­
esis using the technique based on that described by Smithies 
(1955).
Hydrolyzed starch (Connaught Medical Research Laboratories, 
Toronto, Canada) was used at approximately 12 per cent (w/v) 
concentration, modified according to the batch of starch 
employed. Electrophoresis was carried out between metal cooling 
plates at approximately 10°c at voltages and times as specificied 
for the individual system. Banding patterns were developed on 
the surface of the sliced gels after electrophoresis.
Fifteen polymorphic systems were studied for every population. 
Serum Protein systems
1 Haptoglobin Hp
ii Transferrin Tf
iii Ceruloplasmin Cp
iv Group Specific Protein Gc
V Properdin factor B Bf
vi Complement factor Cv2
Red cell enzyme systems
vii Esterase-D EsT-D
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viii Glyoxalase I GL01
ix Acid Phosphatase PHs
X Adenylate kinase AK
xi Adenosine deaminase ADA
xii Phosphoglucomutase I PGM^
xiii Phosphoglucomutase II p g m2
xiv Glutamic pyruvic transaminase GPT
XV 6-Phosphogluconate dehydrogenase 6PGD
Serum protein systems
For haptoglobin, transferrin and ceruloplasmin, Ashton 
and Bradon (1961) discontinuous buffer system was used. The 
plasma samples, separated from the red cells were thawed and 
inserted into the gels on strips of Whatman No. 3 filter paper.
Electrode buffer
Solution A gm/1
Lithium hydroxide 1.2 gm
Boric acid 11.8
Gel buffer
Solution B
Citric acid 1.6 gm
Tris 6.2 gm
pH = 8.0
The solution B was diluted 9B : 1A for the preparation of gels. 
Voltage reading on the meter was 400 v., the gels were electro- 
phoresed for 4 hours.
Staining
Gels were sliced for staining of ceruloplasmin and hapto­
globin on one half using the following reagents;2mg.0-dianisidine 
dissolved in 1 litre distilled water with 5 ml acetic acid. It 
was mixed and filtered. The gels were incubated at 36°C solution 
for h hour; faint orange bands of ceruloplasmin appear. 1 ml
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per gel of hydrogen peroxide was then added and the dark green 
bands of Hp-Hb complex appear below the ceruloplasmin zone, 
after a further 10-15 minutes. On the other half of the same 
gel, transferrin was visualized using amido black stain: 2 gms
of the dye dissolved in a methanol-water-acetic acid solution 
in proportions 50-50-10 respectively. Staining requires only 
a few minutes, after which the gel is decolorized in the same 
solution without the dye. The transferrin band is clearly 
recognized behind the free haemoglobin protein band.
Properdin factor B and Group Specific Component
Immunoelectrophoretic methods were used for identifying 
Properdin factor B and the Group Specific Component (Gc). This 
involves the initial electrophoretic separation of the serum 
protein components followed by immunofixation against anti­
human properdin factor B serum and anti-human Gc globulin 
serum. These were obtained from Atlantic Antibodies, U.S.A.: 
Anti: GBG Grade N (goat) and Anti: Gc globulin Grade SP (goat).
Electrophoresis was carried out using Agarose gel as a 
medium (cone 1%) on glass plates 6 x 6  3/4-". Buffer system 
used for Gc and Bf was that given by Johnson et aZ (1975).
The quantity of plasma used is 2-3 yls per sample.
Stock buffer gm/litre
Barbitone (barbituric acid) 2.5
dissolved in hot water
Sodium Barbital 15.4
Calcium lactate 0.616
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The gel buffer was 2 parts stock buffer and 1 part distilled 
water- Stock buffer was used in the electrode vessels. A 
voltage gradient of 13 volts/cm and electrophoresis for 1 to 
1.5 hours was conducted for Gc, after which anti-Gc sera was 
layered and incubated for 1 hour at room temperature. Staining 
was carried out by using the coomassie blue dye, dissolved in 
4.5:1.4.5 proportion of methanol-acetic acid-water. The quantity 
of antisera was determined at 0.2 mis diluted with 0.8 mis 
saline per gel. The same procedure was followed for Bf, the 
difference being:
a) electrophoresis for longer time - 4 hours, voltage
gradient (13 v/cm).
b) use of anti-Bf antisera.
c) concentration of antisera 0.2 ml diluted in 1.5 ml
saline per gel.
Complement component C'2
The methods widely used for the separation of complement 
components have been by gel electrophoresis, usually in agarose 
and isoelectrofocussing in polyacrylamide gels. In the case of 
C'2 complement component isoelectric focussing technique was 
used, as described by Lachmann and Hobart (1978). The solutions 
used were:
Acrylamide solution gm/500 mis
Acrylamide
nn' methylenebis acrylamide 
Taurin (dissolved in distilled water)
33.5
0.9
16.68
To the above is added: 
Ampholyte 1.5 mls/gel (Pharmacia) 
pH range 4-6.5
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Temed 15 yl
Riboflavin 7 mis
The mixture is degassed and poured into a 1 mm thick glass mould 
and left under a fluorescent tube light source until polymeriza­
tion has taken place.
Serum samples 20 yl, in good condition are applied on 
Whatman 3 mm paper strips placed 1" from one end of the gel.
Isoelectrofocussing
This is done by placing the loaded gels with samples, face 
downwards across the carbon-rod electrodes of focussing box with 
the gel in continuous contact with the electrode and the samples 
to the inside of the anode. Voltage is set to a maximum of 
1000 v. with a current less than 10 mA/gel, and electrophoresis 
carried out for 18 hours, overnight. The bands of C^2 complement 
activity were revealed using a haemolytic assay in an agarose 
overlay. Before the application of gels overlay, the gels are
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soaked in an iodine solution for 30 minutes at room temperature, 
made as follows:
Stock solution gm/100 mis
Samples
Iodine 0.25
Potassium iodide 8.3
dissolved in phosphate 
Buffer 0.5 M 40 mis, made up to
100 mis with distilled water.
pH = 6.0
Iodine solution
Iodine stock solution 25 mis
NaCl 4.5 gm made up to 500
mis with distilled water
The gels are later soaked in complement fixation diluent (CFD) 
tablets from Oxoid Ltd., London, for 30 minutes at room tempera­
ture. Perspex strips are placed around the area of the gel where 
bands are expected and are sealed in position with agarose. The 
overlay for the staining procedure was made using the following 
reagents:
Phosphate buffered saline (PBS)
2% by volume of 0.2M phosphate buffer (pH 7.2) in 0.85% NaCl. 
EDTA-Saline
0.01M EDTA in PBS prepared by adding 5% by volume of 0.2M 
EDTA (pH 7.2) to PBS.
Sensitized sheep red cells
ISheep red cells were collected in Alsevers solution, spun to 
separate cells from plasma, washed three times in PBS and suspended 
in 10% PBS solution. Since the complement system is a triggered 
enzyme system of the blood plasma, its action is usually initiated 
by the combination of antibody and antigen. The sheep red blood 
cells are coated with antibody, then known as EA.
For 1 ml EA :
1 ml 10% E (erythrocytes)
1 ml EDTA - saline
10 pi rabbit antisheep antibody (Wellcome Rabbit haemolytic
serum)
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Antibody is added to EDTA solution and mixed with 10% E at 4°C 
for 10 mins. This mixture is spun and washed once in EDTA - 
saline and twice in CFD and reconstituted to 1 ml with CFD.
C^2 deficient serum
This was prepared by heating selected normal human serum 
to 50°C for 20 minutes.
Gel overlay
7.5 mis of CFD for each gel is heated in a water bath (about 
50°C), 7.5 mis of 2% agarose solution is added. After removing 
from water bath 0.75 mis of 10% sensitized sheep red cells and 
0.2 ml C"2 deficient human serum is added. This is mixed well 
and poured over the gel spreading evenly. The overlay is 
allowed to set before removing the perspex strips. The gels 
are then placed in an airtight box containing a moist sponge 
and incubated at 4°C for 1 hour and then at 37°C until bands of 
lysis appear.
Red cell enzyme systems
As indicated above all red cell enzyme systems were typed 
using horizontal starch gel electrophoresis techniques, with 
buffer systems and substrate procedures appropriate to each 
system. In all cases haemolysates prepared from frozen and 
thawed packed red cells were inserted into the gels on strips 
of Whatman No. 3 filter paper, except for GPT where No. 17 
paper was employed. With the exception of PHs and 6PGD enzymes
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hemolysates, the other systems were first treated before 
inserting in the gel, incubating with 0.01 ml 1% 2-mercaptoe- 
thanol per ml of haemolysates for 30 mins at room temperature 
to improve the sharpness of the bands.
Esterase-D and Phosphoglucomutase (locus 1 and 2)
Electrode buffer gm/litre
Tris 12.1 
Maleic acid 11.6 
EDTA Na2 3.7 
Magnesium sulphate 2.4
Adjusted to pH 7.4 with NaOH (approximately 4.5 gm/L).
Gel buffer
Electrode buffer diluted 1:15 for PGM^ and PGM^
Voltage used : 170v. on meter.
Staining
The gels are sliced and the top half used for staining EsT-D 
with 2.5 mg of 4-methylumbelliferyl acetate dissolved in a small 
quantity of acetone in acetate buffer (diluted 1 in 10) pH 5.2 
(Spencer et at, 1964). Filter paper is soaked in 10 mis 
of the above solution and placed on the gels for 10 minutes 
after which they are read under u.v. light. The bottom half is 
stained for PGM^ and PGM^ using a reaction mixture composed of:
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mg/ge1
Glucose-l-phosphate 30
Magnesium sulphate 5
Nicotinamide adenine
dinucleotide phosphate (NADP) 7
Phenazine methosulphate (PMS) 5
(3- (4,5-di-methyl-diphenyl teterzolium 
bromide MTT) 5
Glucose-6-phosphodehydrogenase (G6PD) 4yl
Dissolved in 10 ml 0.1M Tris-hydrochloric acid buffer pH 8.2
oto which is added 10 ml of 1% (w/v) agar at approximately 60 C. 
This is overlayed on the gel and incubated for 10-15 minutes at 
36°C. PGM^ and PGM^ appear dark blue.
Glyoxalase I gm/litre
Electrode buffer
Tris 12.1
Citric acid 7.1
Boric acid 2.4
Lithium hydroxide 1.0
pH = 7.2
Gel buffer
Electrode buffer diluted 1 in 10. Voltage used 80v.
Staining
This is a two step procedure, Kompf et aZ (1975b)
First step - filter paper overlay
Methylgloyoxal (pyruvic aldehyde) 0.23 mls/gel 
Glutathione 7.5 mg/gel
This is dissolved in a buffer mixture of 2.75 ml/gel monobasic 
phosphate buffer and 2.25 ml dibasic phosphate buffer of pH 6.8.
The gels are incubated for 30 minutes.
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Second step - Agar overlay
18 mg of MTT dissolved in 0.1M Tris-hydrochloric acid buffer,
15 mls/gel pH 8.5. To this was added approximately 4ml dichloro- 
indophenol, a blue dye, in the same quantity of agar as the 
buffer. The gels were incubated for 10-15 minutes at 36°C.
Glyoxalase I bands appeared light green and the three phenotypes 
were discriminated according to Kompf et als (1975b).
Acid phosphatase
Electrode buffer gm/litre
Sodium dihydrogen phosphate 38.2
Tri-Na-citrate 44.1
di-Sodium EDTA 1.3
pH = 6.0
Gel buffer
Electrode buffer diluted 1 in 100. Voltage used 150v.
Staining
Procedure is a simple filter paper overlay, soaked in 2 mg
of 4-methylumbelliferyl phosphate in 10 mis of 0.05M citrate
buffer and incubated for 15-20 minutes (Karp and Sutton 1967). To
C A Bdiscriminate the phenotype PHs from PHs and PHs the alternative 
method by Hopkinson ct at, (1964) was used. The substrate consists of:
Phenolphthalein diphosphate 143 mg
Citric acid 10.5 gm/1
Sodium hydroxide 5.3 gm/1
dissolved in 50 ml of 0.05M citrate buffer, pH 6.0. The gels 
are incubated in this solution for 3-4 hours. 2 mis of concen­
trated ammonium hydroxide is then added, when pink coloured strong
bands are visible
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Adenylate kinase and adenosine deaminase
Electrode buffer gm/1
Solution A:
Potassium dihydrogen phosphate 68.0
Solution B:
Disodium hydrogen phosphate 70.9
The two solutions in proportion 1 : 2 i.e. 38 mis soln.B mixed
with 76 mis soln.A, are made up to pH 6.5 (Fildes and Harris 1966) 
Gel buffer
Electrode buffer diluted 1 in 10 mis. Voltage used lOOv.
Staining
AK mg/gel
Glucose 40
Magnesium chloride 200
Adenosine -5' diphosphate (ADP) 
Nicotinamide adenine dinucleotide
25
phosphate (NADP) 15
Phenazine methosulphate (PMS) 5
MTT 5
Dissolved in 10 ml (per gel) of Tris/hydrochloric acid buffer 
pH 8.2. Enzymes G6PD - 0.4 yl and hexokinase 0.08 yl are 
added to the solution. Equal quantity of 1% agar is mixed and 
poured over the gel. Dark blue bands appear close to the origin
ADA mg/1
Adenosine 9
MTT 2
PMS 2
Nuci&oside phosphorylase (NP) 20 yl
Xanthine oxidase (XOD) 40 yl
Dissolved in 10 ml/gel Tris-hydrochloric acid buffer pH 8.5,
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with equal quantity of agar and poured over the gel. Dark 
bands appear at the centre of the qel.
Glutamic pyruvic transaminase
Electrode buffer gm/1
Tris 12.1
Citric acid 6.1
pH = 7.5
Gel buffer
Prepared by diluting electrode buffer 1 in 10 ml distilled 
water. Voltage used 240v.
Staining
quantity for 6 gels
Alanine solution (100mg/ml in tris 0.1M HCL pH 7.6) 7.2 mis. 
a-ketoglutarate soln.(10mg/ml in tris 0.1M HCL pH 7.6) 7.8 mis.
Nicotinamide adenine
dinucleotide hydrogen (NADH) 40 mg
Lactate dehydrogenase 100 pi
Dissolved in 25 ml Tris/HCL pH 7.6, soaked on to No. 1 filter paper
and incubated for 3-5 hours and observed under U.V. light (Chen and
Giblett 1971).
6-Phosphogluconate dehydrogenase
Electrode buffer mg/1
Di-sodium hydrogen phosphate 
(anhydrous) 28
Citric acid 4.6
pH = 7.0
Gel buffer
Electrode buffer dilute 1 in 20 mis (Fildes and Parr 1963)
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voltage used 80v.
Staining mg/gel
NADP 2
6-Phosphogluconic acid 10
PMS 0.4
MTT 2
Dissolved in 10 mis Tris/HCL buffer pH 8.2 and equal quantity 
of agar is added. Incubation period of 10 minutes shows blue 
bands at the anodal end.
Statistical methods
Gene frequencies
The loci studied in the present investigation are all 
controlled by autosomal codominant alleles. Gene frequencies 
therefore were estimated directly be gene counting. Goodness-of- 
fit to random mating proportions, assuming Hardy-Weinberg equil­
ibrium was tested by the appropriate chi-square test (Cavalli- 
Sforza 1971).
Test for association
The data were categorized into contingency tables for two 
populations at a time (controls vs. patients) and association 
examined by chi-square tests for heterogeneity. Whenever a
9significant x appeared the situation was examined more closely 
to identify where the heterogeneity lay and to see whether 
similar trends occurred in the different sexes and different 
age groups. This typically involved the grouping together of
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some phenotypes- The method of Woolf (1955) advocated for 
associations analysis is most suitable for large sample sizes, 
but it was applied, in some cases, to confirm the significant 
results -
Distance/multivariate analysis
Analysis of heterogeneity within diabetes mellitus, repre­
sented by various affected populations, was examined also using 
statistical program of genetic distance analysis between popula­
tions. In this case the disease groups were subiected to such 
an analysis using a program for Morton's Biokin distance pro­
vided by the Department of Human Biology. This procedure 
essentially follows Wahlund' s(Morton 1970) approach and compares gene 
frequencies of subdivisions of the population with the population 
mean (Friedlaendqr1974). The computer program, Topol Arbor, 
was used to provide the dendrograms and two dimensional eigen- 
vectorial representation for the population distance.
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Chapter 3
AUSTRALIAN POPULATIONS 
Section 1 : Melbourne
The discussion for this chapter will be considered in two 
sections. Section 1 discusses the series of diabetic patients 
from Melbourne and Section 2, those from Kalgoorlie and Gerald­
ton in Western Australia (See chapter 2 for details of the 
series). For comparison with the patients, non-affected persons 
as controls were derived from blood donors in Canberra and Sydney.
- those on insulin treatment and below age 40 years (IDDM)
- those not on insulin but treated by a controlled diet
and oral agents, with age 40 and above (NIDDM)
- a third category, described for the present study alone,
are those 40 and above but receiving insulin therapy 
currently. These are categorized below as Mature 
insulin dependent diabetes mellitus (MIDDM).
The observations have been made with particular reference
firstly to non-HLA chromosome 6 marker genes as described
earlier: glyoxalase, properdin factor B and complement
factor C^2. The studies of markers on other chromosomes
will be discussed later.
Note: Due to the inability to type some samples for the
serum proteins and red cell enzyme systems, the totals shown 
in the tables are, therefore, not all the same. This applies 
to all populations discussed in the subsequent chapters.
Chromosome 6 markers 
Glyoxalase I (GLO)
The results obtained are shown in table 3.1.1. In the
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Table 3.1.1
Distribution of glyoxalase (GLO) phenotypes and gene frequ­
encies in the total diabetic and control series 
population of Melbourne
Popula­
tion
Phenotypes No.tested Gene frequency
1-1 2-1 2-2 GLO1 2GLO
Control 72 195 115 382 0.4437 0.5563
IDDM 46 128 75 249 0.4418 0.5582
NIDDM 44 97 88 229 0.4040 0.5960
MIDDM 17 33 31 81 0.4136 0.5864
Test for heterogeneity of phenotypic distribution NIDDM vs.
control: x2 = 5.30 p<0.05
2
MIDDM vs. control:
IDDM vs. control:
When combined NIDDM+MIDDM vs. control: 
Gene frequency NIDDM vs. control:
NIDDM+MIDDM vs. control:
X2 = 2.5 P<0.22
X2 = 0.01 n.s.
X2 = 6.56 P<0.02
2
X2 = 1.89 P>0.25
1
X2 * 1.44 P<0.20
1
Note
The control data compatible with random mating (H.W. equilibrium)
pX = 0.32 while the combined classes of diabetics NIDDM+MIDDM 
1  ^ ? deviate from this hypothesis x =
1
4.78 (0.05<P<0.02).
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NIDDM and MIDDM series, the phenotypic distributions show an 8-10% 
decrease in the heterozygotes GLO 2-1, with a corresponding 
increase in the homozygotes GLO 2-2 as compared with controls 
and IDDM series. When tested for heterogeneity for the distri­
bution of phenotypes in NIDDM versus control series, the chi- 
square value for 2 degrees of freedom obtained was 5.30
(P<0.05). For the MIDDM series versus controls x2 = 2.5
2
(P<0.2). When the above two series are combined into a single
series of maturity onset diabetes and tested for heterogeneity
X2 = 6.56 (P<0.02).2
Part of this heterogeneity may be due to ethnic stratifi­
cation of the patient population compared with that of the
2controls. The disturbance shows an increase of GLO gene
frequency and also a relative deficiency of 2-1 heterozygotes
which is reflected in the Hardy-Weinberg test for random mating
and which, in the case of NIDDM of the present series, gives a
X2 = 4.8 (0.05>P>0.02).
1
To check if ethnic stratification is playing a significant 
role in giving these results, the patients and controls were 
classified on the basis of family name or by response to questions, 
into groups by region of origin in Europe. People of Southern 
and East European and Middle East origin constituted approximately 
25% of the total. The remainder were North European (mainly 
British) in origin. Table 3.1.2 gives the distribution of GLO 
phenotypes for patients and controls of north European origin 
only. Heterogeneity between the two series has been greatly 
decreased and there is no longer any significant difference
(X2 = 3.8;0.2>P>0.1).
2
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Table 3.1.2
Distribution of glyoxalase phenotypes and gene frequencies 
in the North European diabetic and control series 
population of Melbourne
Series Phenotypes Gene frequency
1 21-1 2-1 2-2 GLO GLO
Control 31 88 54 0.4370 0.5630
NIDDM +
MIDDM
51 101 91 0.4177 0.5823
Test for heterogeneity of phenotypes in patients
pvs. control series x = 3.80 P<0.12
Table 3.1.3
Distribution of glyoxalase phenotypes and gene frequencies 
in the diabetic population of Poles, Russian and 
Czechoslavakian in the Melbourne series
Series Phenotypes Gene frequency
n = 45 1-1 i—iiCM 2-2 GLO1 2GLO
NIDDM + 
MIDDM
6 18 21 0.3333 0.6667
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Among the Eastern European (Poles, Russian and Czech)
2population, there were 45 people of Polish origin and the GLO 
allele had a high frequency of 0.6667 among them (table 3.1.3) 
contributing to the excess of the GLO 2-2 phenotypes in the 
total series. Since the Southern Memorial Hospital is located 
in an area with a large population of East European origin, 
which could result in the excess of those members attending the 
hospital and therefore contributing to the distortion in the 
GLO phenotypes observed in the diabetic patients.
Complement factor .: Properdin factor B(Bf)
As seen from table 3.1.4, from a total of 242 IDDM patients,
the number of persons with the Bf factor was 28 as compared to
8 in the control series. The frequency of the two rare alleles 
Ft StBf 1 and B_f 1 were increased significantly when compared to 
F-icontrols. Bf x is present in 1.0% of the controls, whereas it is
6.0% in the IDDM series and 0.40% and 0.0 among the NIDDM and
MIDDM patients. Bf^l shows an increase of 0.9% in the IDDM when
compared to controls. It is 1.1% in NIDDM and 0.6% in the MIDDM
S 'series. Gene frequency for the Bf_ allele shows an increase of
S3% in the IDDM in the present series: Bf = 0.8285 compared with
SBf = 0.7906 in controls. This does not correspond with the
increase of 16.2% shown by Cudworth et al (1977) among their IDDMs
Fbelow 30 years. However, there is a sharp decrease in the Bf_
Fallele frequency in this IDDM series to Bf = 0.0971 from 0.1937 
in controls.
When subjected to analysis of heterogeneity of gene frequen­
cies in patients versus control series (table 3.1.4a), the increase
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Si Fof the rare alleles Bf •*- and Bf_ 1 in IDDM patients was highly
significant (x2 = 22.8 P<<0.001). Further analysis of the 
1
North European population alone showed the combined frequency 
F Siof Bf 1 and Bf 1 also to be significantly increased over controls 
? F(X - 18.5 P<0.001). The Bf frequency also was decreased
1 —
psignificantly (x = 16.4 P<0.001). These results demonstrate
1
a strong association of Bf factors with IDDM in the Melbourne 
IDDM patients.
No significant differences in the occurrence of rare 
alleles were observed in the NIDDM and MIDDM series when com­
pared to controls.
The individuals with the Bf F^ factor can be said to be 
at a relatively greater risk than those without. The relative 
risk value calculated for the Australian IDDM patients with 
Bf F^ factor is 6.2 and when combined with Bf S^, RR = 5.3.
This value is much lower than that shown by Raum et dt, 1979 
on the U.S. white population (table 3.1.5) where RR for Bf F^ = 
15.0. Other workers have shown, for the Newfoundland population 
of Canada, a relative risk for Bf F^ = 5.3 (Dornan et at, 1980) 
and, in the German population, RR = 3.4 (Bertrams et at> 1979;
Mouzon et at, 1979) also showed an increase of Bf F, in the1
French Basque children with a relative risk value of 11.4 
for those with the Bf F^ factor.
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Table 3.1.5
Relative risk values of Bf reported in different
populations.
Reference R.R.
Raum et dl, 1979 
Bertrams et al} 1979 
Dornan et al, 1980 
Present study
15.0
6.20
3.37
5.55
The discrepancy in the estimates of relative risks between 
the U.S. and Australian IDDM series for the Bf factor, may 
well reflect a different age composition in the two studies.
Age relationship between insulin-dependent diabetes and rare 
alleles of Properdin factor B.
Since the onset of IDDM is related to age, a further break­
down into groups based on age of onset, was carried out. It may 
be noted that the results published earlier (Kirk et al, 1979), 
differ from those described below in the use of the age criteria, 
although the trend of distribution for Bf F^ remains the same. 
Since more detailed information was available on the IDDM 
individuals, accurate analysis was performed based on the age 
of onset of the individuals.
The age groups included a range of 0-4; 5-9 and 10-14 years. 
Distribution of the Bf F^ factor in these age groups is shown 
in figure 3.1. The frequency of Bf F^ in the age groups 0-4, is 
18.5% and in the 5-9 group, 13.6%, falling to 11.1% in the 10-14 
age group, in comparison to the controls with a frequency of 3.2%. 
However, for the other factor, Bf S^, although a progressive 
decline with age is not observed, interestingly in the 0-4 and
5-9 age groups,
Pe
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N IDDM
Fig. 3.1. Relationship of age of onset to frequency of rare 
Bf factors in Melbourne IDDM patients.
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the Bf frequencies are 3.7% and 7.5% respectively, falling 
sharply in the 10-14 and over age groups. The relative risk for 
Bf and Bf combined is 9.4 in patients below 10 years. The 
rapid decline in the frequency of Bf with increasing age of 
patients with IDDM is compatible with a viral stimulus for 
initiating the disease process. Implications of this consideration 
will be discussed in greater detail in the last chapter. Such an 
age-based correlation in IDDM has been reported previously with 
HLA-B15 (Dausset 1977).
Analysis of HLÄ and Bf factors.
Since the Bf locus resides within the HLA complex, studies 
for the assocation of HLA antigens with Bf factors were carried 
out. This analysis was made possible by using the results of HLA 
typing carried out by Mr. Philip Kiely in Melbourne. Only the 
HLA-A and B antigens were typed and, due to the non-availability of 
the serum,HLA-B18 was not included in the array of antigens tested.
The percentage of HLA-B antigens present in the IDDM and 
control series is shown in table 3.1.6. The comparison reveals 
a significant increase of B8 (48% vs.24%) and B15 (21% vs. 8%). 
There is a significant decrease of Bw35 (3% vs. 16%).
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Table 3.1.6
Per cent distribution of HLA-B antigens in 
Melbourne IDDM patients and controls 
(from Kiely et al3 1978)
HLA-B IDDM CONTROL
B7 17 21
B8 48 24
B12 21 25
B15 21 8
B21 4 1
B35 3 16
Pairwise associations were tested for significance by 2 x 2
9contingency tables using Fisher's x test of significance.
Examples of these contingency tables are given in tables 3.1.7A,
B and C. The derived probability values for these pairwise 
comparisons are summarized in table 3.1.7. Significant positive 
disequilibrium at probabilities of P = 0.05 or lower in the case 
of IDDM patients, was demonstrated for HLA-A1 with Bf F: signifi­
cant negative disequilibrium values were obtained for HLA-B8 with 
Bf F, F^ and and also for HLA-Bw35 and BfF.
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Table 3.1.7A
2 x 2  contingency tables for HLA antigens 
and Bf factors in IDDM patients and controls
ControlsIDDM patients 
B8 B8
+ +
5 1 - 21 43
78 77
s
0 3+
x2 = 1.371 x2 = 0.144
1 1
p = 0.241 p = 0.750
B 8 B8
- + - +
62 73 - 25 16
21 5
F
+ 21 5
x2 =  9.248 x 2 = 2.897
1 1
P =  0.002 p — 0.10 0
NOTE: That BfF factor is in significant negative
disequilibrium with HLA-B8 antigens in IDDM
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Table 3.1.7B
2 x 2  contingency tables for HLA antigens 
and Bf factors in IDDM patients and controls
IDDM patients 
B8
Controls
B8
= 4.012
1
P = 0.045
77 78
6 0
y2 = 4.015
1
P = 0.045
exact P = 0.034
B8
- +
68 73
15 5
B8
3.568
1
0.10<P< 0.05 
exact P = 0.123
NOTE: That the BfF^ and factors in IDDM patients
show significant negative disequilibrium with 
HLA-B8 antigen as compared to controls.
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Table 3.1.7C
2 x 2  contingency tables for HLA antigens 
and Bf factors in IDDM patients and controls
IDDM patients 
Bw35
+
134 1
22 4
X2 = 11.050
1
P = 0.0009
Controls
Bw35
+
X2 = 1.979
1
P = 0.250
Al
+
72 63
20 6
A! = 4.037
P = 0.044
Al
+
1.680
0.250
NOTE: A highly significant negative disequilibrium
in the patient series occurs between HLA-Bw35
and BfF factor.
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Table 3.1.7.
Selected HLA antigens and Bf factors: 2 x 2  probability 
values for IDDM patients and controls
HLA BF S si F Fi S si F Fi
Ai 0.367 0.081 0.045 0.138 - - 0.025 -
B8 0.242 0.045 0.002 0.045 0.750 0.500 0.100 0.050
B15 0.518 0.669 0.463 0.788 - - - -
B35 0.451 0.451 0.0009 0.868 - - 0.250 -
As expected, the positive association of HLA antigens with a Bf 
factor is almost always paralleled by a negative correlation 
with the other Bf factor (Albert et at, 1977). For this 
reason the negative disequilibrium between HLA-B8 and Bf F 
probably reflects the known strong positive disequilibrium 
between B8 and Bf S in the normal European population (Albert 
et at, 1977; Arnason et at, 1977).
The negative disequilibrium value between HLA-B8 and Bf 
and Bf F^, both of which have significantly increased 
frequency in the present investigation of Melbourne IDDMs, 
suggests that there is a diabetic susceptibility allele in
F tlinkage disequilibrium with HLA-B8 in some cases and with Bf^  1 
and Bf^l in others.
Family Investigation
In the introductory chapter it was pointed out that the HLA
polymorphism has provided a powerful tool in genetic studies of
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IDDM, providing possible clues to its aetiology. Using the 
information of HLA association and linkage on chromosome 6, 
several investigations of the mode of inheritance were attempted 
by noting the percentage of pairs of diabetic siblings who share 
the same HLA haplotype in families with more than one child 
affected. The frequency of pairs of diabetic sibs with identical 
haplotypes was 50-60%, much higher than the 25% expected by chance 
(Cudworth and Woodrow,1975; Barbosa et at, 1977;Rubinstein
et at, 1977; Spielman et at, 1978). This suggests the close 
linkage of the IDDM susceptibility allele within the MHC complex.
In the present study, segregation at another linked locus 
(Bf) within the HLA complex, is examined. Segregation of the Bf 
rare alleles independently and in Jinkage with other HLA alleles 
is considered, although very few families are informative for the 
rare alleles.
Thirteen multiple case families were available from the Royal 
Children's Hospital, Melbourne and fourteen from the Newcastle 
area of N.S.W. (kindly made available by Dr.H. Bashir). These 
families showed either an affected parent and child or only affected 
children. In the former series three families were informative for 
the Bf rare alleles and five of the latter series. Combining the 
total of eight informative families, four had either parent and 
one child affected or both sibs affected and, in the remaining four, 
only one child was affected.
Number of IDDM affected + Bf = 8
Number of unaffected + Bf = 10
Both normal and affected persons are almost equally positive
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for Bf F .
Family 1 shows BfFl to be transmitted from a normal parent
Fito two sibs, both diabetic and Bf positive. When HLA haplo- 
F1types with Bf 1 are examined, the diabetic sibs possess B18
Ft FtBf Drw3 GLO 2. B18 being strongly linked with Bf_ 1. In both
cases the heterozygote Drw 3 Drw4 is present, constituting the
high risk haplotype.
F tFamily 2 shows a diabetic parent with Bf 1, transmitted to 
two non-diabetic offspring. In the same family the diabetic sib
Fidid not possess Bf_ . However, when the HLA haplotypes are con­
sidered, the two non-diabetic offspring are B18 Drw3 Drw3, 
whereas the diabetic sib is Drw3 Drw4 Bf^ , possessing the 
heterozygote which constitutes the increased combined risk.
In family 3, with normal parents, both the affected and
F tunaffected offspring carry the Bf ± factor and thus the haplotype 
B18 Bf F^ Drw3. The above examples thus show that not all IDDM 
cases carry the Bf F^ factor, and not in every case is the hap­
lotype Bf F^ with B18 Drw3 definitely diabetogenic.
The number of alleles, at one or more loci, required for the 
manifestation of IDDM continues to be debated. Based on the 
hypotheses that Drw3, Drw4, in combination, imply the presence 
of two IDDM susceptibility alleles, the segregation of Bf F^ in 
the presence of either of these will be examined. Since Bf F^ 
is strongly associated with IDDM (evidenced from this and other 
studies) and confers a risk of'6.2 in the general population, then 
it is expected that this allele will accompany the high risk 
alleles in a haplotype combination for the manifestation of IDDM
in some cases.
FAMILY 1
a = A24B^v^Cw4Drw6 BfsGLO^ C2
b = A24Bl2(w44 )w4 Cw4Drw4BfsGL02C2
c = A2B^44jw4Cv^Drw4BfsG L02C2
d = A2®18w6"^rw3 B^lGL02C2
Family 1: Two children with insulin-dependent diabetes mellitus.
Males designated by squares, females by circles. HLA; 
Bf, C'2 and GLO types are shown for each individual. 
Refer text for description.
FAMILY -  2
A = A^g-Wß- Drw^BfsGLO^C2 
B = A30B18w6~Drw3ßf FjGLO1^
C = A] BgCw^w^ Drw3BfsGLO^ C2
D: A2ßw44Cw4w4Drw6BffGL02C2
Family 2: One parent and child affected by IDDM. Males repre­
sented by squares, females by circles. HLA, Bf, C"2 
and GLO types are shown for each individual. Refer 
text for description.
FAMILY - 3
A' : A30Bl8D3Bf' ,GLO' 
B 1: A3 B7D3BfsGLOi
C ‘ = A30B4 0 D4BfsGLOl
d ’ = a 3 b 7 Di B^GLO1
Family 3: Two male children affected by IDDM one (male) non-
affected. HLA, Bf and GLO types are given for each 
individual. C'2 types are not included in this 
family.
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If the heterozygote Drw3,Drw4 reflects the presence of two 
IDDM susceptibility alleles, then either Drw3X (where X is any other 
antigen except 4) or Drw3 Drw3 will have one susceptibility allele 
and Drw4X (where X is any antigen except 3) or Drw4 Drw4 will have 
the other. From the present observations examples of families simi­
lar to Family No.2 and Family No.3 above were not uncommon. The 
sibs, homozygous for Drw3 and positive for Bf F^ are unaffected 
(eg. family 2). That is they have one susceptibility allele with the 
additional risk factor Bf F^ but do not manifest IDDM. The other 
child in the family with Drw3X or Drw3 and BfS is diabetic, and 
in family 3 the affected and unaffected have the same haplotype 
combination. Since the non- affected sibs also have the two high 
risk factors, and are in the ages between 9-14 years, there is a 
possibility that they may still develop diabetes at a later stage.
If non-familial cases, i.e. where only one sib is affected,
are investigated separately, we can observe the segregation of the 
FIBf allele. To define a non-familial case, the criteria used were 
outlined by Svejgaardei at (1980); i.e. a family having no first degree 
relatives affected and where there is at least one healthy sib at the 
age of 20 years or more. Only one family from the present study 
fulfils these criteria. Examination of the Bf F^ factor in the 
affected child showed the following combination Bl8,Bf F^,Drw3,i.e. 
heterozygous at the D locus. The emphasis thus rests on the above 
haplotype being of risk for a specific type of IDDM. Children with 
this combination (Bl8,Bf F^,Drw3), may be different from those 
without this combination in the familial and non-familial cases, 
conferring the appropriate genetic susceptibility to the
individual.
79
Since the RR for Bf is higher than for the HLA-B locus 
alleles, its independent effect in conferring risk is likely 
(Dornan et at, 1980) and the possibility of one of the IDDM 
susceptibility alleles being closely linked to BfF-*- (Raum et at, 
1979) is great.
Complement component C'2
The results of typing for complement C'2 on the same IDDM 
population studied by Kirk et aZ(1980)have been used in the 
following discussion of the analysis with the Bf polymorphism.
The codominant alleles controlling structural variants 
of complement C'2 are present in Europeans. Three phenotypes 
C'2 1-1, 2-1 and 2-2 are possible, of which C'2 2-2 is rare 
and was not observed in the study. In the IDDM series, an 
increase in the C'2 2-1 phenotypes was observed, 13.5% com­
pared to 5% and 6.9% in NIDDM and control series (table 3.1.8 
taken from Kirk et at, 1980) comparing well with results of
Alpor (1976) ; Olaison et at (1978). The relative risk
„ 2in IDDM for persons carrying a C 2 gene is 2.2. Chi-square for
, 2heterogeneity of C 2 gene frequency between IDDM and controls:
x2 = 4.4 P<0.02; X2 IDDM vs. NIDDM = 8.1 P<0.001.
1 1
The locus controlling the synthesis of C'2 has been local­
ised to the HLA region (Fu et at, 1974) and further studies 
showed a close localization to the HLA-B locus (Raum et at,
1976; Alper and Rosen, 1976). For this reason, an analysis 
for associations, or interaction, between alleles of C'2 and Bf, 
which is also close to the HLA-B locus, was carried out.
Table 3.1.8a shows the distribution of Bf phenotypes in
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Table 3.1.8
Distribution of C '2 types in diabetes and control 
populations of Melbourne
Series
C'2 Phenotypes
No.
tested
Per cent 
Gene
frequency
C'221-1 2-1
Controls 175(93.1%) 13 (6.9%) 188 3.5%
IDDM 179 (86.5%) 28(13.5%) 207 6.8%
NIDDM 191 (95%) 10 (5%) 201 2.5%
Heterogeneity of gene frequency for IDDM vs. controls:
X2 = 4.4 0.05<P<0.02 
1
IDDM V S . .NIDDM:
8.1 0.01<P<.001
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Table 3.1.8a
Distribution of Bf phenotypes in relation to the C'2 
phenotypes among the IDDM and controls series 
of Melbourne. The expected values are given 
in parenthesis
Bf
IDDM
Total
CONTROL
TotalC"2
1-1 2-1
u
rH1
rH
2
2-1
S 121 17 138 99 8 107
(118.8) (19.1) (99.2) (7.7)
FS 28 3 31 43 4 47
(26.7) (4.3) (43.6) (3.4)
F 3 1 4 4 0 4
(3.4) (0.6) (3.7) (0.29)
SFl 17 5 22 3 0 3
(18.9) (3.0) (2.7) (0.21)
FFl 2 0 2 2 0 2
(1.7) (0.3) (1.8) (0.14)
SSI 3 2 5 3 0 3
(4.3) (0.7) (2.7) (0.21)
TOTAL 174 28 202 154 12 166
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relation to the C'2 phenotypes among IDDM and control individ­
uals. From the expected values (given in parenthesis) it is 
clear that the distribution of Bf and C'2 are independent of 
each other. The BfS is present in all the C'2 2-1 individuals.
Of the rare factors, among the IDDM individuals, 7 of 28 with 
or Bf have C"2 2-1 phenotypes, as compared to none in 
the control series. However, from the pairwise analysis of the 
Bf and C"2 2 factors none of the chi-square values obtained 
reach the 5% level of significance (table 3.1.8b). Therefore, 
although there is an apparent association between Bf rare 
factors and C'2 2 in patients, which probably has some biologic 
importance, it needs further studies of these associations.
The locus for C'2 and GLO are on the same chromosome and, 
in order to test any disequilibria between them, examination of 
the joint phenotypic distribution was carried out (table 3.1.8c). 
Following a x2 test for the respective series, the factors were 
found to be distributed at random and no genetic disequilibrium 
was observed.
Non-chromosome 6 markers
In addition to the markers controlled by genes on chromosome 
6 discussed in detail above, a further 10 genetic systems were 
investigated controlled by loci not linked to chromosome 6.
Three of these systems are detectable in serum: the remaining
seven are red cell enzymes.
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Table 3.1.8b
Chi-square values for pairwise analysis of associations 
between individuals positive for Bf and C^2 factors 
in IDDM and control series
FACTORS IDDM CONTROLS
Bf C? C22
S 0.04 0.24
F 0.35 0.04
SI 2.93 0.12
FI 1.10 0.20
S1&F1 3.00 0.37
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Table 3.1.8c
The distribution of GLO and C^2 phenotypes among IDDM 
and controls of a Melbourne population 
(expected values are shown in.parenthesis)
IDDM CONTROL
GLO
CNu
1—1 1r—\ 2-1
Total C '2
1-1 2-1
Total
1-1 27
(26.6)
4
(4.4)
31 23
(23.4)
2
(1.6)
25
2-1 72
(74.7)
15
(12.2)
87 73
(71.9)
4
(5.0)
77
2-2 48
(46.0
5
(7.4)
53 46
(46.7)
4
(3.2)
50
TOTAL 147 24 171
i___
142 10 N= 152
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Serum proteins
The Group Specific Component (Gc)
Table 3.1.9 gives the distribution of Gc types and gene
frequencies for patients and controls in the Melbourne series.
2The decrease of 4.8 % in the Gc frequency among NIDDM patients
tends towards significance. (x2 = 3.06; 0.05>P>0.10).
1
In contrast the Gc gene frequency for the IDDM patients is not
significantly different from the controls. In the MIDDM series
2the frequency of Gc is 3.2% higher than in controls, though
the difference is not significant (y2 = 0.62: P>0.5).
1
An earlier study by Cleve (1966) showed a decrease in the
2Gc frequency among German diabetic patients (insulin status
not disclosed) less than 60 years of age, with moderate or
severe arteriosclerosis of the peripheral vessels. Jörgensen
2and Hopfer (1967) also noted a decrease of the Gc allele in 
their study. However, Berg et al, (1967) in the same year in a study of 
patients aged 14-86 in Oslo, did not find any significant 
difference.
It is of interest that the difference for NIDDM patients 
in the present study is even more marked when only the patients 
with a north European origin are considered (table 3.1.9a), and 
even though the MIDDM frequencies are still in the opposite sense, 
if all mature onset patients are combined (NIDDM and MIDDM) the 
Gc phenotype distribution is still significantly different from
that of the controls ( x2 = 6.10: P<0.02). The Gc system there-
2
fore is clearly one which needs further study in relation to 
diabetes and this will be discussed further at a later stage of
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Table 3.1.9
Distribution of Group Specific Component (Gc) phenotypes 
and gene frequency in the total diabetic and 
control population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 Gc Gc
Controls 168 148 42 358 0.6760 0.3240
IDDM 110 103 23 236 0.6843 0.3157
NIDDM 111 104 10 225 0.7244 0.2755
MIDDM 33 37 10 80 0.6438 0.3562
Heterogeneity of phenotypes in controls vs. IDDM:
X2 = 0.71 P>.75 2
VS. NIDDM:
X2 = 6.26 0.05<P<0.02 
2
gene frequency in controls vs. NIDDM:
X2 = 3.06 0.05>P>0.10 
2 . ^Presence of Gc vs. absence Woolf's chi-square = 0.36 n.s.
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Table 3.1.9a
Distribution of Group Specific Component and gene frequency 
in diabetic and controls in a North European 
population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 Gc Gc
Controls 75 61 23 159 0.6635 0.3365
IDDM 100 88 17 205 0.7024 0.2980
NIDDM 87 74 7 168 0.7411 0.2619
MIDDM 26 27 9 62 0.6370 0.3630
Test for heterogeneity of phenotypes in IDDM vs. controls:
X2 = 0.71 n.s.
2
in MIDDM+NIDDM vs. controls:
X2 = 6.10 P<0.02 2
in NIDDM vs. controls:
X2 = 10.5 PcO.OOl2
gene frequencies in NIDDM vs. controls:
X2 = 4.3 0.05<P<0.02 
1
in MIDDM+NIDDM vs. controls: 
X2 =0.71 n.s.
Woolf's RR-0.40; x = 25.1 P>.001
1
for NIDDM vs. control
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this thesis.
Haptoglobin (Hp)
Table 3.1.10 shows the distribution of phenotypes and gene
frequencies of haptoglobin in patients and control series. A
2decrease of 3.6% and 3.1% in the H]3 allele frequency is noted
in the IDDM and MIDDM series. But in NIDDM there is an increase 
2of 3.2% in Hp allele frequency, compared to controls. These 
differences are not statistically significant.
Early studies have shown a non-significant increase of 
Hp 1-1 phenotypes among diabetics in some series (Berg et at, 1967) 
and a decrease of Hp 1-1 in others (Simpson et at, 1962;
Jorgensen and Hopfer 1967). In this study, there is a
decrease of 4.7% in the Hp 2-2 phenotypes in the IDDM series 
when compared to controls, but there is no significant hetero­
geneity in phenotype distribution between the two series
(x2 = 1-47 P<0.5).
2
It has been hypothesized, on the basis of studies of Hp 
distribution in other diseases and normal controls that distur­
bances of this kind are due to the effects of selection on the 
alleles at the Hp locus (Workman et at, 1963; Peacock, 1966). 
However, it seems clear that no definite conclusion can be drawn 
until more data on larger samples, show consistent increase or 
decrease in Hp alleles in diabetic individuals.
Transferrin (Tf)
Variants of the iron-binding protein, transferrin are 
uncommon in Europeans with approximately 98% of persons havinq,
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Table 3.1.10
Distribution of haptoglobin (Hp) phenotypes and gene 
frequency in the total diabetic and 
control population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 Hp Hp
Control 52 172 149 373 0.3700 0.6300
IDDM 40 116 85 241 0.4066 0.5934
NIDDM 29 95 102 226 0.3385 0.6620
MIDDM 15 35 31 81 0.4012 0.5990
Heterogeneity of phenotypes in controls vs. IDDM:
X2 = 1.47 P<0.502
controls vs. NIDDM
X2 = 1.41 P<0.50
2
gene frequency NIDDM vs. controls
X2 = 1.22 P>0.30
1
IDDM vs. NIDDM+MIDDM
3.43 0.10>P>0.25
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only the common transferrin TfC. The present study shows this 
to be true for both the diabetic and control series (Table 3.1..11) 
and there are no significant differences between patient and 
controls in the number or gene frequency for rare alleles.
Ceruloplasmin (Cp)
The distribution of the protein ceruloplasmin, an 
globulin is known to have fast moving electrophoretic variants 
which are of very rare occurrence in most populations with the 
exception of American Negroes. Cp BB is the most common phenotype 
and exists with a frequency of 99% in non-negro populations 
(Shreffler et at, 1967). In the present investigation,no 
variants were observed and there was 1.00% distribution of the
gCp allele in all the populations examined. Therefore, this 
system will be excluded from discussions in this and the 
subsequent chapters.
Non -chromosome 6 markers - Red cell enzymes 
Esterase-D (EsT-D)
This is a two allele codominant system,for which three
phenotypes, Est-D 1-1,2-1 and2-2 exist. Est-D 2-2 is relatively
rare among Europeans. Table 3.1.12 gives the distribution of Est-D
phenotypes and gene frequencies for the present study.
In the diabetic population, there is a non-significant •:
2decrease in Est-D frequency of 1.9%, 2.2% and 1.2% in the IDDM, 
NIDDM and MIDDM series compared to control series. The IDDM series
shows a significant absence of the Est-D 2-2 phenotype when
\compared to contols and mature onset diabetics. This may be due 
to a sampling error and further study is needed.
91
Table 3.1.11
Distribution of transferrin (Tf) phenotypes and gene 
frequency in the diabetic and control population of
Melbourne
Series Phenotypes 
CC CD CB2
No.
Tested
Gene
TfC
Frequency
mjrDl B2Tf Tf
Controls 361 1 6 368 0.9918 0.0014 0.0082
IDDM 248 0 2 250 0.9960 - 0.0040
NIDDM 227 1 1 229 0.9978 0.0022 0.0022
MIDDM 80 0 1 81
1
0.9938 0.0062 0.0062
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 1.19 P> 0.502
NIDDM vs. controls:
X2 = 2.36 P< 0.25 2
IDDM vs. NIDDM+MIDDM:
0.66 n.s.
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Table 3.1.12
Distribution of Esterase-D phenotypes and gene frequencies 
in the total diabetic and control population of 
Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
jGene j
Frequency
1 2 Est-D Est-D
Control 290 79 10 379 0.8694 0.1306
IDDM 193 55 0 248 0.8891 0.1109
NIDDM 187 37 4 228 0.9013 0.1086
MIDDM 62 17 1 80 0.8813 0.1187
Test for heterogeneity of phenotypes in controls vs. IDDM:
X2 = 5.67 0.05>P>0.10
2
controls vs. NIDDM+MIDDM:
X2 = 2.29 P<0.25 2
gene frequency in controls vs. NIDDM+MIDDM:
X2 = 2.30 P<0.10
1
phenotypes in IDDM vs. NIDDM:
X2 = 6.35 0.05<P<0.0252
gene frequency in IDDM vs. NIDDM:
X2 =0.36 n.s.
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Williams and Cartwright (1978) studied Est- D in a 
diabetic population based on age categorization, but no signifi­
cant difference in any age group was noted. To test whether age 
categorization would show a difference in the distribution of 
Est-D phenotypes, the present series was also subjected to a 
similar analysis. The results, like the previous study, were 
negative, supporting the observation of the above authors.
Acid phosphatase (PHs)
The phenotypic distribution in the diabetic and control
population is shown in table 3.1.13a. There is a decrease of
C3% in the frequency of the PHs allele among the IDDM patients 
when compared to controls and of 1.7 and 0.6% in the two mature 
onset diabetic series. When tested for heterogeneity of gene 
frequency and phenotypes, there was no significant difference 
in any of the series.
One previous study (Lucarelli et at, 1978) reported a 
difference in the acid phosphdases among diabetics in Rome when 
the population was divided on the basis of sex. Among males, 
the CB phenotypes were under-represented when compared with 
controls. In the present series, when divided by sex, there is 
also a deficiency of CB phenotypes among males in the IDDM series 
(0% vs. 8.9% in controls). The situation is reversed in females 
and combining both sexes the CB phenotype is 5.1% in IDDM and 6.8% 
in controls, the difference being non-significant (table 3.1.13b).
Phosphoglucomutase I and II
At the PGM^ locus, no variation was observed in the control
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and diabetic series.
At locus 1, shown in table 3.1.14a,the frequency of PGM^ 
in controls is comparable and agrees well with the published 
frequencies for Europeans. In the NIDDM and MIDDM, there is an 
increase of 3.8% and 7.3% in the phenotype PGM 1-1 frequency as 
compared to controls. When tested for heterogeneity of pheno­
types and gene frequency in the total series, however, this was 
not significant.•
When only the North European population is considered
(table 3.1.14b) there is an increase of 11.9% and 9.9% in the
PGM 1-1 among the NIDDM and MIDDM series respectively. There
is a corresponding decrease in the PGM 2-1's in both and PGM 2-2
in the NIDDM series and this is reflected in a decrease in the 
2PGM., gene frequency among the mature onset patients. The
-A-
difference in the gene frequencies in NIDDM vs. controls shows 
significance at the 2 per cent level.
One earlier study noted an increase of PGM  ^among the 
older age group of unaffected white South African women (mean 
age 82.7 years) (Gordon and P.iser, 1966). It is possible, there­
fore, that the increase of 1-1 phenotypes found in the present 
study, which is significant among patients of North European 
origin, may be due to an age effect. Of NIDDM and MIDDM Melbourne 
patients, for which relevant information was available, 25.9% were 
in the age group 70 years and over (the distribution of per cent
gene frequency based on age groups is given in table 3.1.14c.
2Those of 70 years and above show a 5% decrease of PGM  ^allele as 
compared to the 40-69 years age group), whereas none of the controls
were aged above 60 years. The present study suggests that further
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Table 3.1.14a.
Distribution of phosphoglucomutase (PGM) (locus 1) phenotypes 
and gene frequency in total diabetic and 
control population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2PGM PGM1 1
Control 221 128 31 380 0.7500 0.2500
IDDM 141 91 18 250 0.7460 0.2540
NIDDM 140 73 13 226 0.7810 0.2190
MIDDM 53 21 7 81 0.7840
_
0.2160
Heterogeneity of phenotypes in IDDM vs. control:
X2 =0.45 n.s.
2
MIDDM+NIDDM vs. controls:
X2 = 1.76 P>0.502
IDDM vs. NIDDM+MIDDM:
X2 =2.48 PcO.252
gene frequency in NIDDM+MIDDM vs. control:
1.94 P<0.25
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Table 3.1.14 b.
Distribution of phosphoglucomutase I phenotype and gene 
frequency in the diabetic and control North 
European population of Melbourne
Series Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2PGM, PGM,
1 1
Control 95 63 13 171 0.7400 0.2602
IDDM 117 82 12 211 0.7488 0.2512
NIDDM 112 50 6 168 0.8155 0.1850
MIDDM 36 15 4 55 0.7910 0.2090
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 0.34 P<0.82
NIDDM vs. control:
X2 = 5.40 0.10<P<0.052
combined MIDDM-NIDDM vs. controls:
x2 = 4.4 0 P<0.10
2
gene frequency in NIDDM vs. controls:
X2 = 5.58 P>0.025
1
Woolf's RR 1.55 x2 = 5.56 0.01>P>0.025
1
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Table 3.1.14c*
Distribution of PGM^ per cent gene frequency in different 
age groups among the NIDDM series of Melbourne
1PGM1 2PGM1
40-69 78.04 21.96
yrs
70 and 83.20 16.80
over
All ages 80.60 19.43
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investigation of this phenomenon is needed.
Glutamic pyruvic transaminase (GPT)
The data for this study in diabetic and control are given 
in table 3.1.15. In all three diabetic series, there is a 
decrease of GPT 1-1 phenotypes when compared to controls and 
a corresponding increase in the heterozygotes as well as homo­
zygotes in cases of NIDDM and MIDDM, but these differences are 
not significant when tested for heterogeneity of phenotypes. 
However, when NIDDM and MIDDM are combined there is a significant 
decrease in the GPT1 gene frequency and corresponding increase
2 oin GPT compared to controls (x^  = 3.90 P = 0.05). Again further --- 1
study of this phenomenon is required.
Other enzyme systems
Three other polymorphic red cell enzyme systems were 
investigated during the present study: 6-phosphogluconate
dehydrogenase (6PGD) adenosine deaminase (ADA) and adenylate 
kinase (AK). The phenotype distributions and gene frequencies 
are given respectively in tables 3.1.16, 3.1.17 and 3.1.18.
None of these systems revealed significant differences between 
controls and any of the patient series for either phenotype or 
gene frequency distributions.
Distance analysis
The comparison of the different subgroups within a popula­
tion, based on genetic markers, gives information at each locus 
under study, as has been described. In order to gauge the vari-
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Table 3.1.15
Distribution of glutamic pyruvic transaminase (GPT) phenotypes 
and gene frequency in the total diabetic and 
control population of Melbourne
Series Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 GPT GPT
Control 63 89 37 189 0.5688 0.4312
IDDM 64 128 44 236 0.5424 0.4576
NIDDM 55 117 49 221 0.5136 0.4864
MIDDM 17 41 20 78 0.4808 0.5200
Heterogeneity of phenotypes in control vs. IDDM:
X2 = 2.80 P<0.252
control vs. NIDDM+MIDDM:
X2 = 5.12 0.05>P>0.1
2
gene frequency in controls vs. NIDDM+MIDDM:
X2 = 3.90 P = 0.05 
1
control vs. NIDDM:
X2 = 2.10 P<0.10 
1
phenotypes in IDDM vs. NI+MIDDM:
1.60 P<0.25
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Table 3.1.16
Distribution of 6-Phosphogluconate dehydrogenase (6PGD) 
phenotypes and gene frequencies in the 
total diabetic and control population 
of Melbourne
Series
Phenotypes 
AA AC CC
No.
Tested
Gene
Frequency 
6PGDa 6PGDC
Control 366 16 0 382 0.9791 0.0210
IDDM 233 16 1 249 0.9640 0.0361
NIDDM 219 10 0 229 0.9782 0.0218
MIDDM 78 2 0 80 0.9875 0.0125
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 3.03 P<0.20 2
gene frequency in IDDM vs. controls
X2 = 3.20 0.05>P>0.1 
1
phenotypes in IDDM vs. NIDDM+MIDDM:
3.68 P>0.20
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Table 3.1.17
Distribution of adenosine deaminase (ADA) phenotypes and 
gene frequency in the total diabetic and 
control population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 ADA ADA
Controls 347 34 0 381 0.9554 0.0446
IDDM 190 25 0 215 0.9419 0.0581
NIDDM 184 17 0 201 0.9580 0.0420
MIDDM 64 4 0 68 0.9706 0.0300
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 1.31 P<0.50
2
NIDDM+MIDDM vs. controls:
X2 = 0.31 P>0.902
NIDDM+MIDDM vs. IDDM
X2 = 2.44 P = 0.30
2
gene frequency in NIDDM+MIDDM vs. IDDM
X 0.89 n . s
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Table 3.1.18
Distribution of adenylate kinase (AK) phenotypes and gene 
frequency in the total diabetic and control 
population of Melbourne
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 AK AK
Controls 353 26 1 380 0.9632 0.0368
IDDM 241 8 0 249 0.9839 0.0321
NIDDM 208 20 0 228 0.9561 0.0439
MIDDM 74 6 0 80 0.9625 0.0375
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 3.60 P>0.202
NIDDM+MIDDM vs. controls:
X2 = 1.54 P>0.502
gene frequency in NIDDM vs. controls:
0.85 n.s.
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ation, or similarity at a number of loci, a composite measure 
which could represent the relationships of the groups within 
a population is desirable. In order to achieve this, on the 
basis of gene frequency data, the population in the present 
study were subjected to a multivariate analysis using the 
Biokin genetic distance method of Morton (1970). The method and 
program used for this purpose has been described in Chapter 2.
The results obtained on the basis of analysing the data for 
13 genetic marker systems are depicted in figures 3.1.1a and 
3.1.1b by an eigenvector representation and a dendrogram.
From the previous discussions of the results, among the
important markers which revealed significance among specific
disease groups were Bf alleles. The distribution of some of
the Bf genes in the IDDM group was significantly higher than
the two mature diabetic and control series. Subsequently the
strong association of the Bf factors in the IDDM series and
not in NIDDM and MIDDM specifies a distinction in the types
of diabetes. One other locus studied on chromosome 6, C^2, also
2shows an increased frequency of the C^2 allele in the IDDM 
series. The possibility that the differences in the gene 
frequencies of the markers on chromosome 6 would cause the 
IDDM series to be sufficiently separated from the rest of the 
series, is likely, and this is apparent in the dendrogram and 
also on the eigenvector diagram. In the case of NIDDM and 
MIDDM, there is a separation of the mature diabetic series 
treated by insulin, from those on oral tablets or diet treatment 
and this may be due, in part, to the disturbances in the alleles 
of the Gc, GPT and PGM loci, which do not occur in the IDDM
Figure 3*1 ‘la
MlDDM ■
CONTROL ■
I DDM ■
NIDDM ■
Fig. 3.1.1a. Eigenvector representation of the differences
between the patients and control groups, in the 
Melbourne population.
Figure 3-1 -lb
CONTROL
MIDDM
NIDDM
IDDM
1 ri• 004 003 002 001
Fig. 3.1.1b. Differences between diabetic and control groups, 
represented by a dendrogram, in a Melbourne 
population.
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series. However, the error due to sample size cannot be 
estimated.
Although the differences in the separation due to chromosome 
6 markers and non-chromosome 6 markers are not depicted, the 
importance of both must be realized in the separation of the 
subgroups of diabetics from each other and the control series.
SUMMARY
In the study of the Melbourne series of diabetics and 
controls, the screening of genetic markers on chromosome 6 and 
not on chromosome 6 have provided interesting results. In the 
IDDM series, a strong association of two non-HLA markers is 
demonstrated, that due to allele of the Bf locus and of the 
complement component C'2. The distinction of IDDM from the 
rest of the series due to these markers, show that other markers 
within the HLA complex may also be involved in disease processes 
and confer a genetic susceptibility to individuals. It is of 
interest also that the other chromosome 6 locus studied, glyox- 
alase, which is further away from the HLA region, does not 
contribute to the distinction between the IDDM and NIDDM or 
MIDDM series.
There is nothing to suggest that the Bf or C'2 loci have 
any direct connection with susceptibility to IDDM, it is most 
likely that they are important only because alleles at these 
loci are in linkage disequilibrium with specific disease suscept­
ibility genes and that tests for these systems are important there­
fore in extending the detail of haplotypes which are characteristic
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of the chromosomes carrying particular susceptibility alleles.
No definite marker in the case of NIDDM or MIDDM series 
can be demonstrated in this study. The significant disturbances 
at the Gc, GPT and PGM loci, however, indicate the importance of 
further study. In the case of Gc, it is known to be associated 
with other diseases and immune related functions for it has been 
suggested. Thus there is a possibility of a non-HLA, non­
chromosome 6 marker being involved in the mature onset disease 
process. Further sudies will be necessary to draw any definite 
conclusions. The study also demonstrates the effects of ethnic 
stratification which may produce artifacts of association and 
indicates the importance of specifying carefully the ethnic 
origins of both patients and controls. In the case of the PGM^ 
association with the NIDDM and MIDDM series, it shows also that
the age of patients may be of importance as a confounding factor.
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Chapter 3
AUSTRALIAN POPULATION 
Section 2: Western Australia
The series studied was derived from three populations in W.A. 
Geraldton (n = 100), Perth (n = 33) and Kalgoorlie (n = 141) .
Details are given in Chapter 2. Patients were subdivided for the 
Melbourne series. Since the sub-division resulted in small numbers 
in each category, the three populations were combined for analysis.
Chromosome 6 markers 
Glyoxalase I (GlO)
The glyoxalase data for the combined Western Australia series 
are shown in table 3.2.1. In the small samples of 42 IDDM patients, 
the distribution of glyoxalase phenotypes shows an increase of 14.5% 
in GLO 1-1 as compared to controls; correspondingly there is a 
decrease of 13% and 1.1% in the GLO 2-1 and 2-2 phenotypes. The 
difference, when tested for heterogeneity, is not significant.
In the MIDDM series there is an 8.8% increase of GLO 1-1 
which also is non-significant. The NIDDM series compares closely 
to controls with a difference of 1.6% in GLO 1-1 and a decrease of 
GLO 2-1 by 5%. Even when the two mature onset diabetic series 
(MIDDM and NIDDM) are combined the differences from controls in 
the two series are not significant. This is unJike the results 
shown in the Melbourne NIDDM series, where there is a distortion 
in the GLO phenotypes. It was suggested that this is due probably
to the ethnic stratification of the Melbourne population. Unfortun-
109
Table 3.2.1
Distribution of glyoxalase (GLO) phenotypes and gene frequency 
in diabetic and control population of Western 
Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 GLO GLO
Control 72 195 115 382 0.4437 0.5563
IDDM 14 16 12 42 0.5238 0.4762
NIDDM 24 58 43 125 0.4240 0.5760
! MIDDM 18 32 15 65 0.5231 0.4769
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 5.3 0.05>P>0.10 2
NIDDM vs. controls:
X2 = 1.0 P<0.52
MIDDM+NIDDM vs. controls:
X2 = 0.96 n.s.2
gene frequency in IDDM vs. controls:
X2 = 2.0 P<0.1
1
in NIDDM + MIDDM vs. controls:
X2 =0.26 n.s.
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ately information about ethnic origin of patients in the W.A. 
series was not available so that no analysis of this point could 
be made
Complement factor : Properdin factor B (Bf)
The strong association of IDDM with Bf rare factors demonstra­
ted in the Melbourne population can also be observed in the Western 
Australian series. Of the 39 IDDM individuals, there are 5 (13%)
with factors BfS^ and BfF^ (table 3.2.2) as compared to 12 (3.2%)
FI SIin controls. The increase of combined Bf and Ilf genes in the 
IDDM patients is significant (x2 = 8.25: 0.01<P<0.001).
When the age distribution is considered, the individuals with 
the Bf rare factors were 4, 9, 27(2) and 28 years at the time of 
onset. In the remaining IDDM patients the ages ranged from 14-39 
years, with only 3 individuals below the age of 10 years. This 
higher age of diagnosis of IDDM patients in the W.A. population, 
as compared with the Melbourne series, is due to the different 
method of ascertainment in the two localities, particularly the 
reliance in Melbourne on obtaining IDDM patients from a children's 
hospital.
There is no significant increase of the Bf rare alleles among
the NIDDM and MIDDM series: x2 = 0.037 (n.s.). Like the Melbourne
1 Sseries, there is an increase of the Bf allele in all three W.A.
diabetic series, 5.2% in the IDDM and MIDDM and 4.8% in the NIDDM
Fseries. A corresponding decrease of Bf_ allele is also noted and is
significant in the IDDM series (9.8% compared to controls) with a
probability at less than the 2 per cent level. In the NIDDM and
FMIDDM series this decrease of the Bf allele is 5.2 and 5.1%
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respectively. When the two series are combined the difference
is significant at the P = 0.05 - 0.02 level.
The association of the Bf rare factors in both the W.A. and
Melbourne IDDM series confirms the importance of these as markers
for susceptibility to the insulin-dependent form of the disease,
at least in populations of European origin.
It is of further interest, however, that in the mature-onset
Fpatients in W.A. there is a significant decrease in the Bf allele. 
A similar decrease was present in the Melbourne series though it 
was not significant.
Complement Component C'2
The increased frequency of C^2 2-1 phenotype described for the
Melbourne IDDM series, is also seen among the West Australian IDDM
series, but does not reach a significant level (table 3.2.3). The
NIDDM and MIDDM series compare well with the control series. The
2allele frequency for C^2 is 3.4% higher in the IDDM series and 
less by 1.0% in NIDDM and MIDDM respectively when compared to 
controls.
Analysis for association between C"2 and Bf factors was under­
taken to see whether there was any disequilibrium between the
factors of the two systems. Table 3.2.4 gives the observed and
oexpected values (in parenthesis). The x values obtained do not 
show significance and therefore the distribution of phenotypes in 
the two systems is independent. This compares well with the 
results in the Melbourne IDDM series. None of the Bf rare factors 
are present in the C"2 2-1 positive individuals either in the IDDM
or the control series in this population.
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Table 3.2.4
Distribution of joint phenotypes of C'2 and Bf factors 
in control and IDDM population of 
Western Australia
IDDM CONTROL
Bf C'2
1-1 2-1
Total C'2
1-1 2-1
Total
SS 20
(19.4)
3
(3.6)
23 99
(99.2)
8
(7.7)
107
FS 4
(5.0)
2
(0.94)
6 43
(43.6)
4
(3.4)
47
FF - - 4
(3.7)
- 4
SFl
(0.84)
- 1 3
(2.7)
- 3
: FFi _ - - 2
(1.9)
- 2
i  SSI 2
(1.6)
- 2 3
(2.7)
- 3
| TOTAL
1
27 5 32 154 12 166
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Non-chromosome 6 markers - Serxm proteins 
Group Specific Component (Gc)
The data obtained for this series are shown in table 3.2.5.
On examination of the phenotype distribution, there is an increase
of Gc 2-2 phenotypes by 11.8% and a decrease of Gc 2-1 by 6%
among the IDDM series as compared to controls. Correspondingly
2the gene frequencies show an increase by 8.8% in the G£ allele.
These differences, however, are not significant.
There is a tendency of slight increase in the Gc 2-1 and 2-2 
phenotypes among the NIDDM and MIDDM series. But more interesting 
is the increase in Gc 1-1 by 7% and 9% respectively, when compared 
to controls. These differences are not significant in either 
series independently, but when combined as NIDDM+MIDDM, and then 
tested for heterogeneity of phenotypes, it is marginally signifi­
cant. For heterogeneity of gene frequencies it is significant at 
less than the 2 per cent level..
Since the disturbance seen in the distribution of phenotypes 
and alleles in the Melbourne NIDDM and MIDDM series is also noted 
in the West Australian NIDDM and MIDDM combined series, it suggests 
that the Gc groups, which are the expression of genetically control­
led variants of one of the a-globulins, are of importance in 
relation to susceptibility to mature-onset diabetes in the Australian 
population.
Haptoglobin (Hp)
Unlike the Melbourne series, there is an increase of 6.4% in 
Hp 1-1 and a 10% decrease of Hp 2-1 phenotypes in the MIDDM as
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Table 3.2.5
Distribution of Group Specific Component (Gc) phenotypes 
and gene frequencies in diabetes and control 
population of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
-
No.
Tested
Gene
Frequency
1 2 Gc Gc
Control 168 148 42 358 0.6760 0.3240
IDDM 14 12 8 34 0.5882 0.4120
NIDDM 38 29 4 71 0.7394 0.2610
MIDDM 29 20 2 51 0.7647 0.2353
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 4.57 P<0.102
gene frequency in IDDM vs. controls:
X2 = 1.70 P>0.20
1
phenotypes in NIDDM+MIDDM vs. controls:
X2 = 5.52 0.10<P<0.05 2
phenotypes in MIDDM vs. controls:
X2 = 3.70 p<0.20 2
gene frequency in NIDDM+MIDDM vs. controls:
X2 = 4.39 0.05<P<0.02 
1
0NIDDM vs. control x =
1
2.83 P>0.1
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compared to controls. The increase of Hp 1-1, however, is con­
sistent in all three W.A. diabetic series, being 1.8%, 0.7% and 
6.4% in the I, NI and MIDDM series respectively. Although these 
results support the observations of Berg (1967) , who also showed
an increase of Hp 1-1 among the diabetic series, the distribution 
of Hp phenotypes and gene frequencies in the three W.A. series do 
not deviate significantly from that in controls (table 3.2.6).
Transferrin (Tf)
The distribution of Tf variant phenotypes is shown in table
3.2.7. There is an increase of 2.9%, 0.8% and 3.2% of the CB^
phenotype in the IDDM, NIDDM and MIDDM series, with a decrease of
2.5%, 1.3% and 6% in the CC phenotype respectively. When tested
for heterogeneity the differences are not significant. A decrease
Cof 1.6%, 0.6% and 3.1% in T£ allele frequency and an increase of
B 21.8%, 0.4% and 1.6% is noted in the Tf allele frequency is noted 
in the IDDM, NIDDM and MIDDM series respectively.
Non-chromosome 6 markers: Red cell enzymes
Esterase D
The results in table 3.2.8 for the phenotype and gene 
frequency distribution in the W.A. series shows for MIDDM an 
increase of EsT-D 2-1 phenotypes by 8.4% compared to controls; 
and an absence of 2-2 phenotypes compared to 2.6% in controls, 
but these differences are not statistically significant. The 
NIDDM compares well with controls. No significant deviation is 
seen in the IDDM series for the phenotypes and gene frequency
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Table 3.2.6
Distribution of haptoglobin (Hp) phenotypes and gene 
frequencies in diabetes and controls of 
Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 Hp Hp
Control 52 172 149 373 0.3709 0.6300
IDDM 6 16 16 38 0.3684 0.6320
NIDDM 18 58 47 123 0.3821 0.6208
MIDDM 13 23 28 64 0.3828 0.6201
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 1.33 P=0.5
2
MIDDM vs.~ controls:
X2 = 3.08 P<0.22
NIDDM+MIDDM vs. controls:
0.69 n.s.
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Table 3.2.8.
Distribution of Esterase-D (EsT-D) phenotypes and gene 
frequencies in a diabetic and control 
population of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 EsT-D EsT-D
Control 290 79 10 379 0.8694 0.1306
IDDM 29 9 1 39 0.8590 0.1410
NIDDM 96 26 3 125 0.8720 0.1280
MIDDM 46 19 0 65 0.8538 0.1462
Heterogeneity of gene frequency in IDDM vs. controls:
X2 = 0.076 n.s.
1
NIDDM vs. controls:
X2 = 0.268 n.s.
1
NIDDM+MIDDM vs. controls: 
X2 = 0.231 n.s.
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distributions.
Acid phosphatase (PHs)
The distribution of phenotypes and gene frequencies in the 
control and diabetic series for acid phosphatases is given in 
table 3.2.9a. A decrease of 4.2% in the CB phenotypes is noted 
among the IDDM series, when compared to controls and an increase 
of 8% in the AB heterozygotes.
To examine if the decrease of CB was specific in any particu­
lar group of individuals, the data was broken into 2 categories, 
male and female. The numbers in the two categories are very small 
but the decrease of CB is noted in both sexes. In females the CB 
phenotype is absent while only one individual with CB is noted in 
the male IDDM series. In Melbourne, CB was absent among the male 
IDDMs. However, the data show the trend in one direction, that of 
a decrease in CB phenotypes in insulin-dependent diabetics. This 
can also be noted for the CA phenotypes in the IDDM series of this 
population (table 3.2.9b).
CThe allele frequency of PHs in the IDDM series correspondingly 
shows a decrease by 3.8% when compared to controls and the NIDDM 
series. PHs is decreased by 4.9% in the MIDDM series.
Although none of the above differences show statistical
significance, the decrease in the phenotypes controlled by the 
CPHs allele in the two IDDM series (Melbourne and W.A.) is of 
interest and further data should be collected to confirm whether
this trend is maintained.
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Phosphoglucomutase PGM I and II
There was no variation observed at the PGM^ locus in this 
series.
Table 3.2.10 shows the distribution of PGM^ phenotypes and 
gene frequency in the controls and diabetic series.
As compared to controls, there is a decrease in PGM 2-1 
phenotypes of 5.4% in the IDDM series and an increase of 3.4% 
in the MIDDM series, while the NIDDM compares well with controls. 
None of the differences noted are significant. An age effect 
was observed in the Melbourne NIDDM and MIDDM series, with a 
decrease of PGM 2-2 phenotypes in the older ages compared to 
controls. Such a trend is not present in the W.A. series. In 
Melbourne 25.9% of the mature-onset series are in the age range 70 
and over; in the W.A. series only 11% are in this range and, 
therefore, this may explain the lack of a relationship between PGM 
and mature-onset diabetes in the W.A. series.
Glutamic pyruvic transaminase (GPT)
Table 3.2.11 shows the phenotypes and gene frequency distri­
bution for the GPT enzyme. In the IDDM patients there is a non­
significant decrease of 7.5% in the GPT 2-1 phenotype. For the 
NIDDM and MIDDM series, however, as shown in the Melbourne series, 
there is an increase of 2.6% and 13.8% in the GPT 2-2. This 
difference in the excess of 2-2 phenotypes does not reach signifi­
cance in the MIDDM vs. controls but when the gene frequency compar­
ison with control is made it is significant•at less than the 2 per 
cent level. Therefore the importance of another non-chromosome 6 
marker is demonstrated in the Melbourne and W.A. mature-onset
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Table 3.2.10.
Distribution of phosphoglucomutase 1 (PGM^ ) phenotypes 
and gene frequencies in diabetics and control popula­
tion of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 PGM^ PGM_L
Control 221 128 31 380 0.7500 0.2500
IDDM 25 11 3 39 0.7821 0.2179
NIDDM 75 40 10 125 0.7600 0.2400
MIDDM 36 24 5 65 0.7385 0.2615
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 0.577 n.s.2
gene frequency in TDDM vs. controls:
'X2 = 0.306 n.s.
phenotypes in NIDDM+MIDDM vs. controls:
0.240 n.s.
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Table 3.2.11
Distribution of glutamic pyruvic transaminase (GPT) phenotypes 
and gene frequencies in diabetics and control series 
of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 GPT GPT
Control 63 89 37 189 0.5688 0.4312
IDDM 14 17 12 43 0.5233 0.4770
NIDDM 31 50 23 104 0.5384 0.4620
MIDDM 10 22 16 48 0.4375 0.5625
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 2.00 P<0.30 2
MIDDM vs. controls:
X2 = 4.96 P>0.10 2
NIDDM vs. controls:
X2 = 0.48 2
gene frequency in MIDDM vs. controls:
X2 = 5.30 p<0.02 
1
NIDDM+MIDDM vs. controls:
X2 = 2.30 P<0.10 
1
NIDDM vs. control x2 = 0.48 n.s.
1
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diabetic series.
Other systems
These include 6 Phosphogluconate dehydrogenase (6PGD), 
adenosine deaminase (ADA) and adenylate kinase (AK). No signifi­
cant variation in any of the diabetic series were observed in the 
phenotypes or gene frequency distributions. The data for the above 
systems are given in tables 3.2.12; 3.2.13; 3.2.14 respectively.
Multivariate analysis
As illustrated in figures 3.2.1 a and b, for the W.A. series, 
when subjected to a multivariate analysis of differences between 
the disease groups vs. controls, using information from 13 polymor-- 
phic systems, dispersion of the groups, to some extent, resembles 
the Melbourne series. The IDDM series is distant to the control and 
the mature-onset diabetics. However, the two mature-onset diabetic 
groups are not widely separated as in the Melbourne series, but are 
closer together. This may reflect differences between the populations 
of the two localities, and will be taken up for further discussion 
in a later section.
SUMMARY
The results obtained for the polymorphism in the W.A. pop­
ulation demonstrates yet again the strong association of Bf factors 
with the IDDM series. There is also an association of Cv2 
complement component although in W.A. it does not reach the level 
of statistical significance but it should certainly encourage the
Figure 3-2-la
CONTROL«
NIDDM ■
■  MIDDM
IDDM ■
Fig. 3.2.1a. Eigenvector representation of the differences 
between the patients and control groups in a 
Western Australian population.
F i g u r e  3•  2* 1 b
CONTROL 
IDDM 
NIDDM 
M IDDM
•02 •0
Fig. 3.2.1b. Differences between diabetic and control groups, 
represented by a dendrogram in a Western Austra­
lian population.
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Table 3.2.12
Distribution of 6-phosphogluconate dehydrogenase (6PGD) 
phenotypes and gene frequencies in a diabetic and 
control population of Western Australia
Series
Phenotypes 
AA AC CC
No.
Tested
Gene
Frequency
A C6PGD 6PGD
Control 366 16 0 382 0.9791 0.0209
IDDM 39 0 0 39 1.0000 -
NIDDM 122 3 0 125 0.9880 0.0120
MIDDM 64 1 0 65 0.9923 0.0077
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.86 n.s.
1
NIDDM+MIDDM vs. controls:
X2 = 1.75 P>0.2
1
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Table 3.2.13
Distribution of adenylate kinase (AK) phenotypes and 
gene frequencies in a diabetic and control 
population of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 AK AK
Controls 353 26 1 380 0.9632 0.0368
IDDM 39 0 0 39 1.0000 0.0000
NIDDM 114 10 0 124 0.9597 0.0403
MIDDM 61 4 0 65 0.9692 0.0310
Heterogeneity of gene frequency in NIDDM+MIDDM vs. controls:
X2 = 0.06 n.s.
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Table 3.2.14
Distribution of adenosine deaminase (ADA) phenotypes and 
gene frequencies in a diabetic and control 
population of Western Australia
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 ADA ADA
Control 347 34 0 381 0.9554 0.0446
IDDM 34 4 0 38 0.9474 0.0526
NIDDM 113 12 0 125 0.9520 0.0480
MIDDM 52 12 0 64 0.9063 0.0937
Heterogeneity of gene frequency in IDDM vs. controls:
X2 =0.14 n.s.
1
NIDDM+MIDDM vs. controls:
X2 = 2.70 P=0.1 n.s.
1
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collection of further data. Glyoxalase, on the other hand, does 
not contribute to the differences between the disease groups.
The distribution of Gc and GPT phenotypes and gene frequencies 
in the V I . A . , as in the Melbourne series, indicate the importance 
of other non-chromosome 6 markers which may be associated with 
mature-onset diabetes in patients of European origin. However, 
no consistent differences could be demonstrated between the 
NIDDM and MIDDM series, which were examined separately in this 
study.
FA further point of interest is the decrease of the Bf allele 
in both the NIDDM and MIDDM series in W.A. and in Melbourne but 
it is statistically significant only in W.A. Since no HLA markers 
are known to be associated with mature-onset diabetes, the 
disturbance at a closely linked locus, Properdin B, in mature- 
onset diabetes, is of great interest. It suggests a possible 
association of a chromosome 6 marker with at least some forms of 
NIDDM.
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Chapter 4 
INDIAN POPULATION
Diabetes among the Indian population is known to vary 
according to diet, social stratification as well as different 
ethnic groups (Moses and Kannan 1976), but it is not clear 
whether these differences are determined by genetic or environ­
mental factors (Ahuja 1976). A characteristic type of pancreatic 
diabetes is known to occur, particularly in South India, in those 
with very low socioeconomic and nutritional status, this is 
particularly true in the 16-30 age group (Viswanathan 1980).
In this age group, the frequency of diabetes is much lower 
than that in the European population and in several Indian series 
of diabetes, it is less than 1 per cent in the 16 years age group 
(Viswanathan et at, 1966; Patel and Talwalker1966) . A characteristic 
feature in the lean population of Tropics is the resistance to 
ketosis despite withdrawal of insulin (Ahuja et at, 1965;
Tripathy et at, 1976).
For the present investigation, however, although the details 
are not disclosed the samples were derived from patients attend­
ing the diabetes clinic at the All India Institute of Medical 
Research, New Delhi, and were kindly supplied by Professor Ahuja 
(details in Chapter 2). The division into disease categories 
includes two types based on the clinical diagnosis.
1. (IDDM) Insulin dependent diabetes, aged below 40 years.
2. (NIDDM) Non-insulin dependent diabetes aged 40 and above 
(including only 3 individuals who were below 40, but diag­
nosed NIDDM).
Since all the mature-onset patients were non-insulin diabetics,
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there was no third category of MIDDM patients in the Indian 
population under study. In addition, samples from 50 non­
diabetic individuals in New Delhi were used as controls.
Chromosome 6 markers 
Glyoxalase I (GLO)
The data are given in table 4.1. The distribution of pheno­
types and gene frequencies among the control and IDDM series 
compare well with the published figures for other unaffected 
Indians of New Delhi (Ghosh 1977).
In the NIDDM series, however, there is an increase of 16% 
in the GLO 2-2 phenotypes. This difference is not statistically 
significant, and can be readily explained when the composition 
of the patient population is examined. There is a higher pro­
portion of residents of Punjab city (31 of 47) among the NIDDM 
series and 18 of the 31 are homozygous GLO 2-2 phenotypes. This 
is in comparison to (2 of 12) in controls. This distribution of 
2-2 phenotypes is unusual and may be why there is an excess
in the NIDDM series when compared to the controls. The increase
2of 4.8% and 10.8% in the GLO allele in the IDDM and NIDDM 
respectively is not significant.
Complement factor: Properdin factor B (Bf)
The distribution of the Bf phenotypes among diabetic and
Scontrols is shown in table 4.2. The frequency of the B£ allele 
in the IDDM series is increased by 5.4% and decreased by 4.7% in 
the NIDDM series. This is unlike the Australian series where
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Table 4.1
Distribution of glyoxalase (GLO) phenotypes and gene 
frequency in the diabetic and control population
of Indians from New Delhi
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 GLO GLO
Control 4 16 13 33 0.3636 0.6364
IDDM 1 10 8 19 0.3160 0.6842
NIDDM 3 18 26 47 0.2603 0.7446
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 2.24 P<0.302
gene frequency in NIDDM vs. controls:
2.20 P<0.10
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Bf frequency was increased in all the diabetic series. The 
numbers tested, however, are small and the differences non­
significant .
Studies from this department (unpublished) and those of
Mauff et at (1976) on the South African Indians show an absence 
FIof Bf in that population. In the present Indian series, while 
there is one BfFF^ individual among the controls, is absent 
in the IDDM and NIDDM series.
FThere is a decrease of Bf allele by 11.4% in the same
series. The heterogeneity of distribution of alleles in the
IDDM and NIDDM series reaches significance at the 5 per cent
level but does not show significance when compared to controls.
FOf further interest is the increase of Bf allele among the
NIDDM individuals. In this point the Indian series do not
resemble either of the localities of the Australian series,
Fwhere a decrease of Pf allele was noted. However, the increase 
F -of Bf in the Indian NIDDM is also non-significant.
Although Indians appear to have a very low frequency of the
FI SIBf allele, the other rare allele, Bf , is increased in frequ­
ency compared to frequencies reported for European populations
where the gene frequency approximates 1.0%. In the present study 
SiBf has a frequency of 3.2% among controls but is 11.4% in the 
IDDM patients. It is increased slightly in the NIDDM series 
where it is 5.7%.
Unfortunately, the number of patients and controls studied
SIis small, but the results do suggest that Bf might be of
significance as a marker among Indian IDDM patients in the same 
FIway that Bf is a marker for IDDM in patients of European origin,
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Further study of this is needed.
Complement Component C'2
Insufficient serum was available for this test to be carried
out.
Non-chromosome 6 markers - Serum proteins
Group Specific Component (Gc)
Table 4.3 shows the distribution of phenotypes and gene 
frequencies in the control and diabetic series of N. India.
Large differences in the distribution of phenotypes are observed, 
both in the IDDM and NIDDM series, due to the small numbers 
examined. These differences show an increase of Gc 1-1 and 
Gc 2-1 in both diabetic series. An increase of Gc^ in NIDDM 
is similar to that of the Melbourne and W.A. series, but it is 
not statistically significant.
Haptoglobin (Hp)
As discussed in the earlier chapter (3.1) reports of distur­
bances in the phenotypic distribution of haptoglobin were noted 
with interest in view of the hypothesis of there being an effect 
of selection on the Hp 1-1 types.
In the IDDM series (table 4.4) an increase of 1.4% and 1.3% 
in the Hp 2-1 and Hp 2-2 are noted, whereas, in the NIDDM series 
a decrease of 10.4% and an increase of 6.3% are noted respectively 
in the above phenotypes. This compares well with the Melbourne
series where similar observations were made. However, the differ-
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Table 4.3
Distribution of group specific (Gc) proteins phenotypes 
and gene frequencies in the diabetic and control 
population of Indians from New Delhi
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency 
Gc1 Gc2
Control 18 14 4 36 0.6944 0.3056
IDDM 11 2 2 15 0.8000 0.2000
NIDDM 17 8 3 28 0.7500 0.2500
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.52 n.s. 
1
Table 4.4
Distribution of haptoglobin (Hp) phenotypes and gene 
frequency in the diabetic and control 
population of Indians from New Delhi
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
„ 1 2 Hp Hp
Control 1 16 31 48 0.1895 0.8125
IDDM 0 8 15 23 0.1740 0.8260
NIDDM 3 11 34 48 0.1770 0.8230
Heterogeneity of phenotypes in IDDM vs. controls:
X2 = 0.49 n.s.
2
NIDDM+IDDM vs. controls:
X2 =0.79 n.s.2
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ences are non-significant.
A range of Hp 0 frequency within 0.6% to 6.8% is known to 
occur among the general population of India (Kirk 1968), but in 
this series none were present in the controls and only two, one 
in each diabetic series, were noted.
Transferrin (Tf)
A total of only 3 transferrin variants were observed in all 
the persons tested. There was no deviation in the rare variants 
in the phenotype or gene frequency distribution in the diabetic 
and control series. Data are given in table 4.5.
Non-chromosome 6 markers: Red cell enzymes
Esterase-D (EsT-D)
Table 4.6 shows the phenotypes and gene frequency distribu­
tions in diabetics and controls. In a small sample of 25 IDDM 
patients, there were no EsT-D 2-2 phenotypes, compared to 10% in
NIDDM and 6% in the control series. A corresponding decrease in 
2the EsT-D allele frequency of 17% and 13% is also seen in com­
parison to control and NIDDM respectively. This is marginally
significant in the latter comparison. The difference of 4% in 
2EsT-D between controls and NIDDM is non-significant.
Acid Phosphatase (PHs)
The observations for this system are shown in table 4.7 .
In the IDDM series, there is a decrease in the phenotypic 
frewuency of PHs BB and PHs CB by 12% and 4% respectively while
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Table 4.5
Distribution of transferrin (Tf) phenotypes and gene 
frequency in the diabetic and control population 
of Indians from New Delhi
Series
Phenotypes 
CC CB2 CD
No.
Tested
----------------- 1
Gene frequency
TfC TfB
Control 49 1 50 0.9900 0.0100
IDDM 25 25 1.0000 0.0000
NIDDM 48 2 50 0.9800 0.0200
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.50 n.s.2
Table 4.6
Distribution of Esterase-D (EsD) phenotypes and gene 
frequency in the diabetic and control population 
of Indians from New Delhi
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 EsT-D EsT-D
Control 32 15 3 50 0.7900 0.2900
IDDM 19 6 0 25 0.8800 0.1200
NIDDM 30 15 5 50 0.7500 0.2500
Heterogeneity of gene frequency in IDDM vs. control:
X2 = 1.83 P>0.2
1
IDDM vs. NIDDM
3.20 0.10<P<0.05
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an absence of PHs CB is noted in the NIDDM series, with a 10% 
increase of PHs AA. As pointed out for the Australian series, 
there is a trend of decrease in the CB phenotype in IDDM and 
NIDDM (W.A.) series. This is also true for the Indian IDDM and 
NIDDM series. The analysis on the basis of sex revealed both 
individuals with the CB phenotype to be present in the male IDDM 
series as compared to 5 female individuals with CB phenotypes in 
the control series.
AThe frequency of allele PHs is increased by 12% in the IDDM
Cseries, and that of PHs by 2%. There is a similar 10% increase 
A Cof PHs and 6% of PHs in the NIDDM series.
All the above observations, although interesting, do not 
reach statistical significance and are therefore only suggestive 
of the influence of the acid phosphatase system in this Indian 
diabetic series. Once again the importance of further studies 
must be noted.
Phosphoglucomutase PGM I and II
At the PGM^ locus the distribution of phenotypes was mono- 
morphic, both in controls and the diabetic series.
For the PGM^ locus, the NIDDM series differs from the controls 
in the distribution of PGM 1-1 and PGM 2-1 phenotypes (table 4.8). 
There is an 11.2% decrease in PGM 1-1 and a 7.8% increase of PGM 
2-1. The same trend is seen in the IDDM series, the differences 
being largely due, probably, to the small numbers examined and 
are not statistically significant. The corresponding decrease of 
the PGM  ^allele is seen in both the IDDM and NIDDM series, the
decrease being 7.4% and 7.3% respectively, and being non-significant
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Table 4.8
Distribution of phosphoglucomutase I (PGM^) and gene 
frequency in the diabetic and control population 
of New Delhi Indians
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
1Gene frequency
1 2 PGM PGM
Control 21 13 4 38 0.7237 0.2763
IDDM 8 10 2 20 0.6500 0.3500
NIDDMi 21 20 7 48 0.6508 0.3541
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 1.36 n.s.
1
IDDM vs. controls:
X2 = 0.72 n.s.
1
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The effect of increasing age, showing a decrease in PGM 
2-2, which was noted in the Melbourne series, is not observed 
in the Indian diabetic series. However, on examination of the 
age range in this population only 10% of the NIDDM individuals 
are in 60-65 years of age with none over 65 years, while the 
remaining individuals lie in the 38-59 age group. This may 
account for the lack of age effect in this series when compared 
to the much older age structure in the mature-onset cases in 
Australia.
Other systems
In this series, the results obtained for ADA and GPT were 
not included in the analysis due to the unreliability of the 
samples.
For the following systems, adenylate kinase (AK) and 6- 
phosphogluconate dehydrogenase (6PGD) there was no significant 
difference in the phenotypes or gene frequencies among the 
diabetic and control series. The data is given in tables 4.9 
and 4.10.
SUMMARY
Of the chromosome 6 markers, the distribution of the pheno­
types and allele frequency at the glyoxalase locus, does not 
yield informative results in contributing to the differences 
between the control and diabetic series.
There is an apparent association with BfS^ . factor in the 
IDDM series, suggesting its importance as a marker for this
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Table 4.9
Distribution of adenylate kinase (AK) phenotypes and 
gene frequency in the diabetic and control 
population of Indians from New Delhi
Series Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 AK AK
Control 35 4 4 43 0.8604 0.1405
IDDM 18 1 2 21 0.8809 0.1200
NIDDM 41 7 2 48 0.9300 0.1150
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.38 n .s.
1
IDDM vs. controls:
X2 = 0.29 n.s.1
Table 4.10
Distribution of 6-phosphogluconate dehydrogenase (PGD) 
and gene frequency in the diabetic and control 
population of Indians from New Delhi
Series
Phenotypes 
AA AC CC
No.
Tested
Gene frequency 
6PGDA 6PGDC
Control 50 - - 50 1.0000
IDDM
I
25 - - 25 1.0000
NIDDM
_
48 2 - 50 0.9800 0.0200
Chi-square test was not applied due to small numbers
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population. The absence of an association between IDDM and 
BfF in India is not surprising, since it seems that the BfF^ 
factor is absent or at least very rare in the normal Indian 
population.
Among the non-chromosome 6 markers, the trend of the
2 Cdistribution for the Gc and PHs noted in the Australian
series, is also in the same direction.
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Chapter 5
PACIFIC ISLAND POPULATIONS 
Section 1: Western Samoa
Extensive studies on the prevalence of diabetes in Pacific 
Island populations are being carried out by various workers. 
Recent interest has stemmed from the increased prevalence rates 
of diabetics among many of these populations (see Chapter 1 for 
a summary).
Zimmet and Kirk (1979) have shown a prevalence of 10.1% 
and 3.6% among the urban and rural Samoans respectively.
Samples from the same urban and rural Samoan population have 
formed the basis for the present study. Persons with a 2 hour 
glucose tolerance level of 160 mg% or higher were classified as 
diabetic. Controls were selected by matching, wherever possible, 
for village, age and sex from among those persons with 2 hour 
plasma glucose levels below 160 mg%.
Unlike Caucasians, diabetes only of the NIDDM type is seen 
in the Samoans, IDDM being rare or absent. The present study 
therefore refers only to the NIDDM type of diabetes.
Chromosome 6 markers
Glyoxalase I l (GLO)
The data in table 5.1.1 show the distribution of glyoxalase
1 in the control and diabetic Samoan series. There is a 10%
decrease in the GLO 2-2 phenotype in the NIDDM compared to
2controls with a corresponding 4.8% decrease in the GLO allele
frequency. This deviation is opposite to that seen in the mature-
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Table 5.1.1
Distribution of GLO phenotypes and gene frequencies 
in the diabetic and control population of 
W. Samoa
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 GLO GLO
Control 1 27 82 110 0.1318 0.8682
NIDDM 2 37 75 114 0.1798 0.8202
Heterogeneity of gene frequency in NIDDM vs. controls:
2.56 P<0.1
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onset patients in both Australian series and the Indian series.
In the present instance, however, the difference is statistically 
non-significant.
Complement factor : Properdin B(Bf)
The results are given in table 5.1.2. There is a marked
decrease of the homceygous BfF phenotypes in the NIDDM series,
Freflected in a 5.2% decrease in the frequency of B£ . Although 
this is statistically non-significant it is in the same direction 
as the two Australian NIDDM series. There was a non-significant 
increase in BfF in the Indian NIDDM series.
Of note is the presence of 2 SF^ and 1 SS^ persons among 
the NIDDM patients in Samoa. No rare Bf types were present among 
the Samoan controls and, indeed, BfF^ and BfS^ have been found 
only very infrequently in Pacific populations (unpublished obser­
vations from this laboratory). Since these three individuals 
with BfF^ or S^ were present exclusively in the NIDDM series, it 
does suggest that these types may be of importance in a small 
proportion of cases.
Complement component C^2
It was not possible to obtain satisfactory typing in this 
system for the controls series. Table 5.1.3 therefore gives 
results only for the NIDDM series. It is of interest only in 
showing that the 2-1 phenotype is present in 5% of these persons, 
but it is not possible to compare this with a suitable non-
affected group.
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Table 5.1.3
Distribution of C'2 phenotypes and gene frequency in a 
NIDDM population of W. Samoa
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency 
C'21 C'22
NIDDM 102 5 0 107 0.9770 0.0233
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Non-chromosome 6 markers - Scrum proteins
Group Specific Component (Gc)
There is no significant difference in the distribution of
either phenotype or gene frequencies between NIDDM and controls
(table 5.1.4). The differences which do exist, however, are in
the opposite sense from those found in the Australian and Indian
series, the Samoan NIDDM series having a slightly decreased 
1 _Gc frequency.
Haptoglobin (Hp)
There is a 7% increase in Hp 1-1 phenotypes in the NIDDM 
series (table 5.1.5) and this is similar to the increase found 
in both the Australian and Indian NIDDM series. None of the 
differences are statistically significant. This is true also 
for the slight increase in the Samoan NIDDM Hp^ allele frequency.
Transferrin (Tf)
In the total Samoan series only 2 transferrin variants were 
found, one CD and one CB^. There was no difference between the 
NIDDM and control series.
Non-chromosome 6 markers: Red cell enzymes
Esterase D (EsT-D)
Table 5.1.6 shows there is a slight decrease in the EsD 1-1 
phenotypes among the NIDDM cases with a 1.4% decrease in the EsD^
allele frequency. These differences are statistically non-
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Table 5.1.4
Distribution of group specific component (Gc) phenotypes 
and gene frequency in the diabetic and control 
population of W. Samoa
Series Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 Gc Gc
Control 60 75 5 140 0.6964 0.3036
NIDDM
_
43 49 8 100 0.6750 0.3250
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 2.68 P<0.302
gene frequency in NIDDM vs. controls:
X2 = 0.26 n .s.
1
Table 5.1.5
Distribution of haptoglobin (Hp) phenotypes and gene 
frequency in the control and diabetic population of
W. Samoa
Series Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 Hp Hp
Control 41 62 22 125 0.5760 0.4240
NIDDM 42 46 21 109 0.5963 0.4037
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 1.29 P< 0.5 02
gene frequency in NIDDM vs. controls: 
X2 = 0.19 n.s.
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significant.
Acid phosphatase (PHs)
CThe PHs allele does not occur normally in Pacific Island 
populations except in persons with part-European ancestry. This 
may explain the solitary person with the CB type among the 
controls (table 5.1.7).
Among the Samoan NIDDM cases there is a decrease of pheno-
p^type AA, but the decrease of the PHs allele frequency is only
plmarginal (1.2%). A decrease of PHs was found also among NIDDM 
patients in both the Melbourne and W.A. series.
Phosphoglucomutase (PGM) I and II
No variation at PGM II locus was noted in control and diabetic
series. As shown in table 5.1.8 there is a decrease of PGM 2-1 and
2-2 phenotype frequencies among the Samoan NIDDM cases compared
to the controls and there is a corresponding decrease of 7.2%
2in the PGM  ^allele frequency, this difference approaching 
significance at the 5% level. The decrease in PGM  ^ is signifi­
cant in the Melbourne NIDDM series among persons of north European
origin and this appears to be due to the decreased frequency of 
2PGM  ^in old persons. It is of interest, therefore, that a similar 
trend is present in Samoans, even though only 7% and 8% respectively 
of the control and NIDDM series were aged 70 years and over.
Other systems
No genetic variation is found for AK in Pacific Island 
populations and this was true for Samoans. In addition, typing
of the Samoan samples was found to be unreliable for the ADA and
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Table 5.1.6
Distribution of esterase-D (Est-D )phenotypes and gene 
frequency in the diabetic and control population 
of W. Samoa
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2Est-D Est-D
Control 39 55 22 116 0.5733 0.4267
NIDDM 31 60 18 109 0.5596 0.4404
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 1.32 P<0.22
gene frequency in NIDDM vs. controls:
X2 = 0.14 n.s.
1
Table 5.1.7
Distribution of acid phosphatase (PHs) phenotypes and 
gene frequency in the diabetic and control 
population of W. Samoa
Phenotypes No.
Tested
Gene frequency
Series
AA AB BB CB APHs BPHs CPHs
Control 8 34 77 1 120 0.2083 0.7875 0.0042
NIDDM 1 45 74 0 120 0.1958 0.8042 0.0000
Heterogeneity of gene frequency in NIDDM vs. controls: A vs. B+C
X2 = 0.11 n.s.
2
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Table 5.1.8
Distribution of phosphoglucomutase I (PGM^) phenotype 
and gene frequency in the diabetic and control 
population of W. Samoa
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 PGM^ PGM^
Control 57 42 14 113 0.6903 0.3097
NIDDM 73 34 11 118 0.7627 0.2373
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 3.10 P>0.252
gene frequency in NIDDM vs. controls:
X2 = 3.08 0.10<P<0.05
1
Table 5.1.9
Distribution of 6-phosphogluconate dehydrogenase (6PGD) 
phenotypes and gene frequency in the diabetic and 
control population of W. Samoa
Series
Phenotypes 
AA AC CC
No.
Tested
Gene frequency
A CPGD PGD
Control 80 23 2 105 0.8714 0.1286
NIDDM 88 28 4 120 0.8500 0.1500
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.40 n . s. 
1
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GPT systems and the results have not been included in the 
present study.
6PGD (see table 5.1.9) shows very similar phenotype 
distributions in the NIDDM cases and controls. There is a 
slight decrease of 2% in the PGD allele frequency in the NIDDM 
series, but the difference is non-significant.
SUMMARY
The Samoan NIDDM series show similarity with the NIDDM
series of Australia at two loci, one on chromosome 6 (Bf) and
the other a non-chromosome 6 marker (PGM). At the Properdin
factor B locus, there is no significant increase of Bf rare
Falleles but a decrease of the Rf is noted in the NIDDM series. 
The trend for GLO 2 phenotypes is, however, in the opposite
direction. At the non-chromosome 6 markers there is an absence
C non- 2
of PHs and a^significant decrease of PGM allele is noted in
2the NIDDM series and the trend for Gc is again in the opposite 
direction to the Melbourne series. At the other loci no signifi­
cant disturbance in the phenotype or gene frequencies were noted.
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Chapter 5 
Section 2: Nauru
The highest known prevalence of diabetes in the Pacific 
Island population is that of 42% among the Micronesians of 
Nauru (Zimmet and Kirk, 1979). The age and sex specific 
incidence shows a higher incidence among the males 53.5%, 
compared to females 48.2% at ages 45-54 years. Based on a 
recent study, Zimmet and Kirk (1979) suggest a genetic difference 
in the Micronesian population when compared with Polynesians 
with respect to the significantly higher plasma insulin concen­
tration in the former.
The Nauru population's experience of diabetes compares 
closely with the prevalence among the Pima Indians. There is 
a marked similarity in the occurrence of a bimodal curve for the 
distribution of two hour blood glucose values in the two popula­
tions and the two components enable the separation into NIDDM 
and normal individuals, unlike the unimodal distribution among 
Caucasians. IDDM type diabetes is absent, or of rare occurrence 
in Nauru.
This study includes individuals in the first and second 
components of the bimodal curve. The criteria used for diagnosis 
are outlined in Chapter 2.
Due to improper conditions of storage of the red cells and 
serum samples, results of certain enzymes (GLO and ADA) and 
complement C'2 were not reliable and are therefore excluded
from the discussion.
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Chromosome 6 markers
Complement factor; Properdin factor B (Bf)
The data obtained for this population is shown in table 
5.2.1. In contrast to the previous observations of other 
populations, there is an absence of homozygotes Bf FF, both in 
the control and the NIDDM series. The frequency of Bf SS is 
higher than that in the Australian series in controls, 
decreasing by 5% in the NIDDM series. The rare types, infrequ­
ent among Pacific populations are absent in Nauruans. There is
Fa non-significant increase of Bj[ by 2.1% in the NIDDM series, 
which is similar to the Indian series, but not with the trend 
observed in the Australian and Samoan series.
Non-chromosome 6 markers - Serum proteins 
Group Specific Protein (Gc)
The results of the observations of the Nauru population are
given in table 5.2.2. The phenotypic distribution in the NIDDM
series, like the Australian and Indian series, shows a tendency
for a decrease in the Gc 2-2 phenotype, which is reflected in the
2slight decrease of Gc_ allele frequency. This difference is, 
however, not significant.
Haptoglobin (Hp)
An increase of Hp 2-1 and 2-2 is noted in the NIDDM series
2(table 5.2.3), reflected by an increase of 5.2% in the Hp 
allele frequency. This trend is similar to that followed in the
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Table 5.2.1
Distribution of Properdin factor B (Bf) phenotypes 
and gene frequencies in the diabetic and control 
population of Nauru
Phenotypes No.
Tested
Gene frequency
Series
SS FS FF BfS FBf
Control 88 15 103 0.9301 0.0781
NIDDM 65 16 81 0.9012 0.0990
Heterogeneity of phenotypes in control vs. NIDDM patients:
X2 = 0.92 n.s.
1
gene frequency in control vs. NIDDM patients:
X2 = 1.00 P = 0.3 
1
Table 5.2.2
Distribution of group specific component (Gc) phenotypes 
and gene frequencies in the diabetic and control 
population of Nauru
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 Gc Gc
Control
NIDDM 
1_
57 40 6
51 25 7
103
83
0.7476 0.2524
0.7650 0.2350
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 1.70 n.s.2
gene frequency in NIDDM vs. controls:
X2 = 0.16 n.s.
161
Table 5.2.3
Distribution of haptoglobin (Hp) phenotypes and gene frequencies 
in the diabetic and control population of Nauru
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 Hp Hp
Control 22 47 33 102 0.4461 0.5539
NIDDM 12 39 29 80 0.3940 0.6063
Heterogeneity of phenotypes in control vs. IDDM patients:
X2 = 1.4 P = 0.50 2
gene frequency in control vs. NIDDM patients:
X2 = 1.8 P>0.2 1
Table 5.2.4
Distribution of Esterase D (EsD) phenotypes and gene 
frequencies in the diabetic and control 
population of Nauru
Series
Phenotypes No. Gene frequency
1-1 2-1 2-2 Tested 1 2EsT-D EsT-D
Control 25 54 30 109 0.4770 0.5230
NIDDM 41 60 44 145 0.4906 0.5104
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 1.8 n.s .
2
gene frequency in NIDDM vs. controls:
X2 = 0.03 n.s.]
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Melbourne, Indian and Samoan series. The difference in this 
series is not statistically significant.
Transferrin (Tf)
CThere is a very high frequency of Tf allele among the 
Pacific populations and this is also true for the Nauru control 
and NIDDM series. No rare variants were observed in this study.
Non-chromosome 6 markers: Red cell enzymes
Esterase-D
Unlike the low frequency of EsT-D 2-2 phenotypes among the 
Australian and Indian series, EsT-D 2-2 is high in Ehcific 
populations as shown for example with the Samoan series. This 
is also true of the NIDDM series in the Nauru populations (table 
5.2.4). There are no significant differences between the control 
and NIDDM in the phenotypes or gene frequency distribution.
Acid Phosphatase (PHs)
A BAcid phosphatase has two alleles, PHs and PHs , in the
control and NIDDM series of Nauru (table 5.2.5). There is an 
Cabsence of PHs allele, as noted also in the other Pacific popula­
tion of Samoa (with one exception). The trend of a decrease of 
the PHs allele is seen in the NIDDM series and also compares with 
that in the Melbourne and Samoan series. This is, however, not
statistically significant.
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Table 5.2.5
Distribution of acid phosphatase (PHs) phenotypes and gene 
frequencies in the diabetic and control 
population of Nauru
Phenotypes No Gene frequencySeries
AA AB BB Tested APHs BPHs
Control 8 44 57 109 0.2752 0.7250
NIDDM 11 51 83 145 0.2517 0.7483
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 0.74 n.s.
gene frequency in NIDDM vs. controls:
X2 = 0.37 n.s.1
Table 5.2.6
Distribution of phosphoglucomutase (PGM) phenotypes and gene 
frequencies in the diabetic and control
population of Nauru
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene frequency
1 2 PGM1 PGMl
Control 87 21 1 109 0.8945 0.1055
NIDDM .105 36 4 145 0.8483 0.1517
Heterogeneity of gene frequency in NIDDM vs. controls:
2.5 P<0.10
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Phosphoglucomutase (PGM) I and II
Like the other populations, the distribution of PGM^ is 
monomorphic also in the population of Nauru.
An increase of 5.6% and 1.9% is noted in PGM 2-1 and PGM^
22-2, reflected in a non-significant increase of 4.6% of the PGM 
allele (table 5.2.6). In this respect, the observation compares 
with the Indian NIDDM series but shows an opposite trend to the 
Australian and Samoan series.
An examination of the age composition shows individuals 
over 70 years of age to comprise only 3.3% and 1.7% of the NIDDM 
and control series of Nauru, which is a much lower percentage 
than that seen in the Australian NIDDM series. The majority 
in the Nauru series belong to the 25-60 age group. Therefore 
the correlation with higher age noted in the Australian series 
does not occur in this population.
6-Phosphogluconate dehydrogenase (6PGD)
The data in table 5.2.7 shows the distribution of 6PGD 
phenotypes and gene frequencies in the control and NIDDM series 
of the Nauru population.
Interestingly, in the NIDDM series, there is an excess of
heterozygote 6PGD AC types, being 6.5% higher than that in
controls. Only 2 homozygotes 6PGD CC are observed compared to
Cnone in controls. The allele frequency 6PGD is consequently
increased by 4.6% and this increase is highly significant at
less than the 0.1% level (x2 = 7.8 0.01<P<0.001).
1
It is of interest to note that reports of association with
variants of 6PGD are known for some infectious diseases, like
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Table 5.2.7
Distribution of 6-pnosphogluconate dehydrogenase (6PGD) 
phenotypes and gene frequencies in the diabetic 
and control population of Nauru
Phenotypes i Gene frequency
Series
AA AC CC
No.
Tested „ A 6PGD c6PGD
Control 107 2 0 109 0.9908 0.0092
NIDDM 131 12 2 145 0.9448 0.0552
Heterogeneity of gene frequency in NIDDM vs. controls:
Individuals with 6PGDC: RR = 2.41
7.78 0.0KP<0.001
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the tuberculoid form of leprosy, where 6PGP*" and gpop^antoat 
were increased in patients with the above form of the disease 
(Serjeantson et at, 1979). Also in patients over 41 years with 
hepatomegaly and splenomegaly, 6PGD AC was reported to be in 
excess (Harrison et at, 1976). Both the above observations were 
made on populations in New Guinea.
CThe possible association with PGP in the NIPPM in the Nauru
Cdiabetic population is intriguing . Pue to low frequency of 6PGP 
in other populations the direction towards an increase or decrease 
cannot be associated. The association may, therefore, be 
exclusively for some forms of NIPPM in the Nauru population.
This study encourages the need for further data to confirm this 
phenomenon.
SUMMARY
The restricted number of genetic markers examined in the
Nauru series show several differences of distribution compared
with the Australian NIPPM series. This is true particularly
for the Bf and PGM polymorphism in which it resembles the
distribution among the Indian NIPPM patients. Similarity with
CSamoans is noted in the absence of the PHs allele
COf some significance is the possible association of 6PGP 
exclusively in the NIPPM series of Nauru. It may contribute 
as a marker, not on chromosome 6, for some forms of NIPPM in 
this population. However, conclusions cannot be drawn until
further data to confirm the above are examined.
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Chapter 6
PIMA INDIAN POPULATION
The American Indians of Arizona have been the focus of 
considerable epidemiologic study during recent years. The 
Pima population has, to date, the highest prevalence of diabetes 
in the world: 50% for those over 35 years of age (Bennett et aZ-,1971).
As pointed out in the previous chapter, there are two 
features in common between Nauruans and Pima Indians; 1. the 
bimoda.1 population distribution of the frequency of blood glucose 
concentration after glucose load which separates individuals 
into normal and diabetic and 2. the IDDM type of diabetes is 
rare or absent. The criteria used for diagnosis is outlined in 
Chapter 2. Controls were selected from individuals with 2 hour 
plasma glucose levels below 200 mg%.
Among those diagnosed as diabetic some were treated by oral 
tablets and, in some more severe cases, insulin was administered.
Due to the difficulties in identification of individuals by the 
form of treatment on the records made available, all the patients 
were regarded as a single category in the NIDDM series.
It is worthy of note that only four genetic markers have been 
examined previously in the Pima Indians. These are two of the red 
cell enzymes, Glyoxalase I and Phosphoglycolate phosphatase 
(Cadien et at, 1979) and two serum proteins, haptoglobin and 
transferrin (Matson et at, 1968; Kirk, 1971).
168
Chromosome 6 markers 
Glyoxalase I (GLO)
The distribution of phenotypes and gene frequencies for 
glyoxalase is given in table 6.1. As can be observed the data 
for the NIDDM series are almost identical with the controls.
The trend of an increase of the GLO 2-2 phenotype, noted in the 
Australian and Indian series, therefore, is not seen among the 
Pima Indians. The possible reasons for these discrepancies 
between the various populations will be discussed more fully 
in the final chapter of this thesis.
Complement factor____; Properdin fac.tor B(Bf).
The Bf system is almost invariant among the Pima Indians.
A single FS individual was noted among the controls and two FS 
and one SS^ persons in the diabetic series (table 6.2). From 
the information provided on ethnic origin, the single individual 
with the Bf SS^ phenotype was found to be admixed with other 
tribes with known European admixture. This may be a possible 
explanation for the occurrence of the solitary SS^ type. Because 
of the very low frequency of variants in the Pimas, Bf is unlikely 
to be of any value as a genetic marker for diabetes in this pop­
ulation .
Complement component C'2
The rare occurrence of C '2 2-2 phenotypes in Europeans is 
also true for the Pima Indians (table 6.3) and the per cent pheno­
typic distribution compares closely with the distribution in the
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Table 6.1
Distribution of glyoxalase (GLO) phenotypes and gene 
frequency in the diabetic and control 
population of Pima Indians
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 GLO GLO
Control 11 59 71 141 0.2872 0.7130
NIDDM 8 46 55 109 0.2844 0.7206
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 0.020 n.s.
2
gene frequency in NIDDM vs. controls:
X2 = 0.005 n.s.
1
Table 6.2
Distribution of properdin factor B (Bf) phenotypes and 
gene frequency in the diabetic and control population
of Pima Indians
Series
Phenotypes 
SS FS FF SSj^
No.
Tested
Gene
M 3
Frequency 
Bf F Bf S1
Control 141 1 - - 142 0.9965 0.0035 0000
NIDDM 106 2 - 1 109 0.9862 0.0092 0.0050
Due to the very small numbers x test was not applied.
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Melbourne series. In this series there is an increase of 3.8%
of C 2 2-1 in the NIDDM series, unlike the decrease noted in the
C^2 2-1 among the NIDDM of Melbourne series.
The heterogeneity of phenotypes in the control vs. NIDDM
2of Pima Indians is not statistically significant. The C^2 
allele frequency is correspondingly increased by 2% and again is 
not statistically significant. More data on this system may be 
of interest among the NIDDM series of Pima Indians.
Non-chromosome 6 markers - Serum proteins 
Group Specific Protein (Gc)
The distribution of phenotypes and gene frequency for Gc
among the controls and NIDDM is given in table 6.4. There is
no significant difference between the NIDDM series and controls.
2It may be noted, however, that the trend of an increase in Gc_ 
noted in the Samoans is also present in the Pima NIDDM series.
Haptoglobin (Hp)
As shown in table 6.5, the distribution of haptoglobin
phenotypes and gene frequencies in the NIDDM series, compare very
2well with controls. No trend of an increase in the Hp noted 
in the earlier populations, can be seen in the NIDDM series of 
Pima Indians.
Transferrin (Tf)
The fast variant CB^ is distributed with almost the same 
frequency in the NIDDM as in controls, and in the controls two
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Table 6.3.
Distribution of complement component C'2 phenotypes 
and gene frequency in a control and diabetic 
population of Pima Indians
Phenotypes No GeneSeries
1-1 2-1 2-2 Tested
Frequency 
C"2 C '2
Control 135 6 141 0.9790 0.0213
NIDDM 101 9 110 0.9591 0.0410
Heterogeneity of gene frequency NIDDM vs. controls:
X2 = 1.3 n. s.
1
phenotypes NIDDM vs. controls:
X2 =2.0 n.s.
2
Table 6.4
Distribution of group specific component (Gc) pheno­
types and gene frequency in a diabetic and 
control population of Pima Indians
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 Gc Gc
Control 113 25 3 141 0.8901 0.1109
NIDDM 85 21 3 109 0.8761 0.1239
Heterogeneity of gene frequency in NIDDM vs. controls:
X2 = 0.31 n.s.
1
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Table 6.5
Distribution of haptoglobin (Hp) phenotypes and gene 
frequency in a diabetic and control population 
of Pima Indians
Phenotypes No GeneSeries
1-1 2-1 2-2
Tested Frequency1 2 H£ H£
Control 43 68 28 139 0.5540 0.4460
NIDDM 34 50 23 107 0.5514 0.4490
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 0.21 n.s.
2
Table 6.6
Distribution of transferrin (Tf) phenotypes and gene 
frequency in a diabetic and control population 
of Pima Indians
Series
Phenotypes 
CC CB
No.
Tested
Gene frequency 
TfC TfB
Control 137 4 141 0.9908 0.0142
NIDDM 105 4 109 0.9817 0.0183
Heterogeneity of gene frequency NIDDM vs. control:
X2 = 0.33 n .s. 1
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of these individuals are admixed Pima Indians. There are no 
significant differences between the NIDDM and control series 
among the Pima Indian population (table 6.6).
Non-chromosome 6 markers: Red cell enzymes
Esterase D (EsT-D)
Table 6.7 gives the distribution of EsT-D phenotypes and
gene frequencies. There is an increase of 7.7% in EsT-D 2-1
and a slight decrease of 2.8% in the EsT-D 2-2 phenotypes,
these differences are not statistically significant.
2A slight increase of EsT-D allele in the NIDDM series 
maintained the trend observed in W.A. and Samoan NIDDM 
populations, although the difference again is non-significant.
Acid Phosphatase (PHs)
Two alleles of the acid phosphatase occur frequently in 
this population (table 6.8). A decrease of the PHs AB pheno­
type by 8% and an increase of PHs BB of 5.3% are noted in the 
NIDDM series and these are statistically non-significant. 
However, the decrease of PHs^ allele is consistent with that
observed in all the other populations except the Indian NIDDM 
Cseries. The PHs allele is frequent only in Caucasoids and is 
a Caucasian gene. The admixture with European population is 
considered to be about 6-7% in the Pima population, which may 
explain the solitary heterozygote CA in the controls.
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Table 6.7
Distribution of Esterase-D (EsT-D) phenotypes and gene frequency 
in a diabetic and control population of Pima Indians
Phenotypes
i
Gene Frequency
Series 1 21-1 2-1 2-2 Tested EsT-D EsT-D
Control 76 57 8 141 0.7411 0.2589
NIDDM 54 52 3 109 0.7340 0.2660
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 2.10 n.s.2
gene frequency in NIDDM vs. controls:
X2 = 0.03 n.s.
1
Table 6.8
Distribution of acid phosphatase (PHs) phenotypes and 
gene frequency in a diabetic and control population
of Pima Indians
Phenotypes 
AA AB BB CA
No.
Tested
Gene Frequency
A B C  PHs PHs PHs
Control 3 51 86 1 141 0.2057 0.7907 0.0035
NIDDM 6 31 73 0 110 0.1955 0.8050 0.0000
Heterogeneity of gene frequency in NIDDM vs. control:
X2 =0.05 n.s.1
phenotypes in NIDDM vs. controls:
X2 = 2.25 n.s.2
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Phosphoglucomutase I and II (PGM)
The distribution at the PGM^ locus was not polymorphic in 
this series of Pima Indians.
At the PGM^ locus, interestingly, there is a decrease of 
PGM 1-1 phenotypes in the NIDDM series by 13.9% as compared 
to controls, and an increase of 3.1% in the PGM 2-2 types 
(table 6.9). This trend is the reverse of that observed in 
the Australian and Samoan NIDDM series, but is similar to 
Indian and Nauru NIDDM population, where also a decrease in 
PGM 1-1 was noted. The decrease in the 1-1 phenotype is 
reflected in the decrease of PGM^ allele, which is significant 
at a 1 per cent level.
There is a difference in the age composition of the Pima
NIDDM patients when compared to the Australian NIDDM series,
in that only 2 individuals over 70 years were included in the
Pima patients, the large majority being in the 18-66 years
range. Therefore the possible association of PGM^ in Pima
NIDDM is seen in a series with a different age composition to 
2that of PGM^ in a higher age range of the Melbourne series.
These observations, therefore, indicate the importance of 
a non-chromosome 6 marker in the Pima NIDDM population and also 
necessitate further data to confirm the above phenomenon.
Glutamic pyruvic transaminase (GPT)
Although the NIDDM series showed differences in the pheno­
typic distributions when compared to controls, there being an 
8.5% increase of GPT 1-1 and a 14.6% decrease of GPT 2-1 (table
6.10), these differences are not statistically significant and
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Table 6.9
Distribution of phosphoglucomutase I (PGM^) phenotypes 
and gene frequency in a diabetic and control 
population of Pima Indians
n
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2PGM1 PGM^
Control 105 34 2 141 0.8652 0.1348
NIDDM 66 38 5 109 0.7808 0.2201
Heterogeneity of gene frequency x2 = 6.25 P=0.01
RR = 1.14 Woolf's x2 = 0.31 n.s.
1
Table 6.10
Distribution of glutamic pyruvic transaminase (GPT) 
phenotypes and gene frequency in a diabetic 
and control population of Pima Indians
Series
Phenotypes No.
Tested
Gene
Frequency
1-1 2-1 2-2 GPT GPT
Control 24 84 30 138 0.4782 0.5220
NIDDM 28 50 30 108 0.4907 0.5103
Heterogeneity of phenotypes NIDDM vs. controls:
X2 = 4.36 P<0.12
gene frequency NIDDM vs. controls:
0.13 n.s.
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may be due to the small sample sizes. Moreover, the GPT 
allele is decreased only very slightly in comparison to 
controls. The earlier NIDDM series in the Australian popula­
tion showed this decrease to be significant.
Phosphoglycolate phosphatase (PGP)
The polymorphism in phosphoglycolate phosphatase (PGP) 
has been described only recently by Barker and Hopkinson (1978) 
and it was not included in the battery of genetic marker tests 
for the other populations in the present study. However, because 
of the recent claim by Cadien et al (1979) of an association 
between PGP’*' and diabetes in the Pima Indians it was decided to 
test for this enzyme system in the samples available for study.
In the present investigation the data observed for the NIDDM 
and control series are shown in table 6.11. There is a 5.9% 
increase of PGP 1-1 and 4.1% decrease of PGP 2-2 phenotypes.
Neither of these differences are statistically significant.
The observations made by Cadien et al (1979) showed a 
large increase of PGP'*' allele frequency (24%) in the NIDDM vs. 
control comparison, which was significant. In the present 
investigation, however, although there is an increase of 5% 
in the PGP'*’ allele frequency, it does not show statistical 
significance. This discrepancy in significance of the two 
observations may well be due to the number of individuals examined: 
total control + NIDDM = 64 in Cadien et al's study vs. control
+ NIDDM = 205 in the present study.
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Table 6.11
Distribution of phosphoglycolate phosphate (PGP) pheno­
types and gene frequency in a diabetic and control 
population of Pima Indians
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency
1 2 PGP PGP
Control 55 46 19 120 0.6500 0.3500
NIDDM 44 31 10 85 0.7000 0.3000
Heterogeneity of phenotypes in NIDDM vs. controls:
X2 = 0.99 n.s.2
gene frequency in NIDDM vs. controls:
X2 = 1.40 n.s.
1
Table 6.12
Distribution of adenylate kinase (AK) phenotypes and 
gene frequency in a diabetic and control 
population of Pima Indians
Series
Phenotypes 
1-1 2-1 2-2
No.
Tested
Gene
Frequency 
AK^ AK2
Control 140 1 141 0.9965 0.0035
NIDDM 108 1 109 0.9954 0.0046
Chi-square test is not applied due to small numbers.
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Other systems
The AK 2-2 phenotype is of rare occurrence among the Pima 
Indians both in control and the NIDDM series (table 6.12), and 
the AK~*~ allele is distributed with 99.5% frequency in the Pima 
Indians. No variation in the NIDDM from the controls were 
observed,
6-Phosphogluconate dehydrogenase likewise shows a 100%
&distribution of the 6PGD allele and in contrast to the
CNauruans, there is an absence of the 6PGD allele in both the 
control and NIDDM series. (The data is not shown in table form).
SUMMARY
In this population, the chromosome 6 markers, GLO and Bf
do not contribute to differences between the NIDDM series and
2controls. A tendency towards an increase of C'2 , noted in
Pima NIDDM's is unlike that found in the Australian series.
The observations for the PGP system in this study do not
support the association with NIDDM claimed by other workers.
Among the other markers studied there is a significant 
2increase in the PGM^ allele among the Pima NIDDM patients 
which contrasts with a decrease of this allele in Australia and 
Samoan NIDDM's. No significant differences in gene or pheno­
typic frequencies were observed in any of the other systems
studied.
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Chapter 7
DISCUSSION
The objective of this investigation has been an attempt to 
demonstrate how genetic markers can be used to throw further 
light on the complexity of diabetes mellitus. This has involved 
an examination of serum protein and enzyme markers under genetic 
control, in a series of patient and control populations. The 
series of diabetic patients and controls were derived from two 
distinct localities of Australia - Melbourne and Western Austra­
lia, and others from widely separated geographical and environ­
mental areas provided by a series from North India, Micronesia 
(Nauru), Polynesia (Samoa) and from an Aboriginal population of 
North America.
The patient series were divided where possible into two 
categories: IDDM or type I - insulin dependent, aged less than
40 years at onset, and NIDDM or type II - mature-onset, aged 40 
years and above. This latter group, particularly in the Austra­
lian series, was further divided into those receiving insulin 
(MIDDM) and those being maintained either by diet alone or diet 
supplemented with oral hypoglycaemic agents (NIDDM). This 
division into M and NIDDM types is undoubtedly arbitrary, since 
the form of treatment may change from that at the time of 
diagnosis. A patient on a treatment by diet or oral agents alone 
may transfer to insulin after several years, and such a sub­
division, which distinguishes the duration of treatment in some 
patients, may be necessary in view of the heterogeneity of 
diabetes. Further studies should take such sub-division into
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account, but large series will be required since each specific 
sub-division reduces the number of patients to a point where 
statistical significance is harder to achieve, when associations, 
even if real, are not strong. The problems of small numbers of 
patients has been troublesome in the present study and is demon­
strated particularly with respect to all series except those in 
Australia. This makes many of the present conclusion only 
tentative and it will require further indepth study to either 
confirm or refute some of the associations reported.
The significant associations found, as well as the trends 
observed in each population, have been summarized in table 7.1 
and the importance of these associations and trends are discussed 
in detail below.
The genetic markers investigated have been considered in two 
separate groups - those controlled by loci on chromosome 6 and 
those controlled by loci on other chromosomes. This distinction 
was made- because previous studies demonstrated highly significant 
associations between HLA genes, controlled by at least 4 loci on 
chromosome 6 and the IDDM type of diabetes.
Chromosome 6 markers
This study has demonstrated a highly significant association 
between the IDDM type and one of the markers on chromosome 6 
(Properdin B). Some details of which have been published 
recently (Theophilus et at, 1980; Kirk et at, 1979) and
also confirmed by simultaneous studies of Raum et at, 1979,
Deschamps et at, 1979; Bertrams et at, 1979).
In the present series the increased relative risk, particularly
Table 7.1
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Comparison of the distribution of associations and trends in
AUSTRALIA
SYSTEM MELBOURNE W..A.
IDDM NIDDM IDDM NIDDM
* *
Increase S^ Increase 
Decrease
* *
Increase 0
BfF **Decrease Decrease **Decrease ★Decrease
C'22 * *Increase Decrease Increase Decrease
GLO2 0 tIncrease +Decrease Increase
2Gc Decrease ++^Decrease Increase ^Decrease
2Hp Decrease Increase 0 Decrease
CPHs Decrease Decrease Decrease Decrease
CB male CB male
APHs Increase Decrease Decrease Decrease
2PGM 0 * * -f-Decrease Decrease Decrease
2
GPT - Increase - Increase
15PGDC Increase 0 0 Decrease
2EsT-D +Decrease Decrease Increase Decrease
PGP1 - - - -
*Significance of gene frequency P=0.05
* *
P=0.02-0.01
phenotypic frequency + P=0.05
++ HOO1CNOOIIA
no difference = 0
Those not done are represented by
-  183 -
serum proteins and red cell enzymes in different diabetic populations
INDIA SAMOA NAURU PIMA
IDDM NIDDM NIDDM NIDDM NIDDM
Increase Increase Rare Absent Rare
Decrease Increase Decrease Increase 0
- - - - Increase
Increase Increase Decrease - Increase
Decrease Decrease Increase Decrease Increase
Increase Increase Decrease Increase 0
Decrease Decrease Absent Absent Absent
Increase Increase Decrease Decrease Decrease
* * *Increase Increase Decrease Increase Increase
- - - - Decrease
**0 0 Increase Increase Absent
Decrease Decrease Increase Decrease Increase
Increase
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for the Bf factor was demonstrated first for the IDDM 
patients in the Melbourne series, but increased frequencies 
were present also in the Western Australian IDDM series, and 
in the north Indian series for the Bf factor. Bf F^ is 
absent, or has only a low frequency, in north Indians so it is 
of interest that there is a suggestive increase in the 
frequency in the small IDDM series from Delhi. This will be 
discussed again.
It is important to note also that among Samoans, Nauruans 
and Pima Indians, Bf F^and are also absent or of rare 
occurrence and when they do occur may indicate admixture with 
persons of European descent. It is of significance also, perhaps, 
that in these populations IDDM of the classical European type is 
absent or of very rare occurrence.
Examination of the ages of IDDM patients in the Melbourne 
series showed a striking association between Bf and age of 
onset. Approximately 20% of patients aged 0-4 years had the 
F^ factor, and this fell rapidly to the frequency of controls 
in older IDDM patients. MIDDM and NIDDM patients also had 
frequencies of Bf F not significantly different from that of 
controls.
This striking association of Bf F^ with younger IDDM patients 
raises interesting possibilities about the biological mechanism 
involved in this association. One such possibility is that the 
gene controlling the F^ factor may result in a decrease in the 
level of properdin factor B in the serum, and it is known from 
animal experiments that decreased levels of properdin increase 
the risk of infection (Pillemer et at, 1954, 1955; Newman et at,
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1978). However, the present study shows no evidence at 
present to support such a mechanism in relation to the involve­
ment of properdin in an infectious aetiology of IDDM.
The more likely mechanism is that Bf is in linkage disequil­
ibrium with IDDM susceptibility alleles, and these latter alleles 
are the ones involved in controlling the immune responses seen in 
the development of IDDM. The specific susceptibility allele(s) 
of significance for failure to combat an infection leading to 
irreversible B cell destruction in the young child appears to be 
in strong linkage disequilibrium with the factor, at least in 
a significant proportion of cases of IDDM in Europeans.
Further evidence to support the view that Bf factors are 
in linkage disequilibrium with specific immune functions in 
IDDM is provided by studies on lymphocytotoxic antibodies in 
IDDM in children. One study (Serjeantson et at, 1981) showed 
a correlation of the presence of LCA's in IDDM children with 
the time since onset. In IDDM patients 12 months after onset 
sera show 55% LCA's compared to 25% in those after one to two
years and 15% in those after five years since onset of disease.
FIIn the same study it has been demonstrated that Bf allele is
in significant positive association with LCA's than in patients
F SIwithout this allele. Conversely, the alleles Bf_ and Bf are 
associated with a reduced frequency of LCA's, significantly less 
than patients without these alleles.
When investigated for an association of LCA with HLA-B locus 
antigens the IDDM patients positive for HLA-B18 had a high risk 
for LCA's (RR 7.16). It may be noted that since BfF^ and HLA-B18 
are in stronger positive linkage disequilibrium in IDDM than in
controls, their significant association with LCA is as expected.
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However, this is not true for HLA-B8 and BfF^ association, since
from the data shown earlier, they are in negative disequilibrium
among the IDDM patient series.
The studies of Bf were extended to the Indian population
where the apparent association in IDDM is with the BfS^ factor.
The absence of an association between IDDM and BfF^ is not
surprising since as noted above the BfF^ is absent, or at least
very rare in normal Indian populations. For the Indian IDDM
series, it would seem that B f m a y  confer increased risk in
IDDM, comparable to BfF^ in the European series.
Although HLA studies were not performed on the north Indian
series, information from other sources show a different HLA
profile in India compared to European populations. One study on
South African Indians (Hammond and Asmal 1980) shows a slight
increase of HLA-B 40.2 in the 'Aryan' Indian IDDM patients and,
unlike the European, no increase in the frequency of HLA-B8 or
B15 was noted. BfS^ is known to be in linkage disequilibrium
with HLA-B21 in the European population but this may differ in
the Indian series, a likely candidate may be B40.2, but this
speculation needs further data. It would be of interest to note
whether the IDDM susceptibility allele in the Indian series is
SIin linkage disequilibrium with Bf . The importance of Bf
demonstrated in the IDDM series in the population of European
origin, may not be limited to type I diabetes only. This is
based on the observation of a significant decrease (in the W.A.
Fseries) of Bf among the NIDDM cases. Although this trend of 
decrease was also present in the Melbourne and Samoan NIDDM 
series, it was not significant in the latter while in the Indian 
NIDDM series the trend was in the opposite direction.
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Unfortunately, the extent of genetic variability of the 
Bf system is not so extensive in Pacific and American Indian 
population and its importance as a marker for diabetes in 
these populations is thereby reduced. As pointed out earlier, 
type I diabetes also is known to be infrequent in these
populations. Whether this may be due to the absence of 
susceptibility alleles linked to Bf and HLA is an important 
question demanding further research.
The complement C'2 system also has been shown to be 
important in type I diabetes in Australia. This is not 
unexpected since C'2 is very close to the Bf locus and linkage 
disequilibrium is possible with Bf alleles, although not demon­
strated by present data. It is also suggested that C'2 and 
factor B (Bf), in the classical and alternate pathway 
respectively, may be homologous and tandemly duplicated. This 
is based on the close physico-chemical similarity between the 
two (Lachmann and Hobart, 1978).
Since C'2 has not been investigated sufficiently in other 
populations to warrant any firm conclusions, but indicates 
again that in Pacific populations the C'2 system is relatively 
invariant, so that it is not likely to be of significance in 
those populations in relation to diabetes.
The third chromosome 6 marker, the red cell enzyme system 
glyoxalase, was investigated fully because it is also thought to 
be linked to HLA.
The present study shows some intriguing associations between 
GLO and NIDDM, particularly in the Australian series. GLO was 
not found to be significantly associated with the IDDM series in
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the Australian, or with IDDM, in the Indian series, but there
was a significant disturbance of the GLO 2 phenotypes and 
2GLO allele in the Melbourne NIDDM series. A similar trend
is non-significant in W.A. and in the Indian NIDDM series.
The significant disturbance of GLO phenotypes in the Melbourne
series appears to be, at least to some extent, an artifact of
ethnic stratification in the sample. When the patients were
subdivided on the basis of ethnic origin, into more homogenous
groups, the significance of the difference was reduced although
2the trend of an increase of GLO allele remained the same. A
similar situation of stratification was noted in the increase
2of GLO allele among the Indian NIDDMs although non-significant.
The trend of distribution was opposite in the Samoan NIDDM
2series and the GLO frequencies in the Pima NIDDM and controls 
were almost identical.
One explanation which may apply for the increase of the
2GLO allele frequency, is the presence of a null allele, which has 
been demonstrated in the European population, and may result in 
the excess of GLO 2-2 phenotypes. However, the null allele at 
the GLO locus has very low frequency and it seems unlikely to 
account for the disturbance noted in the Melbourne series.
A second explanation is a suggestion of selection effect upon 
the GLO locus, also noted by other workers (Busi et at, 1979). 
Cadien et at, (1979)reported an association of GLO  ^with diabetes 
in Pacific Island populations. However, observations in the 
present investigation show an increase in the GLO^ allele in Samoan
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diabetes but this is not significant and therefore does not 
support the association suggested by Cadien and his colleagues.
Non-chromosome 6 markers
The reason for studying markers linked to HLA and putative 
disease susceptibility alleles was clear-cut in the study of 
IDDM, where HLA associations had already been established.
The study of non-HLA linked markers, however, requires more 
justification. There are three possible mechanisms which can 
be involved in defence of such a research strategy. (1) the 
locus in question controls a gene product directly involved in 
a pathway important for glucose metabolism; (2) that the locus 
is linked to another locus concerned with an immune mechanism 
or, alternatively, a metabolic control locus of importance in 
diabetes, and (3) that genetic variation at one or more loci 
may reveal a more general genetic differentiation of persons 
susceptible to diabetes from persons in the general population.
As examples of (1) it may be that several of the loci 
studied here may be of potential importance if their variant 
alleles disturbed the normal metabolism of glucose - 6PGD 
for example, or even glyoxalase. In the latter case GLO is 
not directly involved in a glucose metabolism, but it could 
alter equilibrium conditions of glucose metabolism indirectly.
Such suggestions, however, are highly speculative and no 
evidence is currently available to support them.
The second mechanism is of greater significance. Experimental 
work with mice has revealed several histocompatibility loci 
separate from those in the major H2 complex. By analogy there
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may be similar loci therefore in man and if enough polymorphic 
loci are screened it may be possible to find one or more in 
linkage disequilibrium with those other histocompatibility 
or disease susceptibility loci. Finally, if susceptibility to 
diabetes is under polygenic control, as is suggested by some of 
the analyses of diabetic families, then susceptible individuals, 
as a group, will have a constellation of genes linked to 
their multiple diabetic genes which will make them a genetically 
distinctive group.
The present study has focussed attention on two of these 
research strategies, firstly looking for consistent associations 
between alleles at specific loci and, secondly, examining the 
general genetic differentiation of diabetes from controls.
With respect to the first strategy it is important to 
point out that an association between a specific allele and one 
or other form of diabetes need not be the same in different 
populations. Particular linkages may be strong in one population 
but absent in another, as has been demonstrated clearly for the 
association between HLA factors and diabetes in various parts 
of the world and from the association with Bf rare alleles in this 
study.
Other workers, as noted in Chapter 1, have drawn attention 
to associations between the ABO blood groups and also the Lewis 
blood group system and diabetes. For the ABO blood goups there 
is a suggestive effect of age, which may be related to the type 
of diabetes. In the present study it was not possible, however, 
to obtain data on any of the red cell antigen systems.
Among the serum protein systems studied, two have previously 
been implicated with diabetes: the group specific component
191
system (a vitamin D-binding protein) and haptoglobin (a haemo­
globin-binding protein) have both been reported as showing non­
significant disturbances among diabetics in populations of 
European origin.
In four of the six populations investigated here there is
2a decrease in the frequency of the Gc allele in the NIDDM
series. In two Australian series the decrease is significant
and there is also a significant difference in the distribution
of phenotypes between patients and controls. The increase in 
2Gc frequency among NIDDM patients in Samoa and Pima Indians is 
non-significant. The disturbance in the Gc system is most marked 
in the Melbourne and W.A. series. This fact, coupled with 
previous reports of a similar trend in European diabetics, 
certainly suggests that further studies of the association between 
Gc and mature-onset diabetes should be undertaken urgently.
This is of particular importance since the Gc system has been 
implicated also in susceptibility to Kuru in the New Guinea 
Highlands, to leprosy and also to the degree of reaction to 
typhoid vaccination, although Gc cannot be considered an 
immune-response system itself (Cleve, 1973).
Another serum protein system studied here is the haemoglobin­
binding glycoprotein, haptoglobin. Variants of haptoglobin are 
universally polymorphic, and the greater power of the Hp 1-1 
protein for removing haemoglobin from the circulation after 
red cell breakdown compared to the Hp 2-2 protein, has led to 
suggestions that the Hp'*' gene is favoured by selection, at 
least in some situations. The present study, however, does 
not suggest that the haptoglobin locus is of any significance
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with respect to diabetes.
No significant association with the Hp alleles were noted,
nor was there any trend for an increase or decrease of Hp  ^or
2 ,Hp among diabetics in the populations studied. These findings
are consistent with other studies of the haptoglobin types, 
particularly among the NIDDM series, in various populations.
It seems that much larger sample sizes would be needed to 
detect the effects of selection against one or other of these 
alleles, if such in fact does occur.
Among the red cell enzyme loci studied the one which is 
of greatest interest in the present context is that controlling 
red cell acid phosphatase. The precise biological function of 
this enzyme is not clear, but its polymorphic variation in 
human populations makes it a valuable marker for linkage disequil­
ibrium studies. In the present investigations there is a
Cconsistent decrease of the phenotype controlled by the PHs
allele, the CB phenotype in particular, and this is most striking
among male IDDM patients in Australia (both series) and also
Camong IDDM in north India. Since the PHs allele is of rare 
occurrence in Pacific populations and Amerindians it is not a 
useful marker there, although in this respect there is a 
parallel between the absence of rare alleles in the Bf system 
in Pacific and Amerindian populations and the absence of IDDM 
in the same populations. The present observations support the 
earlier report of a decrease of the CB phenotype in an IDDM 
series in Rome (Lucarelli et at, 1978).
The situation is different in the NIDDM series. There is 
a decrease of PHs in NIDDM patients in all the localities
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studied, except in north India. Despite this trend none of 
the differences noted were large, and none were statistically 
significant.
The interpretation of the apparent association between 
the acid phosphatase system and diabetes is difficult. It 
is of interest, however, that Bottini et at (1971) has reported 
an association between red cell acid phosphatase phenotypes and 
favism and that acid phosphatase phenotypes also appear to be 
affected by factors such as diet and temperature (Ananthakrishnan 
and Walter 1972). The association with diabetes may be therefore 
related to some pleiotropic effect of the genes concerned.
One of the more interesting results obtained in the present
investigation involves the phosphoglucomutase system. There
2were decreases in the PGM allele frequency for NIDDM in the 
two Australian series and in the Melbourne series which was 
highly significant for persons of north European ancestry. In
one further population (Samoa) there was also a significant
2decrease of PGM in NIDDM, whilst in the Pima NIDDM series
2 2there was a significant increase of PGM . PGM was increased
also in the north Indian and Nauruan NIDDM series, but these
increases were not statistically significant.
Within Australia there is a contrast between the Melbourne
2and W.A. NIDDM series. The decrease of PGM in the former was
much greater and the reason for this contrast appears to be
related to age. As pointed out in Chapter 3.1, Gordon and
2Riser (1966) showed a decrease in PGM in persons aged 80 years 
and over. When the Melbourne and W.A. NIDDM series are compared
there is a much higher proportion of older persons among the
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Melbourne patients. The PGM' frequency is lowest among those
aged 80 and over, with patients in the 40-69 age group inter-
2mediate in their PGM frequency between the older group and
2the controls. The W.A. PGM frequency for the NIDDM series is
2almost identical with the PGM frequency for the Melbourne 
40-69 group.
There are two possible interpretations for this effect.
2Firstly, persons with the PGM may not be so susceptible to
developing non-insulin dependent diabetes (alternatively
persons with a PGM^ allele are more susceptible). The second
2possibility is that persons with the PGM allele are less
likely to survive to older ages. Since NIDDM increases in
prevalence with age, the diabetic series will be drawn from
2a population with a decreasing PGM frequency as mean age 
of the patients increases.
An urgent study is required to discriminate between those 
two possibilities. PGM typing of a geriatric population 
divided into diabetic and non-diabetic should enable a choice 
to be made.
Since the PGM effect appears to be strongly age-related 
it would be expected that non-significant differences would be 
found between the NIDDM series and controls in populations without 
a large proportion of very old persons. This is true for north 
India and Nauru. The two remaining populations, Samoa and 
Pima Indians, however, are not consistent. The former gives a 
significant decrease and the latter a highly significant 
increase in PGM frequency among NIDDM patients. Lack of 
detailed information on these respective patient series has
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prevented more detailed analysis. The PGM system, however, 
will clearly repay further study.
Four other enzyme systems showing polymorphic variation were
examined in detail, GPT, 6PGD, EsT-D and PGP. With two
exceptions none of the comparisons between diabetes and controls
for any of the populations where tests were made, revealed
significant differences. One of the exceptions was a highly
Csignificant increase in the 6PGD allele among diabetics in Nauru.
CA similar trend of increase of 6PGD was note in Samoan NIDDM 
cases, but in the other populations differences were small.
An increase in 6PGD AC has been reported in tuberculoid leprosy 
in New Guinea (Serjeantson et at, 1979) suggesting that the 
6PGD locus might be involved in susceptibility to some diseases. 
Confirmation of the association with leprosy is needed, and 
further study of the relationship between 6PGD and diabetes in 
Nauru is needed.
The other exception was a decrease of the Esterase-D 2-2 
phenotype among IDDM patients in the Melbourne series. Since 
this was significant only at the 5 per cent level and 9 
comparisons for Est-D were made in total, the difference could 
be due to sampling errors. Of possible interest is a previous 
by Williams and Cartwright (1978) who found also no association 
between Est-D and diabetes even when the diabetics were 
categorized on the basis of age.
The enzyme phosphoglycolate phosphatase (PGP) was studied 
only in Pima Indians. A paper (in abstract only ) by Cadien 
et at, 1979) appeared when the experimental work for this 
thesis was almost complete. Cadien and his colleagues claimed a
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significant increase in the PGP allele among diabetic Pima 
Indians. The Pima series was therefore tested for PGP variants 
to see if their claim could be substantiated. The results of 
these observations did show an increase in PGP  ^ in Pima NIDDM 
compared to controls but the difference was non-significant.
Since the present observations were based on a total series of 
205 persons compared to 64 in Cadien et at*s study, it seems 
unlikely that PGP is associated with non-insulin dependent 
diabetes.
One final question which needs to be addressed is whether 
diabetes in older persons is a heterogenous disorder ? For 
examination of this possibility the diabetic patients in the 
present study, aged 40 and over, who were receiving insulin 
treatment, were separated as a group (MIDDM) from those not 
requiring insulin (NIDDM). This distinction was possible only 
for the Melbourne and W.A. series but the numbers of MIDDM 
patients in both series were not large (81 and 65 respectively).
In comparisons based on individual genetic marker systems there 
were no significant phenotypic or genotypic differences 
between MIDDM patients and controls, nor were there any significant 
differences between MIDDM and NIDDM patients in the same locality. 
The absence of statistical significance in both these sets of 
comparisons indicates no striking associations which would be 
demonstrable even with small numbers. In the next section, 
however, it will be pointed out that MIDDM patients do appear 
to be genetically distinct from IDDM and NIDDM patients.
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Multivariate analysis.
The final research strategy exploited was to carry out a 
multivariate analysis which enables the contribution from all 
the variable genetic systems to be utilized to see if there are 
genetic differences between diabetics as a group, compared to 
the normal population. The technique employed was a measure of 
genetic 'distance', the basis of which was discussed in 
Chapter 2. In the present study it was applied only to the 
Australian series. Future studies could profitably apply 
similar techniques to the other series for which the data is 
generated.
When all markers are included in the analysis, IDDM cases 
clearly are differentiated from both controls and M- and NIDDM 
cases and this is demonstrated both in the Melbourne and W.A. 
series (see Figs 3.1.1a and b and 3.2.1a and b) although the 
distinction is more striking in the Melbourne series that for 
W.A. There is another contrast between the two series, however, 
in the distinction between the NIDDM and MIDDM patients. In 
Melbourne these two groups are genetically quite distinct, but 
in W.A. they are very close to one another, even though both 
groups are distinct from the control and IDDM series.
The multivariate technique, therefore, reinforces the 
classification of diabetes on the basis of insulin dependence 
in persons younger than 40 years, and this is true in two 
separate localities in Australia. It also suggests that a 
further distinction can be made genetically between mature- 
onset cases (40 years and over at time of onset) and controls, 
and, in Melbourne, between mature-onset cases receiving insulin
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and those not.
The fact that this latter distinction does not hold in 
VI.A. could well reflect differences in the structure of the 
patient population in these two localities. It was pointed 
out earlier that the Melbourne NIDDM series had a much 
higher frequency of persons aged 70 years and over, compared to 
W.A., so the two series may not be identical genetically.
The discussion of differences in PGM types has made clear that 
such genetic differences do exist between the two populations.
In addition,there may be problems of ethnic stratification 
reinforcing the genetic differences and possibly contributing 
to the variations in type and severity of the diabetes found 
in either Melbourne or W.A. Further study should explore the 
effects of such differences more fully.
Ideally patients should be matched with controls of the 
same age and economic status from the same ethnic group and be 
subjected to the same set of clinical observations and biochem­
ical tests. Such specific divisions into clinical features is 
important in view of the heterogeneous nature of diabetes, and 
may enable the identity of types within the complex syndrome.
If this can be done for an adequate number of patients a 
better understanding of the role of genetic markers, in relation
to diabetes, certainly would be achieved.
BIBLIOGRAPHY
Ahuja, Vicissitudes of epidemiological studies of
diabetes mellitus. J. All India Inst. Med. Sei. 2: 5-13
(1976) .
Ahuja, M.M.S., Talwalker, G.P., Varma, V.M. et alii. Diabetes 
mellitus in young Indians. Ind. J. Med. Res. 53: 1138-1147
(1965).
Albert, E.D., Ritter, C., Scholz, S., Kuntz, B. and Mickey, M.R.: 
Three point association of HLA-A, B, Bf, haplotype deduced 
in 200 parents of 100 families. Scand. J. Immunol. 6: 459- 
464 (1977).
Allan, W.: Heredity in diabetes. Ann. Intern. Med. 6: 1272
(1933).
Alper, C.A.: Inherited structural polymorphism in human C"2.
Evidence for genetic linkage between C'2 and Bf. J. Exp.
Med. 144: 1111 (1976).
Alper, C .A. and Rosen, F.S.: The genetics of the complement
system. Adv. Hum. Genet. 7: 141-188 (1976).
Altman, D.F., Baker, S.D., McCally, M. et at.: Carbohydrate
and lipid metabolism in man during prolonged bed rest.
Clin. Res. 17: 543 (1969).
Ananthakrishnan, R. and Walter, H.: Some notes on the geographi­
cal distribution of the human red cell acid phosphatase pheno­
types. Humangenetik 15: 177-181 (1972).
Andersen, J. and Lauritzen, E.: Blood groups and diabetes
mellitus. Diabetes 9: 20-24 (1960).
Arnason, A., Laison, B., Marshall, W.G. and Edwards, J.H.: HLA
patterns in Australian patients with insulin dependent diabetes 
mellitus (IDDM). Nature (Lond) 268: 527-528 (1977).
Ashton, G.C. and Braden, A.W.H.: Serum -globulin polymorphism
in mice. Aust. J. Exp. Biol. Med. Sei. 14: 248 (1961).
Baird, J.D.: Diabetes mellitus and obesity. Proc. Nutr. Soc.
32: 199-204 (1973).
Barbosa, J., King, R., Noreen, H. and Yunis, E.J.: The histo­
compatibility (HLA) system in juvenile insulin-dependent 
diabetic multiplex kindreds. J. Clin. Invest. 60: 989-98
(1977) .
Barker, O.B., Commons, R.R., Shelton, E.K.: Sex-linked juvenile
diabetes mellitus. J. Clin. Endoc. 2: 608 (1951).
Barker, R.F. and Hopkins, D.A.: Genetic polymorphism of human
phosphoglycolate phosphatase (PGP). Ann. Hum. Genet. Lond.
42: 143-151 (1978).
200
Belcher, D.W.: Diabetes mellitus in Northern Ethiopia. Ethiop.
Med. J. 8: 73-84 (1970).
Benacerraf, B.: Immune response genes. Scand. J. Immunol. 3:
381-386 (1974).
Bennet, P.H., Burch, T.A. and Miller, M.: Diabetes mellitus in
American (Pima) Indians. Lancet ii: 125-128 (1971).
Berg, K., Aarseth, S., Lundevall, J. and Reinskon, T.: Blood groups
and genetic serum types in diabetes mellitus. Diabetologia 
3: 30-34 (1967).
Bernard, C.: Lecons de Physiologie. Paris: J.B. Bailliere 1855
taken from Diabetes - The Genetic connections. D.A. Pyke: 
Diabetologia 17: 333-343 (1979).
Bertrams, J., Baur, M.P., Grunklee, D., Gries, F.A.: Associa­
tion of Bf F , HLA-B18 and insulin-dependent diabetes mellitus 
Lancet ii : 98 (1979).
Bjorntorp, P., Holm, G., Jacobsson, 13. Schillder-de Jounge, K., 
Lundberg, P.A. et cd. Physical training in human hyperplastic 
obesity: 4. Effects on the hormonal status. Metabolism 26* 
319-320 (1977).
Bloom, A., Hayes, T.M., Gamble, D.R.: A register of newly
diagnosed diabetic children. Brit. Med. J.iii: 580-583 (1975).
Bondy, P.K.: Diabetes mellitus. In Textbook of Medicine by
P.B. Beeson and W. McDermott, Vol. 2: 1294-1315 (1963).
Bottini, E., Lucarelli, P., Agostino, R., Palmarino, R.,
Bisinco, L. and Antognosi, G.: Favism: Association with
erythrocyte acid phosphate phenotype. Science 171: 409-411(1971).
Boucher, D.W. Notkins, A.L.: Virus-induced diabetes mellitus I:
Hyperglycaemia and hypoinsulinaemia in mice infected with 
encephalomyocarditis virus. J. Exp. Med. 137: 1226-1236
(1973).
Braunsteiner, H., Hansen, W., Jung, A., Seiler, A.: Latent
diabetes in the parents of juvenile diabetics. German Med. 
Monthly 11: 227 (1966).
®ri99s» B.R., Jackson, W.P.U., Dutoit, D. and Martin, C.B.: The
histocompatibility (HLA) antigen distribution in diabetes in 
Southern African blacks (Xhosa): Diabetes 29: 68-71 (1980).
Brigham, C.B.: An essay upon Diabetes Mellitus. Boston, Press
of Abner A. Kingman, 1868 (quoted in West 1978).
Busi, B.R., Wells, L.J., Volkers, W.S., Ebeli-Struijk, A.C. and 
Meera Khan, P.: Distribution of Glyoxalase I (GLO) variants
in western Europe and the Indian subcontinent. Hum. Genet.
49: 105-113 (1979).
201
Cadien, J.D., Mamula, P.W. and Hecht, F.: Phosphoglycolate
phosphatase phenotypes and association with Pimalndian 
diabetes. Abstract: Amer. J. Hum. Genet. 31: 40A (1979).
Cammidge, P.J.: Diabetes mellitus and heredity. Brit. Med.
J. ii: 738 (1928) .
Cammidge, P.J.: Heredity as a factor in the aetiology of
diabetes mellitus. Lancet i: 393 (1934).
Cappell, D.F. and McFarlane, M.N.: Inclusion bodies (Proto­
zoan-like cells) in the organs of infants: J. Pathol.
Bacteriol. 59: 385-98 (1947).
Cavalli-Sforza, L.L., Bodmer, W.F.: The genetics of human
populations. W.H. Freeman & Co. 1971.
Cathelineau, G., Cathelineau, L., Hors, J. , Schmid, M.,
Dausset, J.: HLA and juvenile diabetes. Diabetologia
11: 335 (1975).
Cerasi, E., Luft, R.: Insulin response to glucose infusion
in diabetic and non-diabetic monozygotic twin pairs.
Genetic control of insulin response? Acta Endocrinol.
55: 330 (1967).
Chakravartti, M.R.: A statistical appraisal on the relation­
ship between non-ABO blood group systems and diseases. 
Humangenetik 5: 1-27 (1967).
Chen, S-H., Giblett, E.R. : Polymorphism of soluble glutamic-
pyruvic transaminase: a new genetic marker in man. Science
173: 148-149 (1971).
Cleve, H.: The variants of Group Specific Component. Review
of distribution. Isr. J. Med. Sc. 9: 1133-1146 (1973).
Cleve, H.: Die Verteilung der Gc typen und Gc allele bie
kranken mit diabetes mellitus unde chronischer polyarthritis. 
Humangenetik 2: 355-362 (1966).
Coleman, D.L. and Hummel, K.P.: The influence of genetic back­
ground on the expression of the obese (ob) gene in mouse: 
Diabetologia, 9: 287-293 (1973).
Craighead, J.E.: The role of viruses in the pathogenesis of
pancreatic disease and diabetes mellitus. In - Progress in 
Medical Virology. Melrick, J.L. (ed) Vol-. 19: 162-214
(1975).
Craighead, J.E., McLane, M.F.: Diabetes mellitus: Induction
in mice by encephalomyocarditis virus. Science 162:
913-914 (1968).
Creutzfeldt, W., Köbberling, J., Neel, J.V. (Eds). The genetics 
of diabetes mellitus. Springer-Verlag, 1976.
202
Cudworth, A.G.. , Woodrow, J.C. : HLA antigens and diabetes
mellitus. Lancet ii: 1153 (1974).
Cudworth, A.G.. , Woodrow, J.C. : Evidence for HLA linked genes
in juvenile diabetes mellitus. Brit. Med. J. iii: 133-135 
(1975).
Cudworth, A.G., Woodrow, J.C.: Genetic susceptibility in diabetes
mellitus. Analysis of the HLA association. Brit. Med.J. ii: 
846-848 (1976).
Cudworth, A.G., Woodrow, J.C. : The HLA system and diabetes
mellitus. Diab. Metab. 3: 123-125 (1977).
Cudworth, A.G., Usher, N. and Woodrow, J.C.: Factor B phenotypes
in juvenile-onset diabetes. Abstract. Diabetologia 13: 388 
(1977) .
Cudworth, A.G.: Type I diabetes mellitus. Review article.
Diabetologia 14 : 281-291 (1978).
Curtis, 3.W.: Diabetes in twins. J. Amer. Med. Assoc. 92*
952 (1929).
Dausset, J.: Clinical implications (nosology, diagnosis,
prognosis and preventive therapy). In - HLA and disease. 
Dausset, J., Svejgaard, A. (eds). Copenhagen, Munksgaard. 
296-310 (1977).
Deschamps, I., Lestradet, H., Marcelli-Barge, A., Benajam, A., 
Busson, M., Hors, J., Dausset, J.: Properdin factor B
alleles as markers for insulin-dependent diabetes. Lancet 
ii: 793 (1979).
Dintenfass, L.: Significant effect of ABO blood groups on the
aggregation of red cells in patients with diabetes mellitus; 
Role of fibrinogen and serum proteins. Microvas. Res. 7: 
326-341 (1974).
Doniach, D. and Bottazzo, G.F.: Pathobiol. Annu. 7: 327-346
(1977) quoted from Cudworth et al. (1978).
Dornan, J., Allan, P., Noel, E.P., Larsen, B. and Farid, N.R.: 
Properdin factor B (Bf) allele BfFl specifies an HLA-B18 
diabetogenic haplotype. Diabetes 29: 423-427 (1980).
Duquesnoy, R.J., MacDonald, M.J., Mullins, P., Hackbarth, S.A., 
1raisman, H.S. and Levitsky, L.L.: Increased frequency of
HLA-Dw3 in North American Black patients with juvenile-onset 
diabetes. Tissue Antigens, 13: 360-372 (1979).
Edwards, J.H.: The simulation of mendelism. Acta Genet.
10: 63 (1960).
Egeberg, J., Junker, K., Kromann, H. and Nerup, J.: Autoimmune
insulitis. Pathological findings in experimental animal 
models and juvenile diabetes mellitus. Acta Endocrin. (Kbh) 
Suppl. 205: 129 (1976).
203
Ehrlich, R.M., Martin, J.M.: Presence of synalbumin antagonist
in siblings of diabetic children. Diabetes, 15: 400 (1966).
Elston, R.C., Namboodiri, K.K., Nino, H.V., Pollitzer, W.S.: 
Studies on blood and urine glucose in Seminole Indians: 
indications for segregation of a major gene. Amer. J. Hum. 
Genet. 26: 13 (1974).
Fajans, S.S., Cloutier, M.C. and Crowther, R.L.: The Banting
Memorial Lecture. Clinical and etiologic heterogeneity of 
idiopathic diabetes mellitus. Diabetes, 27: 1112-1125 (1978).
Fajans, S.S., Conn, J.W.: An approach to the prediction of
diabetes mellitus by modification of the glucose tolerance 
test with cortisone. Diabetes, 3: 296 (1954).
Falconer, D.S.: The Inheritance of liability to certain
diseases, estimated from the incidence among relatives.
Ann. Hum. Genet. 29: 51-76 (1965).
Fildes, R.A. and Harris, H.: Genetically determined
variation of adenylate kinase in man. Nature, 209: 261 
(1966).
Fildes, R.A. and Parr, C.W.: Human red celd. phophogluconate
dehydrogenase. Nature, 200: 890 (1963).
Finkeistein, S., Zeller, E., Walford, R.L.: No relation between
HLA and juvenile diabetes. Tissue Antigens, 2: 74-77 (1972).
Forrest, J.M., Menser, M.A. and Burgess, J.A.: High frequency
of diabetes mellitus in young adults with congenital rubella. 
Lancet, ii: 332-34 (1971).
Freytag, G.: Do viruses serve as mediators of immunological
reactions? In - Immunity and autoimmunity in diabetes 
mellitus. Eds. Bastenie, P.A. and Gepts, W. Excerpta 
Medica. 247-251 (1974).
Friedlaender, J.S.: A comparison of population distance and
population structure techniques. In - Genetic distance.
Crow, J.F. and Denniston, C. Plenum Press, N.Y. 167-187 
(1974).
Fu, S.M., Kunkel, H.G., Brusman, H. P., Allen, F.H. Jr., Fotino, 
M.: Evidence of linkage between HLA histocompatibility genes
and those involved in the synthesis of the second component 
of complement. J. Exp. Med. 140: 1108-1111 (1974).
Gamble, D.R.: A possible virus aetiology for juvenile-diabetes.
In The genetics of diabetes mellitus. Creutzfeldt, W., 
Köbberling, J,, Neel, J.V. (eds) 95-105 (1976).
Gamble, D.R. Taylor, K.W., Cumming, H.: Coxsackie viruses
and diabetes mellitus. Brit. Med. J. iv: 260-262 (1973)
Gamble, D.R. and Taylor, K.W.: Seasonal incidence of diabetes
mellitus. Brit. Med. J. iii: 631-633 (1969).
204
Ganda, O.P., Soeldner, J.S., Gleason, R.E., Smith, T.M., Charles 
Kilo, R.N., Williamson, J.R.: Monozygotic triplets with
discordance for diabetes mellitus and diabetic microangiopathy. 
Diabetes, 26: 469-79 (1977).
Garovoy, M.R., Carpenter, C.B., Reddish, M., Fagan, G.,
Olivier, D., Gleason, R.: "la" specificities associated
with juvenile diabetes mellitus. Tissue Antigens, 10: 200
(1977).
Gepts, W.: Pathological anatomy of the pancreas in juvenile
diabetes mellitus. Diabetes, 14: 619-633 (1965).
Ghosh, A.K.: Polymorphism of red cell glyoxalase I. With
special reference to south and southeast Asia and Oceania.
Hum. Genet. 39: 91-95 (1977).
Goodman, M.J. and Chung, C.S.: Diabetes mellitus, discrimin­
ation between single locus and multifactorial models of 
inheritance. Clin. Genet. 8: 66-74 (1975).
Gordon, H. and Riser, G.M.: Age and genetical variability.
S.A. Med. J. Abstract 40/47, 1147 (1966).
Gottlieb, M.S., Root, H.F.: Diabetes mellitus in twins.
Diabetes, 17: 693 (1968).
Gray, R.S., Duncan, L.J.P. and Clarke, B.F.: Seasonal onset
of insulin-dependent diabetes in relation to sex and age at 
onset. Diabetologia, 17: 29-32 (1979)
Grey, N. and Kipnis, D.M.: Effect of diet composition on the
hyperinsulinemia of obesity. N. Engl. Med. 285: 827-831
(1971).
Gupta, O.P., Dave, S.K., Gupta, P.S., Hegde, H.S., Agarwal,
Joshi, M.N. and Srivastava, Y.: Aetiological factors in
the prevalence of diabetes in urban and rural populations in 
India. In - Diabetes mellitus in Asia. Baba, S., Goto, Y., 
Fukui, I. (eds). Proc. 2nd Symp. Kyoto, Excerpta Med. 
Amsterdam, 23-34 (1976).
Hammond, M.G. and Asmal, A.C.: HLA and insulin-dependent
diabetes in South African Indians. Tissue Antigens, 15: 
244-248 (1980).
Hammond, M.G., Asmal, A.C. and Omar, M.A.K.: HLA and insulin-
dependent diabetes in South African Negroes. Diabetologia,
19: 101-102 (1980).
Hanhart, E.: Nachweis der ganz vorwiegend einfach rezessiven
Vererbung des diabetes mellitus. Erbarzt 6: 5 (1939)
(quoted from Simpson 1976).
Harris, H.F.: A case of diabetes mellitus quickly following
mumps. Boston Med. and Surg. J. CXL, 465-469 (1899)
(quoted in West 1978).
205
Harris, H.: Incidence of parental consanguinity in diabetes
mellitus. Ann. Eugen. (Lond.) 14, 293 (1949).
Harris, H.: Familial distribution of diabetes: A study of
relatives of 1241 diabetic propositi. Ann. Eugen. (Lond.),
15: 95 (1950).
Harrison, G.A., Boyce, A.J., Hornabrook, R.W. and Craig, W.J.: 
Associations between polymorphic variety and disease 
susceptibility in two New Guinea populations. Ann. Hum. 
Biol., 3: 253-267 (1976).
Herberg, L. and Coleman, D.L.: Laboratory animals exhibiting
obesity and diabetes syndromes. Metabolism 26: 59-98 (1977).
Himsworth, H.P.: Diet and the incidence of diabetes mellitus.
Clin. Sei. Mol. Med. 2: 117-148 (1935).
Hodge, S.W., Rotter, J.I., Lange, K.L.: A three-allele model
for heterogeneity of juvenile onset insulin-dependent 
diabetes. Ann. Hum. Genet., Lond. 43: 399-412 (1980).
Hopkinson, D.A., Spencer, N. and Harris, H. : Genetical studies
on human red cell acid phosphatase Amer. J. Hum. Genet. 16: 
141-154 (1964).
Irvine, W.J. (ed).: The immunology of Diabetes Mellitus.
Edinburgh, Teviot Scientific Publications (1979) (quoted in 
NDDG 1979).
Jackson, W.P.U.: A clinician looks at Genetic problems in
Diabetes, in - Proceedings of the VII Congress of the 
International Federation. Excerpta Medica Series No. 231: 
379-389 (1970).
Jeannet, M., Raffoux, C., de Moerloose, P., Debry, G., Bally, C., 
Streiff, F. and Sisenenko, P.: HLA and Ia-like antigens in
juvenile-onset diabetes. Tissue Antigens, 10: 196 (1977).
Johnson, A.M., Cleve, H. and Alper, C.: Variants of group
specific component system as demonstrated by immunofixation 
electrophoresis. Report of a new variant Gc. Boston (Gc B). 
Am. J. Hum. Genet. 27: 728-736 (1975).
Jörgensen, G., and Hopfer, A.: Die Verteilung der Gc-Phänotypen
und Gc- allele bei einigen krankheiten (Diabetes mellitus, 
leberparenchymschaden, Psoriasis vulgaris). Humangenetik, 3: 
273-276 (1967).
Jorgensen, G. and Hopfer, U.: Die Verteilung der haptoglobin-
phänotypen und haptoglobin allele bei einigen krankheiten 
(diabetes mellitus, leberparenchymschaden, Psoriasis 
vulgaris). Humangenetik, 3: 277-281 (1967).
206
Joslin, E.P., Dublin, L.I. and Marks, H.H.: Studies in diabetes
mellitus I. Characteristics and trends of diabetes mortality 
throughout the world. Am. J. Med. Sei. 186: 753-773 (1933).
Kahn, C.B., Soeldner, J.S., Gleason, R.E., Rojas, L., Camerini- 
Davalos, R.A. and Marble, A.: Clinical and chemical diabetes
in offspring of diabetic couples. New Engl. J. Med., 281:
343 (1969).
Karp, G.W. and Sutton, H.E.: Some.new phenotypes of human red
cell acid phosphatase. Amer. J. Hum. Genet., 19: 54 (1967).
Kibrick, S. and Benirschke, K.: Severe generalized disease
(encephalohepatomyocarditis) occurring in the new-born period 
and due to infection with coxsackie virus group B - evidence 
of intra-uterine infection with this agent. Pediatrics, 22:
857 (1958).
Kiely, P., Cross, R., Court, J., Bornstein, J. and Zimmet, P.:
HLA patterns in Australian patients with insulin-dependent 
diabetes mellitus (IDDM) (In press 1978).
Kirk, R.L., Ranford, P.R., Court, J. and Zimmet, P.: Distribu­
tion of complement C"2 and C^6 types in Australian cases of 
diabetes mellitus. Med. J. Aust. ii: 614-615 (1980).
Kirk, R.L., Theophilus, J., Whitehouse, S., Court, J. and Zimmet, 
P.: Genetic susceptibility to diabetes mellitus: the
distribution of properdin factor B (Bf) and glyoxalase (GLO) 
phenotypes. Diabetes, 28: 949-951 (1979).
Kirk, R.L., Serjeantson, S.W., Theophilus, J., Zimmet, P., 
Whitehouse, S. and Court, J.M.: Age relationship between
insulin-dependent diabetes and rare alleles of Properdin 
factor B. Lancet, i: 537 (1979).
Kirk, R.L.: The haptoglobin groups in man. In - Monographs in
human genetics. 4: (1968).
Kirk, R.L.: A haptoglobin mating frequency segregation and ABO
blood group intereaction analysis for additional series of 
families. Ann. Hum. Genet. 34: 329-337 (1971).
Köbberling, J.: Investigations of the genetics of diabetes
mellitus. A suitable method for age correction. Diabetologia, 
5: 392-296 (1969).
Köbberling, J., Bengsch, N., Bruggeboes, B., Schwarck, H., Tillil, 
H. and Weber, M.: The chloropropamide alcohol flush. Diabetol
ogia, 19: 359-363 (1980).
Kompf, J., Bissbort, S. amd Ritter, H.: Red cell glyoxalase I
(E.C. 4.4.1.5.): Formal genetics and linkage relations.
Humangenetic, 28: 249-251 (1975b).
207
Ksenofontov, Yu. P.: Study of genetic markers in bronchial
asthma and diabetes mellitus: Genetika, 8: 119-22 (1972).
Kuzuya, T., Irie, M. and Niki, Y. : Glucose intolerance among
Japanese professional sumo wrestlers. In - Diabetes mellitus 
in Asia. Baba, S., Goto, Y., Fukui, I. (eds). Proc. 2nd 
Symp. Kyoto. Amsterdam Excerpta Medica. Series 390:
137-143 (1975).
Lachmann, P.J. and Hobart, M.J.: Complement genetics in
relation to HLA. Brit. Med. Bull. 34: 247-252 (1978).
Langenbeck, U. and Jorgensen, G.: The Genetics of Diabetes
Mellitus. A Review of Twin Studies. In - The Genetics of 
Diabetes Mellitus, (eds) Creutzfeldt, W., Köbberling, J. 
and Neel, J.V. Springer-Verlag 21-25 (1976).
Lendrum, R., Walker, G., Cudworth, A.G., Theophanides, C.,
Pyke, D.A., Bloom, A. and Gambles, D.R.: Islet cell anti­
bodies in diabetes mellitus. Lancet ii: 1273 (1976).
Leslie, R.D.G. and Pyke, D.A.: Chlorpropamide-alcohol
flushing: a dominantly inherited trait associated with
diabetes. Brit. Med. J. ii: 1519-1521 (1978).
Levit, S.G., Pessikova, L.N.: The genetics of diabetes
mellitus. Trudy Med. Genet. Inst. Gorky, 3: 132 (1934)
quoted in Simpson (1976).
Lucarelli, P., Scacchi, R., Corbo, R.M., Palmarino, R., Orsini, 
M., Campea, L., Carapella, E. and Pascone, R.: Genetic
polymorphisms in juvenile onset diabetes. Hum. Hered.
28: 89-95 (1978).
Ludwig, H., Schernthaner, G. and Mayr, W.R.: The importance
of HLA genes to susceptibility in the development of 
juvenile diabetes mellitus. A study of 93 patients and 
68 first degree blood relatives. Diab. Metab. 3: 43-48 
(1977).
Ludvigsson, J., Safwenberg, J. and Heding, L.G.: HLA types,
C- peptide and insulin antibodies in juvenile diabetes. 
Diabetologia, 13: 13-18 (1977).
Luxenberger, H.: Untersuchungen an schizophrenen Zwillingen
und ihren geschwistern zur prufüng der realität von 
manifestationsschwankungen. Szchr. Ges. Neurol. Psychiat., 
154: 351 (1935). (quoted in Langenbeck and Jörgensen 1976).
MacDonald, M.J.: Equal incidence of adult-onset diabetes
among ancestors of juvenile diabetics and non-diabetics. 
Diabetologia, 10: 767-773 (1974).
MacDonald, M.J.: Hypothesis: The frequencies of juvenile
diabetes in American Blacks and Caucasians are consistent 
with dominant inheritance. Diabetes 29: 110-114 (1980).
208
Maeda, H., Takeuchi, F., Juji, T., Akanuma, Y., Kasuga, M.,
Lee, Y.S., Kosaka, K. and Tsai, S.H.: HLA-Drw3 in juvenile-
onset diabetes mellitus in Chinese. Tissue Antigens, 15: 
173-176 (1980).
Marine, N., Vinik, A.I., Edelstein, I. and Jackson, W.P.U.: 
Diabetes, Hyperglycemia and glycosuria among Indians,
Malays and Africans (Bantu) in Cape Town, South Africa. 
Diabetes 18: 840-857 (1969).
Matson, G.A., T.A., Podlesky, H.F,M Swanson, J., Sutton, H.E. 
and Robinson, A.: Distribution of hereditary factors in
the blood of Indians of the Gila River, Arizona.
Amer. J. Phys. Anthrop., 29: 311-337 (1968).
Mauff. G., Gauchel, F.D. and Hitzeroth, H.W.: Polymorphism
of Properdin Factor B in South African Negroid, Indian and 
colored populations. Hum. Genet., 33: 319-322 (1976).
May, 0.: The significance of diabetic family history in life
insurance. Lancet, i: 679 (1914).
Mayr, W.R., Schernthaner, G., Ludwig, H., Pausch, G. and Dub,
E.: la type alloantigens in insulin-dependent diabetes
mellitus. Tissue Antigens, 10: 194 (1977).
McDevitt, H.O. and Benacerraf, B.: Genetic control of specific
immune response. Adv. Immunol. 11: 31-74 (1969).
McConnell, R.B., Pyke, D.A., Fraser-Roberts, J.A.: Blood
groups in Diabetes Mellitus. Brit. Med. J-. i: 772 (1956).
Menser, M.A., Forrest, J.M. and Honeyman, M.C.: Diabetes, HLA
antigens and congenital rubella. Lancet ii: 1508-09
(1974).
Menser, A., Forrest, M.A. and Barnsby, R.D.: Rubella infection
and diabetes mellitus. Lancet i: 57-60 (1978).
Mimura, G., Oshiro, S., Koganemaru, K., Haraguchi, Y.,
Jinnouchi, T. and Hashiguchi, H.: Studies on the heredity
of diabetes mellitus in Japan I. Inheritance of the fasting 
blood sugar value in Uto and Tomiai inhabitants. Kumamot. 
Med. J., 17: 45 (1964) (quoted in Simpson 1976).
Mirsky, A.: 1949. (quoted in West 1978).
Moses, S.G.P. and Kannan, V.: The clinical profile of under­
nourished diabetics aged 30 or less with associated compli­
cations in Madras, India. In - Diabetes meZZitus in Asia. 
Baba, S., Goto, Y., Fukui. I. (eds) 259 (1976).
Morton, N.E.: Population structure. In - computer appZications
in genetics. Edited by N.E. Morton, University of Hawaii 
Press. Honolulu 61-68 (1970).
Mourant, A.E.: Associations between hereditary blood factors
and diseases. Bulletin of W.H.O. 49: 93-101 (1973).
209
Mourant, A.E., Kopec, A.C. and Domaniewska-Sobczak, Kazimiera.: 
Blood groups and diseases - A study of associations of 
diseases with blood groups and other polymorphisms. Oxford 
monographs (1978).
Mouzon de A., Ohayon, E., Ducos, J. and Hauptmann, G.: Bf
and C4 markers for insulin-dependent diabetes in Basques. 
Lancet ii: 1364 (1979).
Nakhooda, A.G., Like, A.A., Chappel, C.I., Murray, F.F. and 
Marliss, E.B.: The spontaneously diabetic wistar rat:
Metabolic and morphologic studies. Diabetes, 26: 100-12
(1977) .
Nakao, Y., Fukunishi, T., Koide, M. et alii. : HLA antigens
in Japanese patients with diabetes mellitus. Diabetes,
26: 736 (1977).
National Diabetes Data Group. Classification and Diagnosis 
of Diabetes Mellitus and other categories of glucose intol­
erance Diabetes, 28: 1039-1057 (1979).
Nelson, P.G. Pyke, D .A., Cudworth, A.G., Woodrow, J.C. and 
Batchelor, J.D.: Histocompatibility antigens in diabetic
identical twins. Lancet i: 193-194 (1975).
Neel, J.V., Fajans, S.S., Conn, J.W. and Davidson, R.T.:
Diabetes mellitus. In - Genetics and Epidemiology of 
chronic diseases. Public Health Service Publication 
No. 1163. Eds. Neel, J.V., Shaw, M.W., Shull, W.J. 105- 
132 (1965).
Nerup, J., Cathelineau, Cr., Seignalet, J. and Thomsen, M.:
HLA and endocrine diseases. In - HLA and disease. Dausset,
J. and Svejgaard, A. (eds). 149-167 (1977).
Nerup, J., Platz, P., Anderson, 0.0., Christy, M., Lyngsoe, J., 
Poulsen, J.E., Ryder, L.P., Nielson, L.S., Thomson, M. and 
Svejgaard, A.: HLA antigens and diabetes mellitus. Lancet, ii:
864-866 (1974).
Newman, S.L., Vogler, L.B., Feigin, R.D. and Johnston, R.B.: 
Recurrent septicemia associated with congenital deficiency 
of C^2 and partial deficiency of Factor B and the alterna­
tive complement pathway. N. Engl. J. Med., 299: 290-292
(1978) .
Notkins, A.L.: Virus induced diabetes mellitus. Brief review.
Arch. Virol., 54: 1-17 (1977).
210
Okimoto, K. , Juji, T., Shuntaro, I., Maruyama, H., Tohyama, H. 
and Kinori, K.: HLA-Bw54 (Bw22-J, J-l) Antigen in juvenile
onset diabetes mellitus in Japan. Tissue Antigens, 11:
418-422 (1978).
Olaisen, B., Teisberg, P., Gedde-Dahl, T. and Thorsby, E.:
Genetic polymorphism of the second component of human comple­
ment (C 2). Hum. Genet., 42: 301 (1978).
Patel, J.C., Talwalker, N.G. (eds). Diabetes in Tropics.
Bombay Diab. Assoc, of India, 1966.
Peacock, A.C.: Serum haptoglobin type and leukemia: an
association with possible aetiological significance.
J. Nat. Cancer. Inst. 36: 631 (1966).
Penrose, L.S.: The genetical background of common diseases.
Acta Genet., 4: 257 (1953).
Penrose, L.S. and Watson, E.M.: A sex-linked tendency in
familial diabetes. Proc. Amer. Diab. Assoc., 5: 163 (1945).
Philadelphia Report of the Workshop on "Etiology and Pathogen­
esis of insulin-independent diabetes mellitus. Sept. 8-10 (1977).
Pillemer, L., Blum, L., Lepow, I.H., Ross, O.A., Todd, E.W. 
and Wardlaw, A.C.: The Properdin system and Immunity: I
Demonstration and isolation of a new serum protein, properdin 
and its role in immune phenomenon. .Science, 120: 279-285
(1954).
Pillemer, L. , Schoeberg, M.D., Blum, L. and Wurz, L. : Properdin
system and immunity II. Interaction of the properdin system 
with polysaccharides. Science, 122: 545-549 (1955).
Pincus, G. and White, P.: On the inheritance of diabetes
mellitus I. An analysis of 675 family histories. Amer. J.
Med. Sei. 186: 1 (1933).
Platz, P., Jakobsen, B., Dickmeiss, E., Ryder, L.P., Thomsen, M., 
Svejgaard, A. and Nerup, J.: la and HLA-D typing of patients
with multiple sclerosis (MS) and insulin-dependent diabetes. 
Abstract. Tissue Antigens, 10: 192 (1977).
Post, R.H.: An approach to the question - does all diabetes
depend upon a single genetic locus? Diabetes, 11: 56 (1962).
Prior, I.A.M.: A health survey in a rural Maori community with
particular emphasis on cardiovascular, nutritional and 
metabolic findings. NZ Med. J., 61: 333-340 (1962).
Pyke, D.A. and Taylor, K.W.: Glucose tolerance and serum
insulin in unaffected identical twins of diabetics. Brit.
Med. J. i: 21 (1967).
Pyke, D.A., Theophanides, C.G. and Tattersall, R.B.: Genetic
origin of diabetes: Re-evaluation of twin data. Lancet ii:
464 (1976).
211
Pyke D.A.: Genetics of Diabetes. Clin. Endocrin. Metab.
6: 283-302 (1977).
Rao, P.S., Naik, B.K. and Saboo, R.V. et al. : Incidence of
diabetes in Hyderabad. In - Diabetes in the tropics.
Patel, J.D. and Talwalker, M.G. (eds) Bombay Diab. Assoc, 
of India. 68-75 (1966).
Raum, D., Glass, D., Carpenter, C.B., Alper, C.A. and Schur,
P.H.: The chromosomal order of genes controlling the
major histocompatibility complex, properdin factor B and 
deficiency of the second component of the complement.
J. Clin. Invest. 58: 1240-1248 (1976).
Raum, D., Alper, C.A., Stein, R. and Gabbay, K.H.: Genetic
marker for insulin dependent diabetes mellitus. Lancet i: 
1208-1210 (1979).
Rayfield, E.J. and Seto, Yoshiko: Viruses and the pathogenesis
of diabetes mellitus. Review Diabetes, 27: 1126-1143 (1978).
Reed, R.E.: Caucasian genes in American Negroes. Science,
165: 762-68 (1969).
Rimoin, D.L.: Genetic syndromes associated with glucose
intolerance. In - The genetics of diabetes mellitus. 
Creutzfeldt, W., Köbberling, J., Neel, J.V. (eds).
43-63 (1976).
Rimoin, D.L. and Schimke, R.N.: Endocrine pancreas, in
genetic disorders of the Endocrine glands. St. Louis,
C.V. Mosby Co. 150-215 (1971).
Roberts, J.A., Fraser: Blood groups and susceptibility to
disease. A review. Brit. J. Soc. Med. 11: 107-125 (1957).
Rodney, G.W., White, N. and Frazer, T.E. et alii: HLA-DR
specificities among black Americans with juvenile-onset 
diabetes. N. Engl. J. Med. 301: 801-12 (1979).
Rondeletius, G.: Methodus curandorum omnium morborum
corporis human in tres libros distincta. 1574. (taken from 
Simpson 1976).
Rosenthal, H.B., Goldfine, I.D. and Siperstein, M.D.: Genetic
origin of diabetes: re-evaluation of twin data. Lancet ii:
250-251 (1976).
Roth, J., Lesnaik, M. and Bar, R. et alii. : An introduction
to receptor disorders. Proc. Soc. Exp. Biol. Med. 162:
3-12 (1979).
Rotter, J.I. and Hodge, S.E.: Response: Racial differences
in juvenile-type diabetes are consistent with more than 
one mode of inheritance. Diabetes, 29: 115-118 (1980).
212
Rotter, J.I., Rimoin, D.L.: Heterogeneity in diabetes mellitus
Update, 1978. Evidence for further genetic heterogeneity 
within juvenile onset. Insulin dependent diabetes mellitus. 
Diabetes, 27: 599-608 (1978).
Rubinstein, A.H., Seftel, H.C., Miller, K. et at.'. Metabolic 
response to oral glucose in healthy South African White, 
Indian and African subjects. Br. Med. J. i: 748-751 (1969).
Rubinstein, P., Suciu-Foca, N. and Nicholson, J.F.: Genetics
of diabetes mellitus, A recessive gene closely linked to 
HLA-D with 50 per cent penetrance. New Engl. J. Med. 297, 
1036-1040 (1977).
Sasazuki, T., McMichael, A., Payne, R. and McDevitt, H.O.:
HLA-D antigens in the Japanese population. Tissue Antigens, 
9: 267-272 (1977).
Seignalet, J., Mirouze, J., Jaffiol, C., Selam, J.L. and 
Lapinski, H.: HLA in Grave's disease and in diabetes
mellitus insulin-dependent. Tissue Antigens, 6: 272-74
(1975).
Serjeantson, S., Kirk, R.L., Dry, P.J., Ryan, D.P., Court, J., 
Zimmet, P. and Stepanas, A.V.: HLA studies in Australian
multiple case families of juvenile onset diabetes mellitus. 
Med. J. Aust. i: 107-109 (1980).
Serjeantson, S.W,, Ryan, D.P., Ram, P. and Zimmet, P.: HLA
and non-insulin dependent diabetes in Fiji Indians.
Med. J. Aust. i: 462-463 (1981).
Serjeantson, S., Theophilus, J., Zimmet, P., Court, J.,
Crossley, J.R. and Elliott, R.B.: Lymphocytotoxic antibodies
and histocompatibility antigens in juvenile-onset 
diabetes mellitus. Diabetes 30: 26-29 (1981).
Serjeantson, S., Wilson, S.R. and Keats, B.J.B.: The genetics
of leprosy. Ann. Hum. Biol. 6: 375-393 (1979).
Shreffler, D.C., Brewer, G.J., Gall, J.C. and Honeyman, M.S.: 
Electrophoretic variation in human serum ceruloplasmin; 
a new genetic polymorphism. Biochem. Genet. 1: 101 (1967).
Simpson, N.E.: The genetics of diabetes. A study of 233
families of juvenile diabetes. Ann. Hum. Genet. 26:
1 (1962).
Simpson, N.E, Gunson, H.H. and Smithies, 0.: Frequencies of
blood groups, serum haptoglobins and levels of slow alpha- 
2-globulin in diabetics and their relatives. Diabetes 11,
329 (1962).
Simpson, N.E.: The genetics of diabetes mellitus - a review
of family data. In - The genetics of diabetes. Berlin 
Springer-Verlag, 12-20 (1976).
213
Singal, D.P., Blajchmann, M.A.: Histocompatibility (HLA)
antigens, lymphocytotoxic antibodies and tissue antigens 
in patients with diabetes mellitus. Diabetes, 22: 429-
432 (1973).
Sloan, N.R.: Ethnic distributions of diabetes mellitus in
Hawaii. J.A.M.A. 183: 123-138 (1963).
Smithies, 0.: Zone electrophoresis in starch gels: group
variations in the serum proteins of normal human adults. 
Biochem. J., 61: 629 (1955).
Solow, H., Hidalgo, R. and Singal, D.P.: Insulin dependent
diabetes. HLA-A, B, C and B cell alloantigens. Abstract. 
Tissue Antigens, 10: 195 (1977).
Spencer, N., Hopkins, D.A. and Harris, H. : Phosphoglucomutase
polymorphism in man. Nature, Lond. 204: 742 (1964).
Spielman, R.S., Baker. L. and Zmyewski, C.: Genetics of
juvenile diabetes: dosage of susceptibility genes.
Abstract. Diabetes, 27: 459 (1978).
Stang, J. (1964) quoted in "Is diabetes of infectious 
origin?" Gundersen, E., J. Infect. Dis. 41: 197-202
(1927).
Steinberg, A.G.: The Genetics of Diabetes. A Review.
Ann. N.Y. Academy of Sciences 82: 192-207 (1959).
Steinberg, A.G. , Rushfort, N.B., Bennett, P.H., Burch, T.A. 
and Miller, M.: On the genetics of diabetes mellitus.
In - Pathogenesis of diabetes mellitus. Cerasi, E.,
Luft, R. (eds). Milano. Casa Editrice 237-264 (1970).
Steinberg, A.G. and Wilder, R.M.: A reconsideration of the
phenomenon of anticipation in diabetes mellitus. Proc.
Staff Meetings Mayo Clin. 25: 625-630 (1950) (quoted in
Steinberg 1959).
Steinberg, A.G. and Wilder, F.M.: An analysis of the phenomenon
of "anticipation" in diabetes mellitus. Ann. Intern. Med.
36: 1285-1296 (1952a).
Steinberg, A.G. and Wilder, R.M.: A study of the genetics of
diabetes mellitus. Amer. J. Hum. Genet. 4: 113-135 (1952b).
Suciu-Foca, N. , Nicholson, J.F., Reemstma, K. and Rubinstein, P.: 
The HLA system and the genetics of juvenile diabetes 
mellitus. Diabet et Metabolisme, 3: 193-198 (1977).
214
Sushruta Samhita, 2nd ed. Translated into English by Bhisha- 
gratna, K.K. Varanasi, India: The Chowkhamba Sanskrit.
Series, vol. II, p. 372 (quoted in Simpson 1976).
Svejgaard, S.: Lancet ii: 864-866 (1974) (quoted in Cudworth
1978).
Svejgaard, A., Platz, P. and Ryder, L.P. et alii: HLA types
C-peptides and insulin antibodies in diabetes mellitus. 
Diabetologia, 13: 13 (1977).
Svejgaard, A. and Ryder, L.P. Associations between HLA and 
disease. In - HLA and disease. Dausset. J. and Svejgaard,
A. (eds). Munksgaard, Copenhagen, 46: (1977).
Svejgaard, A., Christy, M., Nerup, J., Platz, P., Ryder, L.P. 
and Thomsen, M.: HLA and autoimmune disease with special
reference to the Genetics of insulin-dependent diabetes, 
in - Genetic control of autoimmune disease. Eds. Rose, N.R., 
Bigazzi, P.E., Warner, N.L. 101-112 (1978).
Svejgaard, A., Platz, P., Ryder, L.P., Nielsen, L.S., Thomsen,
M.: HLA and disease Associations - A survey. Transplant.
Rev. 22: 3-43 (1975).
Svejgaard, A., Platz, P. and Ryder, L.P. Joint results of 
the 8th IDDM Workshop Study (1980).
Tattersall, R.B. and Pyke, D.A.: Diabetes in identical twins.
Lancet ii: 1120 (1972).
Tattersall, R.B., Fajans, S.S.: A difference between the
inheritance of classical juvenile-onset and maturity onset 
type diabetes of young people. Diabetes, 24: 44-53 (1975).
Taylor, K.W., Sheldon, J., Pyke, D.A., Oakley, W.G.: Glucose
tolerance and serum insulin in the unaffected first-degree 
relatives of diabetics. Brit. Med. J. i: 22 (1967).
Then Bergh, H.: Die erbbiologie des diabetes mellitus. Vor­
läufiges ergenbnis der zwillingsuntevsuchungen. Arch. Rassen 
und Gesellschaftsbiol. 32: 289 (1938) quoted in Simpson
(1976).
Theophilus, J., Kirk, R.L., Whitehouse, S., Court, J. and 
Zimmet, P.: The distribution of Properdin factor B (Bf)
and glyoxalase (GLO) phenotypes in diabetes. Pathology,
12: 135 (1980). (Abstract).
Thomsen, M., Platz, P., Ortved Andersen, 0., Christy, M., 
Lyngsoe, J., Nerup, J., Rasmussen, K., Ryder, L.P.,
Staub Nielsen, L. and Svejgaard, S.: MLC typing in
juvenile diabetes mellitus and idiopathoc Addison's 
disease. Transplant Rev., 22: 120-125 (1975).
Thomson, G.: A two locus model for juvenile diabetes.
Ann. Hum. Genet., Lond., 43: 383-397 (1952).
Thomson, G.S.: Genetic factors in diabetes mellitus studied
by the oral glucose tolerance test. J. Med. Genet. 2:
221 (1965).
Thomson, M.W. and Watson, E.M.: The inheritance of diabetes
mellitus, an anlysis of the family histories of 1631 diabetics. 
Diabetes, 1: 268 (1952).
Tripathy, B.B., Panda, N.C. and Tej, S.C.: Diabetes among the
undernourished: Epidemiological and clinical observations.
In - Current topics in diabetes research. Proc. 9th 
Congress of Int. Diabe. Fed., India. Series 400. Bajaj, J.S. 
(ed). 171: (1976).
Vague, Ph., Melis, C., Mercier, P., Vialettes, B. and Lassman,
V.: The increased frequency of the Lewis Negative Blood
Group in a diabetic population - Diabetologia 15: 33-36
(1978).
Vallence-Owen, J.: Causation of diabetes. Proc. R. Soc. 55:
207-210 (1962).
Vallence-Owen, J.: The inheritance of essential diabetes
mellitus from studies of the synalbumin insulin antagonist. 
Diabetologia, 2: 248 (1966).
Viswanathan, M., Mohamed, U. and Krishnamoorthy, M. et alii.: 
Diabetes in the young: Study of 166 cases. In -Diabetes
in the tropics. Patel, J.D., Talwalker, N.G. (eds) Bombay 
Diab. Assoc, of India. 277-281 (1966).
Viswanathan, M.: Pancreatic diabetes in India: An overview.
Secondary diabetes: The spectrum of the diabetic syndromes.
Podolsky, S. and Viswanathan, M. (eds) Raven Press, N.Y. 
105-116 (1980).
Von Kries, I.: Beitrag zur genetik des diabetes mellitus.
Z. Kont-Lehre, 31: 406 (1953). quoted in Simpson (1976).
Watson, E.M.: Diabetes mellitus in twins. Canad. Med. Ass.
J., 31: 61 (1934).
West, K.M.: Response to cortisone in prediabetes glucose -
and steroid-glucose tolerance in subjects whose parents 
are both diabetic. Diabetes, 9: 379 (1960).
West, K.M.: Epidemiology of diabetes and its vascular
lesions. Elsevier, New York (1978).
West, K.M.: Standardization of definition, classification
and reporting in diabetes related epidemiologic studies.
In - Diabetes care. 2: 65-76 (1979).
Williams, D.R.R. and Cartwright, R.A.: Genetic polymorphisms
in diabetics and non-diabetics. J. Med. Genet. 16: 351-
357 (1979).
216
Williams, D.R.R. and Cartwright, R.A.: The Esterase-D poly­
morphism in patients with diabetes or carcinoma of the 
bladder and a matched sample of non-donor controls. Ann. 
Hum. Biol. 5: 281-284 (1978).
Wise, P.H., Edwards and Thomas, D.W.: Hyperglycemia in the
urbanized Aboriginal. The Davenport survey. Med. J. Aust. 
2: 1001-1006 (1970).
Wise, P.H., Edwards, F.M., Craig, R.J. Evans, B., Murchland, 
J.B., Sutherland, B. and Thomas, D.W.: Diabetes and
associated variables in the South Australian Aboriginal. 
Aust. N.Z. Med. 6: 191-196 (1976).
Woodyatt, R.T. and Spetz, M.: Anticipation in the inheritance
of diabetes. J. Am. Med. Assoc. 120: 602-605 (1942).
Woolf, B.: On estimating the relations between blood group
and disease. Ann. Hum. Genet. 19: 251-3 (1954-5).
World Health Organization (WHO). Expert Committee on
Diabetes Mellitus: Technical Report Series 646. Second
Report 1-14 (1980).
Workman, F.L., Blumberg, B.S. and Cooper, A.J.: Selection,
gene migration and polymorphic stability in a U.S., white 
and Negro population. Amer. J. Hum. Genet. 15: 429-437 
(1963).
Yoon, J., Austin, M., Onodera, T. and Notkins, A.L.: Virus-
induced diabetes mellitus. N. Engl. J. Med. 300: 1173-
1179 (1979).
Zavala, C., Morton,N.E., Rao, D.C., Lalouel, J.M., Gamboa,
I.A., Tejeda, A. and Lisker, R.: Complex segregation.
Analysis of diabetes mellitus. Hum. Hered. 29: 325-333
(1979).
Zeidler, A., Loon, J., Douglas Frasier, S., Dinesh Kumar, 
Penny, R. and Terasaki,P.: HLA-Drw antigens in Mexican-
American and Black American diabetic patients. Diabetes, 
29: 247-250 (1980).
Zimmet, P. and Kirk, R.L.: Diabetes mellitus in Pacific
populations - The search for a genotype. In - Proceedings 
of the 10th Congress of the International Diabetes Feder­
ation. Vienna, Austria. Excerpta Med. 517-521 (1979).
Zimmet, P.: Epidemiology of Diabetes and its macrovascular
manifestations in Pacific populations. The medical effects 
of social progress. Diabetes Care. 2: 144-153 (1979).
Zimmet, P., Arbiaster, M. and Thoma, K.: The effect of
Westernization on native populations. Studies on a Micro- 
nesian community with a high diabetes prevalence. Aust. 
N.Z. J. Med. 8, 141-146 (1978).
217
PUBLICATIONS
Kirk, R.L., Theophilus, J., Whitehouse, S., Court, J. and 
Zimmet, P.: Genetic susceptibility to diabetes mellitus:
the distribution of Properdin factor B (Bf) and glyoxalase 
(GLO) phenotypes. Diabetes, 28: 949-951 (1979).
Kirk, R.L., Serjeantson, S.W., Theophilus, J., Zimmet, P., 
Whitehouse, S. and Court, J.M.: Age relationship between
insulin-dependent diabetes and rare alleles of Properdin 
factor B. Lancet, i: 537 (1970).
Serjeantson, S., Theophilus, J., Zimmet, P., Court, J.,
Crossley, J.R. and Elliott, R.B.: Lymphocytotoxic anti­
bodies and histocompatibility antigens in juvenile-
onset diabetes mellitus. (Diabetes, 30: 26-29 (1981).
Reprinted from DIABETES, VOL. 28, NO. 10, OCTOBER 1979
Copyright 1979 by THE JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.
Genetic Susceptibility to Diabetes Mellitus: 
the Distribution of Properdin Factor B (Bf) 
and Glyoxalase (GLO) Phenotypes
I. L. KIRK, JAYA THEOPHILUS, S. WHITEHOUSE, J. COURT, AND P. ZIMMET
SUMMARY
'he distribution of phenotypes controlled by two loci 
>n chromosome 6 has been studied in a series of 239 
»atients with type 1 (insulin-dependent) and 297 pa- 
ients with type 2 (non-insulin-dependent) diabetes 
nellitus. At the properdin factor B (Bf) locus there is a 
significant increase in the frequency of the Bfsi and 
tfF1 alleles for type 1 patients, and the combined in- 
:rease in frequency of BfS1 and BfF1 in those patients 
s highly significant. The relative risk for F1 is 6.2 and 
or F1 and S1 combined is 5.3. These results confirm 
he association with F1 reported recently by Raum 
ind co-workers in Boston. The two rare alleles Bfs1 
ind BfF1 are in significant negative disequilibrium with 
fLA B8.
For the glyoxalase (GLO) locus there is a slight but 
lonsignificant increase in the frequency of the GLO2 
illele, but a significant disturbance in the distribution 
>f the GLO phenotypes for type 2 patients. These re­
sults for the GLO alleles may be due to stratification 
n our series of type 2 patients. Further studies are in 
•rogress to test this hypothesis. DIABETES 28:949-951, 
>ctober 1979.
enewed attention has been given recently to the 
role of genetic factors in susceptibility to diabetes 
mellitus,1 4 and this has received added impetus 
A  from the studies of the distribution of human leu­
cocyte antigens (HLA) in diabetic patients. Several sur- 
'eys5-9 have shown a significant increase in some antigens, 
carticularly HLA B8 and BW15 for Caucasian patients with 
ype 1 (juvenile or insulin-dependent) diabetes mellitus,
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and the association is even stronger with HLA DW 3 and DW 
4. Among Japanese patients with type 1 diabetes, there is 
an increased risk associated with HLA B12 or BW 22.10,11 
These associations with HLA antigens have not been ob­
served for patients with type 2 (maturity-onset or non-insulin- 
dependent) diabetes mellitus. However, twin studies sug­
gest that susceptibility to type 2 diabetes of the non-insulin- 
dependent type does have a strong genetic component.12
As part of the search for further associations between dia­
betes and other genetic markers, Raum et al.13 recently re­
ported a highly significant increase in the frequency of the 
F1 type in the properdin factor B (Bf) system in patients with 
juvenile diabetes. We also have similar evidence for a sig­
nificant increase in the frequency of some phenotypes in the 
serum properdin factor B (Bf) system in patients with type 1 
diabetes, and for an unusual distortion in the distribution of 
phenotypes in the glyoxalase (GLO) system in type 2 dia­
betes. Both the serum system Bf and the cell enzyme system 
GLO are controlled by loci close to HLA on the short arm of 
chromosome 6.14,15 The locus for Bf is very close to that for 
HLA B, while that for GLO is between HLA D and the centro­
mere. Cudworth et al.1,16 previously reported an increase in 
Bfs for type 1 diabetes, but so far there are no reports on the 
distribution of GLO types in either type 1 or type 2 diabetes.
PATIENTS AND METHODS
Blood samples were collected from patients with type 1 dia­
betes attending the Diabetic Clinic at the Royal Children’s 
Hospital in Melbourne and from a further series attending 
the Diabetic Clinic at the Royal Southern Memorial Hospital, 
Melbourne. The majority of patients in the latter series were 
of the non-insulin-dependent type with age of onset 40 yr or 
over. A smaller number in this series were maturity-onset 
cases but were on insulin therapy, while a few cases in this 
older age group were type 1, fully insulin dependent. Con­
trol series of blood samples were obtained from nonse- 
lected blood donors attending the Blood Transfusion Ser­
vice in Canberra and Sydney. Bf and GLO typing was 
performed using standard procedures.17,18
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TABLE 1
Bf types and gene frequencies in diabetes
Bf phenotypes Percent gene frequencies
No. --------------------------------------------------------------------------------------------------  -------------------------------------------------
Series tested S FS F S,F SF, SS, FF, F, Bf s Bf F B f B f F'
Type 1 239 163 38 3 1 25 6 2 1 82.6 9.8 1.5 6.1
(IDDM)
Type 2 292 203 74 8 1 2 4 0 0 83.2 15.6 0.9 0.3
(NIDDM)
Controls 380 248 100 20 1 5 3 3 0 79.5 19.0 0.5 1.0
RESULTS
Bf types. Four Bf alleles segregated in the series studied 
and in the controls. Type 1 patients have a significant in­
crease in the frequency of the rare alleles Sfsi and BfF' when 
compared with the controls (for the two alleles combined x2 
for type 1 versus controls = 22.8. P 0.001). This increase 
in frequency of the rare alleles is not present in the type 2 
patients.
As shown in Table 1 both type 1 and type 2 patients show 
a small increase in the common Bfs allele when compared 
with our normal controls, but the differences are nonsignifi­
cant. For both type 1 and type 2 patients there is a compen­
satory decrease in the frequency of the other common al­
lele, BfF. This decrease is exaggerated in type 1 patients, and 
the difference from controls for BfF for these patients is 
highly significant (x2 =  21.5, P <1 0.001).
GLO types. The distribution of GLO phenotypes and the fre­
quencies of the two GLO alleles is almost identical in pa­
tients with type 1 diabetes and in controls. For type 2 pa­
tients there is a decrease in the frequency of the GLO1 
allele, but the difference between the patients and controls 
is nonsignificant (x2 = 1.48, P =  0.2-0.3). Type 2 patients, 
however, have an unusual distribution of GLO phenotypes. 
There is an excess of homozygous 2 -2  individuals and a 
deficiency of heterozygotes compared with the number 
expected when the gene frequencies derived from the con­
trols are applied to the patient series. Indeed, the type 2 se­
ries, when considered alone, is not in genetic equilibrium 
(x2 = 5.8, P = 0.02)(Table 2).
DISCUSSION
These results confirm and extend the finding of Raum and 
his colleagues of a strong association between insulin-de- 
pendent diabetes and the F1 type in the Bf system, although 
in our own larger series, the level of association is not so 
high. The Boston study reported that 22.6% of their patients 
carry an F1 gene compared with 1.9% of their controls. In
TABLE 2
GLO types and gene frequencies in diabetes
No.
tested
GLO phenotypes
Percent gene 
frequencies
Series 1-1 2-1 2-2 GLO1 GLO2
Type 1 247 46 126 75 44.1 55.9
(IDDM)
Type 2 292 58 121 113 40.6 59.4
(NIDDM)
Controls 382 72 195 115 44.4 55.6
the Australian type 1 patients we have found 11.7% with ai 
F1 gene and 0.6% and 2.1 %, respectively, in type 2 patient 
and controls. We have also found a slight increase in the S 
gene. The relative risk in type 1 patients with FI gene in t il 
Bf system is 6.2, and for F1 and S1 combined it is 5.3.
Since type 1 diabetes is associated with an increase i 
the frequency of HLA B8 and BW15, it would not be surpris 
ing if there was also a change in frequency of Bf alleles, be 
cause the loci for HLA B and Bf are very close. Indeec 
since it has been shown19,20 for European and Icelandi 
populations that HLA B8 is in strong linkage disequilibriur 
with Sfs, the frequency of Bfs should be increased in type 
diabetics. This was found to be true by Cudworth et al.,1 
and in the present series of type 1 patients there is a 3% ir 
crease in the frequency of Bfs. We find a similar increase i 
Bfs frequency, however, in type 2 patients. In neither serie 
is this increase in the frequency of Bfs significant.
Because ß fs1 and ß fF1 are associated significantly wit 
type 1 diabetes, we have examined the linkage disequilit 
rium between HLA and Bf in our type 1 patients. Significar 
disequilibrium values occurred for HLA A1 with BfF and B3 
with BfF. More interesting, however, is the finding that HL 
B8 has significant negative disequilibrium values with Bfs 
BfF\  and BfF.
Our series of type 1 patients shows the increase in HL 
B8 frequency (48% versus 24%)21 found in other studies c 
type 1 diabetes among Europeans. The negative disequilit 
rium values between HLA B8 and ßfs1 and BfF\  both c 
which also have significantly increased frequency amon 
our type 1 patients, suggests that there is a diabetic suscep 
tibility allele in linkage disequilibrium with HLA B8 in som 
cases and with ß fs1 and Bfn in others. The negative disequ 
librium between HLA B8 and BfF probably reflects th 
known strong positive disequilibrium between B8 and Bfs i 
normal European populations.
The lack of significant associations between alleles at e 
ther the Bf or GLO loci for type 2 patients is in agreemei 
with previous studies, which have failed to show associs 
tions between HLA types and type 2 patients. Our own re 
suits indicate, however, a significant disturbance in the die 
tribution of GLO phenotypes with an excess of 2 -2  an 
deficiency of heterozygous 2-1 phenotypes. In the absenc 
of evidence implicating other chromosome 6 markers 
type 2 diabetes, the present results may be due to stratifies 
tion in the series investigated here. Further studies are 
progress to check the reproducibility of the disturbance 
the distribution of GLO phenotypes, with adequate contro 
to eliminate confounding effects.
The genetic heterogeneity of diabetes is again demoi 
strated clearly in our studies of non-HLA loci on chrorm
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me 6. The significant association between type 1 patients 
d some Bf phenotypes is not found in type 2 patients. In 
ntrast, alleles at the other chromosome 6 locus, glyoxa- 
>e, show no significant difference from controls for either 
De 1 or type 2 diabetics.
We are extending these studies to diabetic patients in 
ier parts of the Western Pacific to see if the results re- 
»rted here are supported more generally.
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Relationship of »ge to frequency of rare Bf factor« in 281 Aus­
tralian IDDM patients.
AGE RELATIONSHIP BETWEEN  
INSULIN-DEPENDENT DIABETES AND RARE 
ALLELES OF PROPERDIN FACTOR B
S ir, -The report by Raum and colleagues' of a striking as- 
uation between insulin-dependent diabetes (IDDM) and the 
re genetic type FI in the properdin factor B system has been 
m firmed independently in studies from our laboratories 
ported to a meeting of the Human Genetics Society of Austral­
ia (Queenstown, New Zealand, June 27-29, 1979). Raum 
al. found the Bf FI factor in 22 6% of U.S. White IDDM 
lients compared with 1-9% of the general population, giving 
relative risk of 15 0. In our study of 281 Australian IDDM 
uents 8 9'<' had the IT factor compured with 2 1 f? in 380 
ntrols, a relative risk of 4 5. Our study indicates also that 
ere is a slight increase in the frequency of the other rare Bf 
:tor, SI ,  being 2-8‘V in patients and 11% in controls. Raum 
al. also reported a similar increase in Sl:2-4% v 1 -0%
1 he discrepant estimates of relative risk that people with the 
j factor will have IDDM may well reflect different age com- 
sitions of the two study populations, although Raum et al. 
i not provide age distributions for their U.S. patients. The 
Xjuency ol HI IT is highly agc-dcpcndcnt (sec accompanying 
ure). The FT factor is present in 191% of 47 Australian 
• I'M patients aged 10 years or less, falling progressively to 
3 , in /9 patients over 20 years ol age. If the frequency of 
c Bf hi af'd SI factors arc combined we find a decline from 
4 , m  the youngest to 2-5% in the oldest group, compared 
lh 3 2', among controls. The relative risk for Bf FI + SI 
? 4 in patients 10 years or younger.
Age-depcndcm relative risks in IDDM have peviousiy been 
>orted- lor HLA Bwl5. In our own series relevant HLA data 
■ available for 148 of the IDDM patients. There is no signifi- 
it difference in the frequency of B8 for patients in the var- 
is age categories, but for Bwl5, 14% (13/93) arc in the 0-10 
: group and 9-3 (5/54) arc in the 10-20 age group. The 
mbers are small but the trend is in the same direction as that 
Dausset.3
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The rapid decline in the frequency of Bf FI with increasing 
age of patients with IDDM is compatible with a viral stimulus 
for initiating the disease process. If Bf FI is in positive linkage 
disequilibrium for a susceptibility allele then young children 
carrying the FI allele are more likely not to resist an infection, 
with consequent development of autoimmune responses and 
islet-cell destruction. With increasing age the development of 
partial immunity in the child population may reduce the 
strength of the interaction between the precipitating agent and 
factors linked to the susceptibility allele.
In our laboratories we hgve demonstrated also a high fre­
quency of lymphocytotoxins (LCs) in sera of patients with 
IDDM. There is a strong association between the presence of 
LCs and HLA type: they were present in 37% of patients 
homozygous for either B8 or Bwl5 compared with 16% in 
those not homozygous for either. A similar relationship is pres­
ent for LCs and Bf factors: they were present in 38% of pa­
tients with the Bf FI factor compared with 17% in patients 
without this factor. Since in our data Bf FI is in strong nega­
tive disequilibrium with HLA-B8,1 this relationship between 
LCs and Bf FI is not due to the similar relationship between 
LCs and HLA-B8.
Islet-cell antibodies are also more frequent in sera oflD D M  
patients who arc HLA-B8,* and this relationship is even 
stronger in those patients in whom islet-cell antibodies have 
persisted lor 5 years or more. Wc are now investigating the 
relationship between the frequency of FI and SI and age of 
the patient, together with the significant association between 
FI and the presence of lymphocytotoxins, suggest that Bf typ­
ing will be o f increasing importance in differentiating various 
factors in the artiology and progress o f insulin-dependent 
diabetes.
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